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Hepatitis E virus as an important cause of viral hepatitis  
Infectious diseases are a significant global health problem. Viral hepatitis, including the 
diseases caused by hepatitis B (HBV) and C (HCV) viruses, affected millions of people, and 
especially so the substantial proportion of infected patients in which pathology progressed 
into chronic infection. The latter patients have an increased risk of developing severe 
complications, and major associated pathology includes liver fibrosis and cirrhosis which 
finally culminates into liver failure and hepatocellular carcinoma.1 Among viral hepatitis, 
however, it is the hepatitis E virus (HEV) that is the most dominant cause of acute hepatitis 
worldwide.2 
HEV is a member of the picornavirus family and represents a non-enveloped and positive-
strand RNA virus of 32-34 nm in diameter. Its complete genome is 7.2 kb in length, and 
includes three or four open reading frames (ORFs).2 ORF1-derived proteins are non-
structural viral proteins and are essential for viral replication. Various domains have been 
identified in this region, including a methyltransferase (MeT), a Y domain (Y), a papain-like 
cysteine protease (PCP), a proline-rich hinge domain, an X domain, an RNA helicase domain 
(Hel), and an RNA-dependent RNA polymerase (RdRp) domain. ORF2 encodes a 72 kDa 
protein that is incorporated into the viral capsid and represents the predominant antigen 
targeted by the human host immune system.3-5 ORF3 encodes a 13 kDa protein that 
mediates virus release from infected cells.6 It also interacts with several host proteins and 
thus plays an essential role in  pathogenesis caused by this virus.7,8 A novel ORF4 (nt 2835-
3308) has been recently identified from HEV genotype 1 and has been shown to drive HEV 
replication.9  
Several different genotypes of HEV exist which all cause infection in humans, yet only one 
single serotype has been identified.10 HEV genotype 1 and 2 are mainly transmitted via the 
faecal-oral route and are responsible for many large water-borne outbreaks of Hepatitis E in 
developing countries.11 In contrast, HEV genotype 3 and 4 are zoonotic, mainly causing 
chronic infection in immunocompromised organ transplant recipients in the Western 
world.12 In addition, more distantly HEV-related viruses have been identified in several 
animals, including ferrets, rats and bats.13 
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Generally, HEV infection results in mild disease and thus no specific anti-viral treatments are 
required, irrespective of the genotype involved.2 However, high mortality in pregnant 
women following HEV genotype 1 infection has been observed during many large HEV 
outbreaks in developing countries.11 With respect to developed countries, the burden 
provoked by HEV-related diseases is born by immunocompromised populations, especially in 
orthotopic liver transplant recipients in which HEV genotype 3 infection rapidly causes liver 
cirhhosis and ultimately, loss of the transplanted liver.12 Therefore, HEV represents an 
emerging issue in global health. 
Immunity and antiviral therapy against hepatitis E 
Similar to other viral infections, adequate immune responses to infection are critical with 
respect to the outcome of HEV infection. Innate immunity constitutes the first line of 
defense against viral infections. Recognition of relatively invariant viral components 
activates innate immune signaling pathways that culminate in the production of type I 
interferons (IFNs), tumor necrosis factor α (TNFα) and other antiviral cytokines. 
Subsequently, more specific adaptive immunity develops, including HEV-specific B and T cells, 
and these cell subsets attempt to achieve complete elimination of the virus. Improved 
understanding of HEV-provoked immunity may further the development of better HEV-
targeting vaccines, although the use of anti-HEV vaccines is currently limited to mainland 
China.14 
In the clinic, immunocompromised patients represent the main population requiring 
antiviral therapy for hepatitis E.12 In these patients, i.e. orthotopic organ tranplantation 
recipients, dose reduction of immunosuppressive agents is initially considered as the 
preferred intervention and results in viral clearance in a subset of patients.15 For patients 
failing this strategy, treatment with pegylated IFNα may be appropriate as it has been 
successful in chronic HEV patients in a number of case series and case reports. However, its 
associated adverse events, including graft rejection, limiting  its use in the clinic.16  
Antiviral ribavirin (RBV) monotherapy is considered the first line of antivirals suitable to treat 
chronic HEV.16 RBV leads in about 70-80% of patients to a sustained virological response. 
However, treatment failure and recurrences of HEV viremia have been reported in subsets of 
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patients.16,17 Thus, novel anti-HEV therapy is urgently required to overcome these limitations  
of PEG-IFNα and RBV therapy.14 Currently, the search for new anti-HEV drugs very much 
depends on the alternative use of clinically available antiviral medicine. This approach is 
highly relevant in a clinical setting as there is currently no registered medication for hepatitis 
E. Sofosbuvir (SOF), the direct-acting anti-hepatitis C virus (HCV) drug (targeting HCV RdRp; 
RNA-dependent RNA polymerase), has recently been reported to be a potential anti-HEV 
drug.18 However, subsequent studies showed discrepancies in different models of HEV, 
hampering its further development as novel anti-HEV therapy.19-22 
Importantly, the reaction of the human immune system against HEV (production of HEV-
specific B and T cells) as well as the use antiviral medications in infected patients, provoke 
emergence of novel HEV mutations, leading to evasion of antiviral activity and further 
pathogenesis. HEV evolution may result in escaping variants that evade the host immunity 
and are resistant to antiviral treatment.23 Therefore, development of novel antiviral 
medications and HEV vaccines are necessary for better control of HEV infection-associated 
diseases in the future.14 
Rotavirus and norovirus: The most important viral agents in acute 
gastroenteritis 
Diarrhea poses a high burden to global diseases and significantly contributes to overall 
morbidity and mortality, especially in developing countries. Acute diarrhea is a serious global 
health problem, with 3-5 billion cases and nearly 2 million deaths annually in children under 
five years of age.24 In children aged five years and older, adolescents and adults, there are 
approximately three billion episodes of diarrhea annually, emphasizing the point that 
diarrhea is not only a significant disease in young children.25 The main causes of diarrhea are 
infectious agents, including various bacteria, parasites and viruses. Noteworthy, rotavirus 
and caliciviruses (norovirus and sapovirus) have been identified as the main viral agents of 
acute diarrhea in children under five years of age when the entire world is taken into 
account.26 
Rotavirus mainly infects enterocytes in the gastrointestinal tract and clinically manifests as 
fever, vomiting and watery diarrhea.27 Severe complications, including bloody diarrhea and 
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necrotizing enterocolitis, have been described in rotavirus-infected patients.28 Rotavirus 
diarrhea is highly contagious and most children are infected before the age of five years.29 
Similar to rotavirus, norovirus is highly contagious and norovirus-infected patients shed the 
virus with a high viral load.30 In fact, norovirus is the most frequent cause of acute diarrhea 
outbreaks when assessed globally.31,32 Generally, norovirus infection is self-limiting and no 
specific antiviral treatments are required. However, in a subset of patients, including 
immunocompromised individuals, the elderly and in young children, norovirus is associated 
with severe complications, such as diarrhea recurrence, villous atrophy and 
malabsorption.33,34 Recently, norovirus has emerged as an important cause of chronic 
infections in organ transplant patients.35 
Molecular virology and classification of rotavirus and norovirus 
Rotavirus is a 70-nm icosahedral virus and belongs to the Reoviridae family. The viral particle 
seems like a wheel (Latin word: “rota”), hence its name.36,37 Rotavirus is a double stranded 
RNA virus, containing eleven dsRNA segments which encode six structural proteins (viral 
proteins, VP1-4, VP6 and VP7) and six non-structural proteins (NSP1-6). The rotavirus 
particle is composed of three concentric layers of viral structural proteins. The innermost 
capsid is formed by VP2 proteins. VP6 makes the intermediate shell of the virus and is 
regarded as the main capsid protein. The outermost layer consists of VP4 and VP7 
proteins.38 VP4 forms spikes which protrude from the outer surface. It is a protease-sensitive 
protein that can be cleaved into VP5* and VP8* to facilitate virus attachment to host cells 
and also furthers subsequent penetration into these host cells.39 Importantly, upon 
presentation to the immune system, VP4 and VP7 induce the development of neutralizing 
antibody responses.40 NSPs are synthesized during viral replication cycle and are involved in 
many aspects of rotavirus biology, pathogenesis and host immune responses.41 For example, 
NSP1 is a well-known interferon antagonist. NSP1 induces the proteasome-mediated 
degradation of IRF3, IRF5 and IRF7, leading to attenuation of the virus infection-combating 
interferon response.42-44 NSP4 plays a role as enterotoxin by altering Ca2+ release in the 
infected cells.45,46  
Rotavirus is classified into eight different serogroups (Groups A-H) based on the inner capsid 
protein VP6.47 Recently, novel serogroups (I and J) have been suggested to be present as 
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well.48,49 Group A rotavirus is the most common serogroup with respect to human infection. 
40 VP4 (a protease-sensitive protein) and VP7 (a glycoprotein) proteins are employed in a 
binary classification system of rotavirus into P- and G-genotype, respectively.38 Currently, 
about 28 G-types, 39 P-types and 70 different G-P combinations have been identified.29,50 
Among many G-P type combinations, G1P[8], G2P[4], G3P[8], G4P[8] and G9P[8] are the 
most common genotypes when viewed from a mondial perspective.51  
Following serotype based classification, subsequently also a full genome-based classification 
system for rotaviruses has been introduced. In this system, a specific genotype for each of 
the eleven segments of particular rotavirus strain was assigned. The full descriptor of each 
rotavirus strain is described as Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx and represents the 
genotypes of VP7-VP4-VP6-VP1-VP2-VP3-NSP1-NSP2-NSP3-NSP4-NSP5/6, respectively.52 The 
Rotavirus Classification Working Group (RCWG) works towards further uniformity in 
rotavirus strain nomenclature and produces guidelines for the naming of newly identified 
rotavirus strains.53 The RCWG proposed nomenclature for individual strains works as follows:  
RV group/species of origin/country of identification/common name/year of identification/G- 
and P-type.  
Norovirus is an icosahedral virus and belongs to the Caliciviridae family. It is divided into at 
least six genogroups (GI to GVI), in which GI, GII and GIV are known to infect humans. It is 
further subdivided into more than 40 genotypes.30 Human norovirus is a 7.6 kb, non-
segmented positive-strand RNA genome consisting of three ORFs. ORF1, ORF2 and ORF3 
encode a large non-structural proteins (polyprotein), a major structural protein (VP1) and 
the minor structural protein (VP2), respectively. The polyprotein encoded by ORF1 is 
composed of p48 (NS1/2 or N-term); NTPase (NS3 or 2C-like); p22 (NS4 or 3A-like); VPg; Pro 
(NS6); and RNA-dependent RNA polymerase (RdRp).30 The viral capsid is formed by 90 
dimers of VP1, consisting of a shell (S) and a protruding (P) domain. The inner surface of the 
capsid is also composed of few copies of VP2.54 The P domain plays an essential role for 
binding to histo-blood group antigens (HBGAs) which serve as receptors or co-receptors of 
the host cells, and thus determine genetic susceptibility to norovirus infection in humans.55 
Although more than 40 different genotypes infecting humans have been identified, GII.4 is 
the main genotype and has been responsible for the multiple global pandemics of norovirus-
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mediated gastroenteritis in the last two decades. Novel GII.4 variants emerge and replace 
the previously dominant variants every two to seven years. These variants include US95/96 
(1995-2000 pandemic); Farmington Hilss (2002-2004 pandemic); Hunter (2004-2005 
pandemic); Den Haag 2006b (2006-2010 pandemic); New Orleans (2010-2012 pandemic) 
and Sydney (2013 pandemic). GII.4 remained the dominant strain detected in clinical 
samples in 2016.56,57 However, several reports have recently indicated an emergence of 
GII.17 Kawasaki as a major cause of norovirus pandemics and this strain is predicted to 
replace the currently dominant GII.4 Sydney norovirus as the major cause of norovirus-
associated pathology.58 
Antiviral therapy and vaccines against rotavirus and norovirus 
At present, there are no specific antiviral medicines for the treatment of rotavirus infection. 
Thus patient management is mainly focused on fluid and electrolyte replacement therapy to 
prevent dehydration.59 For infection prevention, two commercial vaccines are available, i.e. 
Rotarix (containing G1P[8] strain) and RotaTeq (containing G1, G2, G3, G4 and P[8] strains), 
and have been universally introduced in more than 50 countries. Both vaccines have 
reduced the burden of rotavirus diarrhea worldwide.60 However, they have not been 
included in National Immunization Program (NIP) in many countries, including Indonesia. 
This is probably associated with vaccine costs and policy considerations.61 In developing 
countries, sustained availability of affordable and effective vaccines is pivotal to reduce the 
burden of vaccine-preventable diseases. Therefore, new rotavirus vaccine candidates have 
been developed and currently are in different phases of clinical development. A monovalent 
human-bovine 116E strain-based vaccine, developed by an Indian company, has now 
completed phase III trials.62,63 Another vaccine, the RV3-BB rotavirus vaccine which was 
developed by a consortium that involved collaboration between BioPharma (Indonesia 
national vaccine company), the Faculty of Medicine Universitas Gadjah Mada (UGM) 
Indonesia, and the Murdoch Children Research Institute (MCRI) Australia, has completed a 
phase IIb trial in Indonesia.64 
For norovirus, no approved specific antiviral medication and vaccines are available to treat 
or to prevent infection. Development of novel antivirals and vaccines was hampered by the 
lack of robust cell culture and animal models of norovirus infections.54 Currently, there are 
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several models available, including a Huh7 cell-based replicon system as well as organoid 
models.65-67 The development of anti-norovirus drugs is currently based on screening 
existing already approved medications.68 Dose adjustments of immunosuppressive 
medications should be first considered for transplant patients at risk of contracting 
norovirus.35 Should those clinical management techniques not successfully clear norovirus, 
effective antivirals are highly needed. Ribavirin, a guanosine analogue, exerts antiviral 
effects against a wide rage of RNA and DNA virus, including rotavirus and norovirus.69,70 
Mycophenolic acid (MPA), an uncompetitive inosine monophosphate degydrogenase 
(IMPDH) inhibitor, potently inhibits rotavirus and norovirus replication.69,71 These results, 
although preliminary, should provide guidance for the management of transplantation 
patients at risk for contracting rotavirus and norovirus infections. 
AIMS AND OUTLINE OF THE THESIS  
Hepatitis E, rotavirus and norovirus provoke a substantial disease burden worldwide, both in 
developed and in developing countries. Hepatitis E virus is the predominant cause of acute 
hepatitis, while rotavirus and norovirus are the main agents for causing acute gastroenteritis 
in children. Improved understanding of the disease burden involved is essential to raise 
awareness of the importance of the diseases. To achieve better control of these diseases, 
development of vaccines and novel antiviral therapies will prove exceedingly useful. Viral 
infections are tightly regulated by many cellular signaling pathways. Dynamic virus-host 
interactions, including host responses and viral mutations, will determine the outcome of 
viral infections.  
Aims of The Thesis 
The aims of this thesis are to describe the burden and epidemiology of hepatitis E, rotavirus 
and norovirus infections, and to improve our understanding of virus-drug-host interactions, 
by exploring antiviral drugs and cellular signaling pathway, including interferon and NF-κB 
pathway.  
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Thesis Outline 
In chapter 2, I first aim to generate a comprehensive description of the global burden 
associated with HEV outbreaks. By performing a systematic review of published studies, I 
show that HEV is responsibe for repeated water-borne outbreaks of acute hepatitis over the 
past century, and thus clearly represents an emerging public health issue warranting further 
research effort. Currently, control measures mainly depend upon the improvement of 
sanitation and hygiene. Although important, this will not prove sufficient to control the 
problem. Therefore, in chapter 3, I discuss the recent progress on understanding innate and 
adaptive immunity in HEV infection. Since immune responses are critical for determining the 
clinical outcome of HEV infection, understanding of HEV immunopathogenesis should 
provide the basis for the devolopment of effective vaccines and therapies to achieve a better 
control of HEV-associated diseases. In this context, it is important to note that the discovery 
of new anti-viral therapies for HEV has hitherto mainly been based on the screening of 
currently clinically available antiviral medicines. In chapter 4, I thus explored the potency of 
sofosbuvir (SOF), a direct-acting antiviral (DAA) agent against hepatitis C virus, to inhibit HEV 
infection. Contrary to a previously published study, I demonstrated that SOF is likely not of 
value for the treatment of hepatiits E. In search for alternative strategies, in chapter 5, I 
explore the molecular evolution of HEV in the human population, documenting 
characteristic mutations and their associations with susceptibility, pathogenesis and 
therapeutic responses. My results indicated that HEV is under substantial evolutionary 
pressure to develop mutations which enable evasion of the host immune response and 
resistance to antiviral treatment. Thus, HEV for now remains versatile in developing novel 
strategies to evade its eradication, and I discuss the implications of these findings in chapter 
12. 
Not discouraged, I then focused on rotavirus and norovirus infections. In chapter 6, I 
explored the role of different types of interferons (IFNs) in regulating the course of rotavirus 
infections. I found that rotavirus predominantly induces type III IFNs (IFN-λ1), and to a lesser 
extent, type I IFNs (IFN-α and IFN-β) in human intestinal cells. In addition, I established the 
essential role of constitutive IFN signaling in constraining rotavirus replication in an 
experimental approach involving the silencing of STAT1, STAT2 and IRF9 genes. Next, 
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chapter 7 describes potent antiviral effects of TNF-α against rotavirus infections, 
independent of type I interferon productions. I then established that the anti-rotavirus effect 
of TNF-α depended on the induction of transcription of NFκB-target genes via the activation 
of classical nuclear factor κB (NF-κB) signaling. My study thus uncovered a somewhat 
unexpected antiviral action of TNF-α which may act against a diverse types of viruses and 
exploiting this novel avenue may prove useful in the fight of humankind against these 
diseases. In chapter 8, I describe the potency of 6-TG, a commonly used drug as an 
immunosuppressive agent for organ transplantation and inflammataory bowel disease (IBD), 
as anti-rotavirus drug associated with a high barrier to drug resistance emergence. In 
conjunction this work opens the way to improve anti-rotavirus therapy as I also discuss in 
chapter 12. 
Following these mechanistic studies, I subsequently turned my attention to a more 
molecular epidemiological characterization of viral infection. In this context diarrhea is 
especially relevant as it significantly contributes to the overall global burden of disease, 
especially so in developing countries. It is well known that rotavirus and norovirus are the 
most dominant viral agents responsible for diarrheal disease globally. Therefore in chapter 9, 
I first performed a comprehensive review of rotavirus and norovirus study in Indonesia. I 
identified, however, very limited data regarding the incidence and circulating norovirus 
genotypes in Indonesia, but with respect to rotavirus the situation was much better. 
Subsequently in chapter 10, I describe the prevalence of norovirus and rotavirus infections 
in children less than five years of age hospitalized with acute gastroenteritis in Indonesia. 
This study reveals a considerably high burden of norovirus and rotavirus gastroenteritis in 
Indonesian children under five years of age. Finally in chapter 11, I describe rotavirus 
surveillance data conducted in Yogyakarta and demonstrated a high burden of rotavirus-
associated diarrhea. Again I integrate these data with the other data in this thesis in chapter 
12, and in conjunction my thesis thus provides insight into the global burden and the 
epidemiological dynamics of important viral infections, the potential of medication and 
immune-based strategies for combating viral disease and the molecular evolution of the 
virus in reaction to such strategies. My conclusion will be that although humanity is currently 
gaining the upperhand, its victory over viral disease is still quite far away. 
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Abstract 
Hepatitis E virus (HEV) is responsible for repeated water-borne outbreaks since the past 
century, representing an emerging issue in public health. However, the global burden of HEV 
outbreak has not been comprehensively described. We performed a systematic review of 
confirmed HEV outbreaks based on published literatures. HEV outbreaks have mainly been 
reported from Asian and African countries, and only a few from European and American 
countries. India represents a country with the highest number of reported HEV outbreaks. 
HEV genotypes 1 and 2 were responsible for most of the large outbreaks in developing 
countries. During the outbreaks in developing countries, a significantly higher case fatality 
rate was observed in pregnant women. In fact, outbreaks have occurred both in open and 
closed populations. The control measures mainly depend upon improvement of sanitation 
and hygiene. This study highlights that HEV outbreak is not new, yet it is a continuous global 
health problem.  
 
Keywords: global burden, Hepatitis E, outbreaks  
 
Key Points 
• India represents a country with the highest number of reported HEV outbreaks. 
• The number of reported HEV outbreaks is most likely underestimation of the actual 
burden of HEV outbreaks globally. 
• In recent years, the burden of HEV outbreaks come from refugee camps in African 
countries. 
• The availability of HEV vaccine should contribute to better control of HEV disease. 
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Introduction 
Hepatitis E virus (HEV) infection is a major cause of outbreaks and acute sporadic hepatitis 
worldwide. HEV infecting humans consists of four different genotypes (genotype 1-4), with 
several sub genotypes exist in each. However, only one single HEV serotype was recognized 
[1, 2]. HEV genotypes 1 and 2 are found mainly in developing countries. They are 
transmitted via fecal-oral route through a contaminated water source, exclusively infect 
humans, and are thus responsible for many water-borne outbreaks. In contrast, HEV 
genotypes 3 and 4 infect humans and animals. They are found mainly in developed countries 
and are responsible for sporadic cases seen in the western world [3, 4]. In 2005, it was 
estimated that HEV genotypes 1 and 2 were responsible for about 20.1 million incidents of 
HEV infections, 3.4 million symptomatic cases, 70,000 fatalities, and 3,000 stillbirths [5]. In 
general, HEV causes a self-limiting infection and does not need specific treatment. The 
mortality rate is low. However, fulminant hepatitis may develop and a high mortality rate (as 
high as 20-30%) is reported in the population of pregnant women after infection with 
genotype 1 [1].  
HEV is a spherical, non-enveloped, single-stranded positive sense ribonucleic acid (RNA) 
virus that mainly infects the hepatocyte [6]. HEV genome was first entirely cloned in 1991 [7, 
8]. Historically, HEV was suggested as a causative agent during jaundice outbreaks with a 
high attack rate among young adults and resulted in a high mortality rate among pregnant 
women [9]. Many large, water-borne, jaundice outbreaks in the past were described as non-
A, non-B (NANB) hepatitis outbreaks due to failure in identifying hepatitis A (HAV) and 
hepatitis B virus (HBV) as the responsible agent of the outbreaks [10, 11]. The existence of 
HEV was already suggested in 1980 during the investigation of the causative agent of a 
NANB hepatitis outbreak in Kashmir Valley, India [12]. 
Since the discovery of HEV, many archived samples obtained during NANB hepatitis 
outbreaks were tested for the presence of HEV [13]. The first retrospectively identified HEV 
outbreak was a large jaundice outbreaks in New Delhi, India, in 1955-1956 with more than 
29,000 suspected cases [13, 14]. Along with the development of serology- and reverse 
transcription-polymerase chain reaction (RT-PCR)-based diagnostic methods, many HEV 
outbreaks were then identified (confirmed), both in the past (NANB hepatitis outbreaks) and 
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in the recent years. Understanding the global distribution of confirmed HEV outbreaks could 
heighten our awareness of this under-recognized and under-reported human pathogen and 
improve HEV surveillance. 
Therefore, we comprehensively reviewed the confirmed HEV outbreaks in the literature. 
More specifically, we described the global geographical distribution of (confirmed) HEV 
outbreaks, the severity (case-fatality rates), outbreak settings and modes of transmission, 
control measures, and the distribution of HEV genotype responsible for the outbreaks. 
Materials and Methods 
Literature search 
A systematic search of available literature (conducted on 10 March 2015) was performed 
using the electronic database Embase.com, Medline (Ovid), the Cochrane library, Web of 
Science, Scopus, and Cinahl (EBSCOhost). Additional references were retrieved from 
unindexed references from PubMed, Lilacs, Scielo, and Google Scholar. Additional references 
were sought by reviewing the reference list of selected studies. The search terms were 
designed by an experienced information specialist (WB). The search was executed without 
any restrictions of publication date or language. The search terms were consisted of two 
main elements: hepatitis E virus (HEV) and outbreak. For each element, multiple synonyms 
were searched in title and/or abstract, and when available thesaurus terms (Mesh for 
medline, Emtree for embase and CINAHL headings for CINAHL). The search strategies for all 
databases are available in Supplementary Table 1. 
Study selection, inclusion and exclusion criteria 
After removing the duplicates, we screened the articles based on the title and abstract. The 
full text copies of included studies based on title and abstract screening were then assessed 
for eligibility. The inclusion criteria include: 1) Original research articles or reports, informing 
an outbreak of hepatitis E. An outbreak was identified by: a) reporting an attack rates; b) 
clearly demonstrated the epidemiological curve; c) reporting large scale, affect several 
hundred to several thousands of people; d) specify the time course, either short (few weeks) 
or long period (few months until year[s]); 2) The study used PCR-based and/or serology-
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based diagnostics (IgM and IgG anti-HEV antibody to confirm the presence of HEV as a 
responsible agent for the outbreak; 3) Studies showing NANB hepatitis outbreak that was 
confirmed later by another study showing that the outbreak was due to HEV; 4) Any studies 
that confirmed previous NANB hepatitis outbreak as an HEV outbreak; 5) Any studies 
reported sequencing analysis of HEV strains derived from the outbreak. The following 
exclusion criteria were used for full-text screening: 1) full-text not available; 2) language 
other than English; 3) not primary study during the outbreak; 4) not sufficient information. 
The selection procedure was performed by two independent investigators (M.S.H. and 
W.W.). Disagreements were resolved by discussion. 
Data extraction 
M.S.H. extracted the data with help of W.W. Data were extracted from the full-text papers 
of the included studies. The following items were extracted: author, year of publication, 
country, specific region (if available), the time of the outbreak (month and year), number of 
suspected cases, attack rate in general population, diagnosis used (serology, RT-PCR, 
sequencing), number of sample tested, number of confirmed cases, case fatality rates (CFR) 
both in general population and pregnant women, outbreak settings, risk factors (modes of 
transmission), control measures, and HEV genotype. Attack rate was defined as the number 
of suspected cases divided by the number of exposed population times 100. CFR was defined 
as the number of deaths divided by the number of suspected cases times 100. Our 
procedures accorded with the PRISMA guidelines for reporting systematic review and/or 
meta-analysis (Supplementary Table 5). 
Results 
Description of the included studies 
Using our search strategy, we identified potentially relevant 3,776 articles. After removal of 
duplicates, 1,653 articles were recorded for title and abstract screening. Of these, 191 
articles met the eligibility criteria based on full-text and abstract screening and 10 articles 
identified from manual search. After assessing 201 full-text articles, we ultimately included 
98 articles in this systematic review (Figure 1).  
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Figure 1. Flow diagram showing literature search and selection results. 
Since we did not restrict the publication date and considering the fact that HEV has caused 
NANB-hepatitis outbreak far before its identification, the publication dates of the included 
studies ranged from 1978 to 2015. Most of these studies describe the incident of HEV 
outbreaks in Asian and African countries, and only 5 studies describe HEV outbreaks in 
American and European countries. Interestingly, a large number of the included studies 
describing HEV outbreaks occurred in one country, India. 
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Confirmed HEV outbreak and overall attack rate 
Asia 
HEV outbreaks have been reported from 12 countries: Indonesia [15-17], Myanmar [18], 
Vietnam [19], Japan [20], China [21], Bangladesh [22, 23], Pakistan [24-29], Nepal [30], Iraq 
[31], Uzbekistan [32], Turkmenistan [33], and India [12-14, 34-65] (Figure 2 and 
Supplementary Table 2 and 3). The first confirmed HEV outbreaks occurred in New Delhi, 
India in 1955 [13]. During this outbreak, about 29,000 suspected cases were reported, with 
an attack rate 2.05%. Retrospective analysis of archived serum samples from 28 patients 
successfully detected IgM anti-HEV antibodies in all samples (100%) to confirm that HEV was 
responsible for this large historical outbreak [13]. After this large outbreak, India has 
repeatedly reported large HEV epidemics, affecting hundreds to thousands of people (Figure 
3). The largest HEV outbreak in India was reported in Kanpur, India during December 1990 - 
April 1991. About 79,000 suspected cases (jaundice patients) were reported, with an attack 
rate of 3.76%. Analysis of 41 serum samples showed evidence of NANB hepatitis outbreak 
[43]. Analysis of stool samples from this epidemic demonstrated the evidence of HEV RNA in 
6 out of 10 samples analyzed (60%), confirming that HEV was the etiologic agent of this 
NANB hepatitis outbreak [42]. Another large HEV outbreak was reported from Nellore (south 
India) with 23,915 suspected cases [62]. From 1975-1994, India experienced 21 HEV 
outbreaks, 13 of them (62%) reported more than one thousand of suspected cases. The 
most recent epidemic in India was reported from Lalkuan (Nainital District, Uttarakahand) 
with approximately 240 suspected cases [65]. The attack rate ranged from 0.34% [37] to 
8.61% [65]. There were only three outbreaks that reported attack rate of more than 10%, i.e. 
Saharanpur, 1992-1993 (14%) [45]; Nainital district, Uttarakhand, July 2005 (16%) [56]; and 
Baramulla district, Kashmir, 2007-2008 (21.6%) [60]. These data suggest that India is highly 
endemic for hepatitis E. 
There were four HEV outbreak reported from Pakistan [24-28]. The first reported HEV 
outbreak was Sargodha outbreak which occurred during March - April 1987 [24, 25]. A large 
water-borne outbreak was reported from the city of Islamabad, affecting 3,827 people, with 
10.4% attack rate [27]. A localized HEV outbreak was occurred in the military unit of 
Abbottabad (August - September 1988), in which more than 100 suspected cases were 
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recorded [26]. In all these outbreaks, the reported attack rates were more than 10%, ranging 
from 10.4% [27] to 20% [24]. 
Bangladesh reported only two HEV outbreaks [22, 23]. An outbreak with more than 4,000 
cases was reported from Arichpur, an urban area near Dhaka, with 4% attack rate [22]. From 
south-east Asian countries, Indonesia reported two HEV outbreaks, in East Java [17] and 
Kalimantan island [15, 16]. Other south-east Asian countries, such as Myanmar and Vietnam 
only reported one outbreak [18, 19]. 
In east Asia, the largest reported outbreak in the world so far was reported from Xinjiang, 
China. A huge number of 120,000 suspected cases was reported during prolonged outbreak 
that lasted from September 1986 - April 1988, with an overall attack rate of 3.0% [21]. In the 
middle-east region, HEV outbreak was only reported from Baghdad, Iraq at 2005, after the 
Iraq war. More than 250 suspected cases were reported during this outbreak [31]. From 
central Asia, a large HEV outbreak occurred in the Dashoguz province of Turkmenistan, with 
more than 16,000 cases were reported [33]. 
Africa 
HEV outbreaks have been reported from 14 countries: Egypt [66], Kenya [67, 68], Sudan and 
South Sudan [69-76], Central African Republic (CAR) [77-79], Uganda [80-84], Chad [73, 76, 
85-89], Republic of Djibouti [90], Algeria [85, 86, 89, 91], Namibia [92, 93], Morocco [94, 95], 
Somalia [96, 97], Ethiopia [98], South Africa [99], and Cameroon [100] (Figure 2 and 
Supplementary Table 2). The first, large, laboratory confirmed HEV outbreak involved more 
than 140 villages in Somalia on early 1988 - late 1989. There were more than 11,000 
suspected cases reported with an overall attack rate of 4.6% [96, 97]. A large HEV outbreak 
was also reported from Kitgum district, Uganda. More than 10,000 suspected cases from 
October 2007 - June 2009 were reported with an overall attack rate of 25.1% [80-82]. During 
the investigation, the outbreak was still ongoing and therefore, the number of suspected 
cases might be increasing. In the last decade, outbreaks of hepatitis E have been reported 
from several area with warfare and conflict, causing human displacement. Several large HEV 
outbreaks, involving hundreds to thousands cases, were reported from refugee camps in 
Chapter 2 
28 | P a g e  
 
Kenya (1,702 cases) [67]; South Sudan (>5,000 cases) [75]; Darfur, Sudan (2,621 cases) [70, 
71]; and Chad (>900 cases) [73, 87]. 
 
Figure 2. The global HEV outbreak distribution. (Note: Sudan and South Sudan are regarded as one 
country). 
 
America and Europe  
Only few outbreaks were reported from European and American countries. In Europe, a 
confirmed HEV outbreak probably related to shellfish exposition and involving genotype 3 
was reported on cruise ship returning to United Kingdom after a world cruise. 33 of 789 
passengers (4%) who provided blood samples were IgM anti-HEV positive, confirming a 
recent acute HEV infection [101]. A small HEV outbreak was reported from Lazio, Italy. Five 
suspected cases were reported and all of them were HEV positive (genotype 4) [102]. In 
America, HEV outbreak was first reported from two villages, Huitzililla and Telixtac, Mexico 
in 1986, with more than 200 suspected cases. The overall attack rate was 5-6% [103-105]. 
No HEV outbreak was reported from Mexico thereafter. Another country, Cuba, reported 
two HEV outbreaks [106]. 
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Figure 3. The epidemic history of large HEV outbreak in India with more than 1,000 suspected cases. 
Case fatality rate (CFR) 
The CFRs were reported in 38 studies (Supplementary Table 4). In overall population, CFRs 
were relatively low, between 1 and 3%. The highest reported CFR of overall population was 
3.6%, in the Kashmir valley outbreak, India, in 1978 – 1979, involving 275 suspected cases 
[12]. One study reported an overall CFR of 33% (6 fatalities out of 18 cases) [28]. This 
outbreak occurred among patients in neurosurgery ward in the hospital. Therefore, the 
underlying disease and condition might be important factors influencing this high CFR.  
Compared with overall population, fatalities are higher in pregnant woman. The CFR among 
pregnant woman ranging from 5.1% in Rajasthan, India during February 2006 [58] to 31.1% 
in refugee camp, Darfur, Sudan during July - December 2004 [70, 71]. From 15 studies which 
reported CFR of both overall and pregnant women population, we found a significantly 
higher CFR in pregnant women compared to overall population (Figure 4). One study 
specifically compared the CFR among non-pregnant and pregnant females population. It was 
shown that the CFR of pregnant females was significantly higher than non-pregnant females 
(11% vs. 1.5%, p<0.01) [96].  
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In addition to a high CFR among pregnant woman, HEV infection during pregnancy may lead 
to worse outcome. In HEV outbreak setting, several studies descriptively reported worse 
pregnancy outcomes such as postpartum hemorrhage, premature delivery, stillbirth, 
miscarriage, and neonatal death [22, 74, 78]. Since these were descriptive studies, the 
relative contributions of HEV infection to pregnancy-related outcome could not be 
determined. Gurley ES et al. [22] reported that pregnancies complicated by acute jaundice 
had an increased risk for miscarriage, stillbirth and neonatal death, as compared to 
pregnancy without jaundice (OR 2.7; 95% CI 1.2-6.1). 
 
Figure 4. Case Fatality Rates (CFR) of overall population and pregnant women. 
Outbreak settings 
Most HEV outbreaks occurred in community-based settings, such as village (rural area), city 
(urban area) or affecting a large area (one province) (Table 1). Several outbreaks occurred in 
a more-restricted (closed) settings, such as military units [18, 26, 30, 49, 51, 98], college [24], 
prison [47], and factory [106]. In recent years, several outbreaks were also reported from 
refugee camps with a big number of suspected cases [67, 68, 70, 75, 92]. Interestingly, one 
study reported an HEV outbreak that occurred on a cruise ship [101]. 
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Outbreak settings  and underlying 
cause (modes of transmission) 
References 
Outbreak settings   
City (urban area) [22]; [23]; [27]; [31]; [37]; [38]; [43]; [45]; [46]; 
[48]; [52-55]; [57]; [59]; [61]; [62]; [65]; [78]; 
[79]; [93]; [106]5 
Village (rural area) [12, 36]3; [17]4; [19]4; [40]; [56]; [58]; [60]; 
[64]; [66]; [91]; [96]4; [100]; [104, 105]3 
Affect large area (district or 
province) 
[33]2; [41]; [50]1; [80-82]3; [84] 
Refugee camps [67]; [68]; [70, 71]3; [75]; [83]; [92] 
Military units or military camps [18]; [26]; [30]; [49]; [51]; [98] 
Hospital [28]; [99] 
Cruise ship [101] 
Prison [47] 
Factory [106]5 
College [24] 
Modes of transmission 
Contamination of drinking water  
Leakage of water pipeline 
(broken, poor construction) 
[18]; [22]; [31]; [38]; [41]; [45]; [49]; [51]; [53]; 
[54]; [57-59]; [61]; [64]; [65] 
Failure of water treatment [24]; [27]; [40]; [43]; [45]; [52]; [60]; [70] 
Use of untreated water from 
river, spring 
[12]; [17]; [56]; [91]; [96] 
Flooding, heavy rainfall [19]; [31]; [69]; [75] 
Leakage of sewage pipelines [38]; [55] 
Food contamination [101] 
1 Two district affected; 2 One province affected; 3 Refer to one outbreak; 4 
Situated along the river; 5 Two outbreaks reported in one study 
Table 1. HEV outbreak settings and underlying cause of HEV outbreaks. 
Risk factors and modes of transmission 
Several risk factors were reported as the underlying cause of the outbreak (Table 1). The 
main mode of transmission reported was water-borne transmission. Leakage of water 
pipeline due to broken or poor construction was the most reported cause underlying the 
outbreak. The broken water pipelines lead to fecal or sewage contamination of the drinking 
water supply. Another underlying cause of the outbreak was failure of water treatment 
(such as filtration or chlorination). This failure led to the supply of grossly contaminated 
drinking water to the household. The use of untreated water from river and spring was also 
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reported as the underlying cause of the outbreak. Several HEV outbreaks occurred following 
flooding or heavy rainfall [19, 31, 69, 75], facilitating contamination of water supplies with 
feces. One study reported food contamination as the likely cause of the outbreak of HEV 
aboard a cruise ship [101]. 
Role of person-to-person transmission 
Several studies investigated the occurrence of person-to-person transmission during HEV 
outbreaks [26, 40, 43-45, 58, 63, 81, 94, 104]. Most of the studies suggest that there was no 
or minimal evidence of person-to-person transmission during HEV outbreak. However, there 
were variations between studies to determine the occurrence of person-to-person 
transmission. Only one study suggested that person-to-person transmission might be 
responsible for HEV outbreak in a large and prolonged HEV outbreak in Uganda [81]. This 
conclusion was supported by several observations: 1) prolonged outbreak, which occurred 
about 2 years; 2) HEV was undetectable from the environment (water sources) and the 
zoonotic sources (pig); 3) improvement of hygiene (such as chlorination) could not stop the 
epidemic; and 4) evidence of close contact and time interval between index and secondary 
cases within household [81]. However, some inquiries have been questioned to argue 
against the evidence [107, 108]. The relative contribution of person-to-person transmission 
therefore deserves further investigation, especially in the large and prolonged outbreaks. As 
HEV transmission occur via fecal-oral route, person-to-person transmission might be 
possible.  
Control measures 
To cope with the outbreak, control measures should be taken to prevent more additional 
cases. However, not all studies described specifically the control measures taken during the 
outbreaks (Table 2). Chlorination of the water supply was the most reported control 
measures during HEV outbreaks, followed by repairing of the broken water pipeline. 
Improving general hygienic precaution (such as hand washing and boiling of drinking water) 
is a simple and low cost intervention to prevent HEV transmission during outbreak. Provision 
of an alternatively safe water supply (such as providing containers of safe drinking water) 
was reported. Lack of proper facilities for disposal of human feces is one of the underlying 
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factors responsible for outbreaks, especially in refugee camps. Therefore, hastening of 
latrine construction was reported as a control measure during HEV outbreaks in the refugee 
camps.  
No Intervention References 
1 Chlorination of the water supply [26]; [37]; [38]; [40]; [44]; [45]; [54]; 
[63]; [65]; [77]; [83] 
2 Repair of water pipelines [26]; [45]; [46]; [49]; [53]; [57]; [59]; 
[61]; [62]; [65] 
3 Improving general hygienic precautions 
(handwashing, boiling water) 
[26]; [38]; [65]; [68]; [75]; [83] 
4 Provision of alternate water supply [27]; [30]; [65] 
5 Hastening latrine construction. [68]; [83] 
6 Surveillance for additional cases (active case 
finding) 
[26]; [75] 
7 Simultaneous closure of of the water supply [24]; [27] 
8 Improving safe drinking water availability [75] 
9 Training of health care workers [68] 
10 Increasing community awareness [68] 
Table 2. Control measures of HEV outbreak.  
 
 
Figure 5. HEV genotype distribution responsible for the outbreaks. (Note: Sudan and South Sudan are 
regarded as one country.) 
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Country Year HEV Region sequenced HEV Genotype Reference 
Asia     
India 
 
2008 RNA-dependent RNA 
polymerase (RdRp gene) 
Genotype 1, subtype A 
 
[62] 
India 2010 ORF1 Genotype 1, subtype A [63] 
India 1981 RNA polymerase Genotype 1, subtype A [109] 
India 1975 - 1976 RNA polymerase Genotype 1, subtype B [109] 
India 1984 RNA polymerase Genotype 1, subtype A [109] 
India 1990 RNA polymerase Genotype 1, subtype A [109] 
India 1991 RNA polymerase Genotype 1, subtype D [109] 
Kyrgyzstan 1987 - 1989 ORF 2 (nt 5972-6319) and 
ORF 1 (nt 71-353) 
Genotype 1 [114] 
Bangladesh 2010 ORF2 Genotype 1, subtype A [23] 
Turkmenistan 1985 ORF2 Genotype 1 [33] 
Pakistan 1987 Full genome (7195 nt) Genotype 1, subtype B [29]; [109] 
China  1986 - 1988 Full genome Genotype 1, subtype B [21] 
Japan 2005 ORF1 Genotype 3 [20] 
Africa     
Morocco 1994 nt 5,014 - 7,186 (the 3’-
terminal region of ORF1, full 
length ORF2 and ORF3, and 
a portion of the 3’-
noncoding region) 
Genotype 1 [95] 
Central African 
Republic 
2002 NS Genotype 1 and 2 [77] 
Sudan and Chad 2004 ORF 2 nucleotides 6,653-
7,100 
Genotype 1 
 
[76] 
 
Chad  1983 - 1984 ORF2 and ORF3 Genotype 1, subtype C [89]; [109]  
Uganda 2007 - 2009 
 
ORF2 Genotype 1 
 
[80] 
Algeria 1986 - 1987 ORF2 Genotype 1 
 
[91] 
 
Algeria 1979 - 1980 ORF2 and ORF3 Genotype 1, subtype C [89]; [109] 
Namibia 1995 - 1996 451 bp region of a 
subgenomic fragment from 
the 3’ end of the genome in 
ORF2 
Genotype 2 [93] 
Europe     
United Kingdom 2008 NS Genotype 3 [101] 
Italy 2011 ORF1 and ORF2 Genotype 4 [102] 
America     
Cuba 1999 and 
2005 
ORF1 Genotype 1 [106] 
Mexico  1986 Nearly complete genome 
(7185 nt) 
Genotype 2 [109]; [110]  
Table 3. HEV genotype responsible for the outbreak. 
HEV genotypes responsible for the outbreak 
Data on the genotype responsible for HEV outbreak were available only from limited number 
of studies (as summarized in Table 3 and shown in Figure 5). The open reading fragment 2 
(ORF2) region was the most frequently region sequenced to determine the HEV genotype, 
followed by ORF 1 region (including RNA polymerase region). In accordance with the global 
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distribution of the HEV genotypes, genotype 1 and 2 were mainly responsible for the 
outbreaks occurred in developing countries (Asia and Africa), while genotype 3 and 4 were 
responsible for small outbreaks in the western world (Europe), i.e. United Kingdom [101] 
and Italy [102]. Genotype 2 was responsible for outbreaks in CAR [77], Namibia [93], and 
Mexico [109, 110]. In Asia, all but one outbreak were due to genotype 1. In Asia and Africa, it 
seems that genotype 1 was more responsible than genotype 2 as the causative agent of HEV 
outbreaks. Moreover, genotype 1 was also responsible for several large HEV outbreaks, such 
as in China (1986-1988, with 120,000 suspected cases) [21]; India (2008, with 23,915 
suspected cases) [62]; Turkmenistan (1985, with 16,175 suspected cases) [33]; and Uganda 
(2007 - 2009, with >10,000 suspected cases) [80]. No large HEV outbreaks so far were 
reported due to genotype 3 and 4. 
Discussion 
Historically, epidemic of jaundice and hepatitis with high attack rates in young adults and 
predominant or exclusive deaths among pregnant women was believed to be due to HEV [9]. 
The first laboratory-confirmed HEV outbreak is Delhi outbreak (1955 - 1956) [111]. Since 
then, many HEV outbreaks were reported in the literature, especially after the availability of 
HEV diagnostic assay (HEV serology and RT-PCR). Our data suggest that HEV outbreak 
occurred repeatedly up to the recent years in many different countries, especially in Asian 
and African countries. It indicates that HEV outbreak is not new, yet it is a continuous health 
problem in developing countries. It is highly possible that our data only represent a tip of the 
iceberg. A higher percentage of HEV outbreaks that have occurred in many (other) countries 
might be not reported and not well-documented, mainly due to the absence of a 
surveillance system of HEV infection or lack of serology and PCR confirmation. For example, 
about 33 outbreaks of acute viral hepatitis in Cuba were not well-reported and therefore 
excluded from our analysis [112]. Similarly, reports from 10 different Asian and African 
countries were not well-documented [113]. We also found a report of an HEV sequence 
derived from a Kyrgyztan outbreak, but we could not find the outbreak description [114]. 
Consequently, the actual number of HEV outbreaks should be much higher than what we 
present in this study. Therefore, the problem of HEV infection should not be underestimated 
by national and international health agencies. 
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HEV represents a significant health problem, especially in the developing countries. Acute 
sporadic form of HEV disease is the most frequent cause of acute viral hepatitis globally [2]. 
Epidemics of HEV, either in a small or large scale, occur periodically up to this moment, as 
reported from India [115, 116]. Many large outbreaks of hepatitis E have been reported 
especially from west and north part of India and thus represent a major health problem in 
the country (Figure 3). Several outbreaks have also been reported from neighboring 
countries such as Bangladesh, Pakistan, and Nepal (Figure 2). The Indian subcontinent, 
therefore, could be the best representation of areas with high endemicity of HEV infection. 
In recent years, several large HEV outbreaks reported from refugee settlements. Because of 
warfare and conflict in some African countries, displaced populations occupy refugee 
settlements and this has led to a new epidemic setting for HEV [67, 68, 70, 75, 92]. As the 
disease is mainly transmitted by fecal contamination of drinking water, the density of the 
resident population, a limited access to a good quality of drinking water, lack of adequate 
sanitation and personal hygiene, may predispose to the occurrence of HEV outbreaks in 
refugee camps [117]. Currently, increasing number of refugee population, resulted from 
wars, persecution, conflict and human rights violations, imposes one of the most pressing 
global challenges. This led to a complex humanitarian crisis, partly due to lack access of 
health service [118]. The most common causes of death in this population are 
communicable diseases, such as diarrheal diseases, measles, and malaria [119]. These 
refugee camps are potential risk settings for water-borne outbreaks including HEV, cholera, 
HAV, and rotavirus [120-123], and they deserve the access of more timely, appropriate, and 
quality health-care services.  
Although our data showed a limited number of reported HEV outbreaks in European and 
American countries, we cannot fully exclude the possibility that HEV could be the future 
threat in the region. HEV was considered as one of the emerging zoonotic swine pathogens 
[124]. Autochthonous HEV infection was reported from several countries in Europe, with 
evidence of zoonotic transmission from pigs [125]. A recent study has reported a small 
outbreak in China, which is caused by the zoonotic genotype 4 HEV and is related to the food 
in the company's cafeteria [126]. Therefore, it is highly possible that HEV genotypes 3 and 4 
could be the potential cause of small-scale outbreaks in the developed countries in the near 
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future, especially with the lack of transmission route identification and the lack of effective 
intervention strategies. 
During HEV infection, the risk of progression towards fulminant hepatitis is higher among 
pregnant women as compared to men and non-pregnant women [127, 128]. Several studies 
during HEV outbreaks demonstrated that HEV infection could result in worse maternal and 
fetal outcome [22, 74, 78]. Similarly, studies of pregnant women presenting with jaundice 
due to acute viral hepatitis in hospital-based setting showed that FHF and mortality rate was 
greater in HEV-infected women than in non-HEV-infected women [128]. HEV-infected 
pregnant women have also a significantly higher risk of developing obstetric complications, 
intrauterine fetal death, preterm delivery, and stillbirth as compared to non-HEV-infected 
pregnant women [128]. It is estimated that HEV is responsible for ~9.8% of pregnancy-
associated deaths in Bangladesh and about 10,500 of annual maternal death in southern 
Asia [129]. Some immunological and hormonal factors have been associated with high 
mortality rate in HEV-infected pregnant women [130-132]. Interventions to prevent the 
occurrence of HEV infections in this high-risk population are therefore urgently required 
[129]. 
Most studies reported fecal contamination of drinking water as the major route of 
transmission during HEV outbreak. The most commonly reported underlying cause of this 
contamination is leakage of water pipeline distribution system, either due to damaged or 
poor construction. As the water pipelines located close to drain or sewerage system, the 
damaged facilitate mixing of sewage materials and drinking water supplied to the household, 
causing water-borne outbreaks such as HEV, hepatitis A virus (HAV), shigellosis and cholera 
[133-135]. A water-borne outbreak of pesticide poisoning was also reported due to damage 
of water pipeline distribution system [136]. Therefore, this kind of outbreak could be 
prevented by proper construction of water pipelines, keeping them away from the drain 
system, and also by monitoring of pipelines for damage.  
Since HEV outbreak is mainly due to contaminated-drinking water, its control would depend 
upon improved hygiene and sanitation, such as increased access to safe water, provision of 
soap and chlorine tablets to improve personal hygiene, and proper sewage disposal. During 
outbreak, it is pivotal to intensively investigate the suspected underlying cause and then 
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initiate targeted intervention to control and stop the outbreak [83]. Mass vaccination of HEV 
could be another effective strategy to control the outbreaks. Currently, an HEV vaccine has 
already been licensed for use in China [137] and give an insight that HEV is a vaccine-
preventable disease [111]. Comparing the experience with HAV vaccination as an effective 
measure to control HAV outbreaks, the HEV vaccine holds promises to control large 
outbreaks. However, it is not known whether the current vaccine works fast enough to 
effectively protect the exposed population for clinical disease during an HEV outbreak and 
how long the protection will be afforded. Moreover, it is also not known whether the 
vaccine is safe and effective in pregnant women, the population in which a high fatality rate 
was seen during the outbreak [129]. In fact, there is disagreement among the HEV experts 
whether the current licensed vaccine is necessary to prevent outbreak following the recent 
earthquake in Nepal [138-140]. 
Limitation of the published literature 
There are some limitations in the published literature of HEV outbreaks. First, the studies 
used different criteria to define suspected cases during HEV outbreak. Some studies only 
used physical symptoms of acute hepatitis (such as jaundice) [27]; whereas other studies 
included laboratory criteria such as liver enzyme (aspartate and alanine aminotransferase) 
[47, 62]. The differences in the criteria may then influences the different calculations of the 
attack rate. Second, the studies on HEV outbreak used different assays and diagnostic 
methods to confirm the presence of HEV as the causative agent of outbreak. Therefore, it is 
difficult to compare the validity of the reports. Third, the outbreaks studied varied in the 
proportion of suspected cases to be tested for HEV. Consequently, the proportion of 
confirmed HEV cases differs markedly between outbreaks. Moreover, these data also 
suggest that some of these outbreaks might have been caused not only by a single agent 
(HEV), but also another agent that may also spread by fecal-oral route, especially HAV. 
Finally, the outbreak studies used different epidemiological methods to investigate the 
outbreaks. Some of those outbreaks were investigated thoroughly, but some of them were 
not. The full versions of epidemiological investigations of several Indian epidemics were not 
available, even though the outbreaks involved a large scale, in which thousands of people 
were affected [13]. 
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Conclusions 
The available data suggest that HEV outbreaks occur repeatedly in many developing 
countries, especially in India and become a significant health problem in Asian and African 
continent, even before its identification. These outbreaks were mainly due to HEV genotype 
1 and 2. Prevention of HEV outbreak in the future is therefore required to reduce the burden 
of HEV disease. The HEV vaccine, which has been licensed in China, could be potentially used 
in the control of HEV infection in the future. However, its safety (especially in pregnant 
women) and efficacy during the outbreak require further investigation. Meanwhile, the 
preventive measures of HEV outbreak would mainly depend upon improved sanitation and 
hygiene. 
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Summary 
Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis worldwide and an 
emerging cause of chronic infection in immunocompromised patients. As with viral 
infections in general, immune responses are critical to determine the outcome of HEV 
infection. Accumulating studies in cell culture, animal models and patients have improved 
our understanding of HEV immunopathogenesis and informed the development of new 
antiviral therapies and effective vaccines. In this review, we discuss the recent progress on 
innate and adaptive immunity in HEV infection, and the implications for the devolopment of 
effective vaccines and immune-based therapies.  
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Introduction 
Hepatitis E virus (HEV) infection is the predominant cause of acute hepatitis worldwide.1 It is 
also the causative agent of many large hepatitis outbreaks and continuously poses a serious 
threat, especially in developing countries.2 HEV was initially thought to only cause acute 
infection where most patients remain asymptomatic.1 However, it has recently been 
demonstrated that HEV can cause chronic infection and rapidly lead to cirrhosis and liver 
failure, mainly in immunocompromised organ transplant recipients.3 Ribavirin (RBV) 
monotherapy may be effective as off-label treatment for chronic hepatitis E.4 However, 
treatment failure occurs in a subset of patients, partially related to the pre-existence or 
subsequent development of mutations in the viral genome.5 Several mutations in HEV 
genome, including G1634R and Y1320H, have been associated with RBV treatment failiure.6 
In addition, reccurences of HEV viremia were observed in a substantial proportion of 
patients following RBV treatment cessation.4 Thus, new effective therapies for HEV infection 
are urgently needed. 
The host immune system is essential to eliminate invading viral pathogens. The recognition 
of viral components produces antiviral cytokines, including type I interferons (IFNs) and 
tumor necrosis factor α (TNFα), to provide a rapid response against the infection.7 These 
components of innate and non-specific antiviral immunity are also pivotal to promote the 
development of more specific adaptive immunity, including virus-specific B and T cells, to 
facilitate a complete eradication of the virus.8 Recent advances in HEV cell culture and 
animal models, as well as studies in patients, have improved our understanding of this 
complex virus-host immunopathogenesis. In this review, we summarise the current 
understanding of innate and adaptive immunity against HEV and its implications for the 
development of HEV vaccines and immune-based therapy.  
Innate Immunity against HEV   
IFN responses following viral infections  
HEV is a small, non-enveloped and positive-strand RNA virus with one serotype but several 
genotypes. Its complete genome is 7.2 kb in length and contains 3 open reading frames 
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(ORF1, ORF2 and ORF3). Recently, a novel ORF (ORF4) is identified in HEV genotype 1 (Figure 
1).1,9  
 
Figure 1. Molecular organization of HEV genome. The HEV genome is a single-stranded positive RNA, 
7.2 kb in length. It has a 7-methylguanylate (m7G) at the 5’ end and a poly-A tail at the 3’ end. ORF1 is 
the largest open reading frame. It has several predicted domains, including methyltransferase (Met), 
Y domain (Y), papain-like cysteine protease (PCP), hypervariable region (HVR), proline-rich domain 
(Pro), X domain (X), helicase (Hel), and RNA-dependent RNA polymerase (RdRp). ORF2 and ORF3 are 
encoded by a subgenomic RNA (2.2 kb). ORF2 is the capsid protein. ORF3 partially overlaps with 
ORF2. An insertion of human sequences (S17) into the HVR domain increases cell culture adaptation 
of HEV genotype 3 Kernow-C1 p6 strain. The novel ORF4 protein (nt 2835-3308), which is overlapped 
with ORF1, is only identified in genotype 1.  
 
Upon infection, HEV will likely be recognized by one or more pattern-recognition receptor 
(PRR) specific for RNA viruses. Foreign RNA sensors include RIG-I-like receptors (RLR) and 
Toll-like receptors (TLR) which sense the presence of viral RNA products in the cytoplasm 
and endosomal compartment, respectively. Among members of RLR are retinoic acid 
inducible gene-I (RIG-I, also known as DDX58) and melanoma differentiation associated gene 
5 (MDA5, also known as IFIH1).7 Among 13 different known TLRs, TLR3, 7 and 8 are the main 
ones responsible for sensing virus-derived RNA.10 Viral recognition by RLR and TLR activates 
their downstream signaling pathways mediated by interferon regulatory factor 3 (IRF3), IRF7 
and nuclear factor kappa-B (NF-κB). Ultimately, these signaling events increase production of 
IFNs and other pro-inflammatory cytokines.7,10 
Once produced, IFNs signal via autocrine and paracrine routes to combat the invading 
viruses. IFNs consist of three different types, type I (IFNα, IFNβ, IFNδ, and other sub-types), 
type II (IFNγ, the only member) and type III (IFNλ1, IFNλ2, IFNλ3 and IFNλ4).11,12 Binding of 
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IFNs to their corresponding receptors activates their common downstream signaling 
pathway, involving classical Janus kinase-signal transducer and activator of transcription 
(JAK-STAT) pathway. Following activation by type I and III IFNs, STAT1 and STAT2 proteins 
are phosphorylated and associate with IRF9. This complex, designated as interferon 
stimulated gene factor 3 (ISGF3), then translocates to the nuclues, to induce transcription of 
hundreds of IFN-stimulated genes (ISGs).11,12 ISGs are the ultimate effector antiviral 
molecules which cooperatively establish an antiviral state against diverse types of viruses.13 
Given the vital role of IFNs in early defence mechanisms, many viruses, including HEV, have 
developed strategies to subvert IFN induction and also IFN-activated JAK-STAT signaling. 
Induction and antagonism of IFNs by HEV 
RIG-I and MDA5 are involved in the HEV-induced IFN response.14 HEV induces predominantly 
a type III IFN response, rather than a type I IFN, to control viral growth.14 Furthermore, lack 
of both RIG-I and TLR3 signaling facilitates HEV replication which can be reversed by 
reconstitution of RIG-I and TLR3.15 This suggests they have functional roles in HEV sensing 
and activation of the downstream anti-viral signaling pathway.15 Consistently, inhibition of 
IRF3 phosphorylation, the key downstream signaling pathway of TLR3, RIG-I and MDA5, 
notably increases HEV replication.14,15  
ORF3 of HEV genotype 4 induces signal regulator protein α (SIRP-α) expression which blocks 
phosphorylation of IRF3 and inhibits IFNβ induction.16 This counteracting mechanism may 
explain the low induction of IFNβ at the early phase of HEV infection, even though it is not 
effective at the later phases.17 Another mechanism involves the X domain of ORF1 which 
blocks poly(I•C)-induced phosphorylation of IRF3; while the PCP domain inhibits activation 
of RIG-I and TBK-1 via its deubiquitinase activity.18 Inhibition of IFN production may 
subsequently block the induction of ISG expression. However, in vitro cell culture studies14,19 
as well as studies in mice with humanized liver20 demonstrated ISG induction upon HEV 
infections. These results indicate that HEV has developed strategies to dampen IFN induction, 
but not a complete inhibition. Interestingly, studies in chimpanzees found that acute HEV 
showed a lower number and magnitude of ISG induction as compared to acute hepatitis C 
virus (HCV), suggesting that HCV is a more potent inducer of IFN response than HEV.21 
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Intriguingly, ORF3 protein of HEV genotype 1 and 3 has been shown to augment type I (IFNβ) 
production. ORF3 protein increases the protein levels and activation of RIG-I.22 The exact 
role of this ORF3-mediated IFNβ induction during various stages of HEV replication is unclear. 
It seems that HEV tightly controls the balance between inhibition and enhancement of IFN 
production at different stages of its life cycle to favour its existence in the infected host 
(Figure 2). These results also indicate that induction or inhibition of IFN production by HEV 
are genotype-specific. 
The role of ISGs in HEV infection 
In kidney transplant recipients with chronic HEV, cross-sectional microarray studies have 
identified the upregulation of 25 ISGs in blood samples. Surprisingly, a higher expression of 
these ISGs was associated with viral persistence23, raising the intriguing question whether 
they serve as an indicator of active virus-host interaction or functionally combat the 
infection. 
Many ISGs are also basally expressed at certain levels in homeostatic conditions without IFN 
stimulation. A prominent role of this basal IFN signaling has been described in restricting 
HEV replication. Gene silencing of JAK1 expression levels as well as the individual component 
of ISGF3 complex facilitates HEV replication.24,25 In these STAT1, STAT2 and IRF9 deficient 
cells, a notably lower ISG expression was found that may explain the increased HEV 
replication. Without IFN activation, the intact unphosphorylated ISGF3 complex is necessary 
to maintain basal ISG expression which subsequently provides a quick and timely immune 
response against invading viral pathogens, including HEV.25 
Many screening efforts have been performed to characterize individual antiviral ISGs against 
specific or a wide-spectrum of viruses, either via gene knockdown or ectopic over-expression 
approaches.13 Among the hundreds of ISGs, only a subset executed specific or broad antiviral 
effects.26,27 Profiling these well-known antiviral ISGs has identified RIG-I, MDA5 and IRF1 as 
potent anti-HEV effectors (Figure 2).28,29 Interestingly, both IRF1 and RIG-I activate a panel of 
ISGs without inducing IFN production.28,29 Thus, these ISGs likely activate a general host 
immune defence mechanism to indirectly combat HEV infection. ISG15 is induced upon HEV 
infection, but has no effect on viral replication. However, it negatively regulates the anti-HEV 
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effect of IFN treatment30, illustrating the diversity and complexity of ISGs in regulating HEV 
infection.  
 
Figure 2.The interferon (IFN) pathway and HEV infection. Upon infection, HEV will likely be 
recognized by the host pattern-recognition receptor. There are several receptors, including RIG-I, 
MDA5 and TLR3, specific for RNA viruses. The recognition activates their downstream signaling 
pathway, involving IRF3 and NFκB and results in IFN production. The subsequent binding of IFNs to 
their corresponding receptors leads to STAT1 and STAT2 phosphorylation. Then, phosphorylated 
STAT1 and STAT2 binds IRF9, to form ISGF3 (IFN-stimulated gene factor 3) complex. This complex 
binds to a specific DNA promoter sequence, ISRE (IFN-stimulated response element) and induces the 
transcription of hundreds ISGs (IFN-stimulated genes). RIG-I, MDA5 and IRF1 have been identified as 
potent anti-HEV ISGs. IRF1 inhibits HEV via the activation of the JAK-STAT pathway. NF-κB, the key 
downstream signaling of TNFα, also has the ability to directly stimulate ISGs. On the other hand, HEV 
has developed strategies to circumvent this innate IFN response. ORF1 inhibits RIG-I and TBK-1 
activation via its deubiquitinase activity. ORF3 blocks STAT1 phosphorylation and thereby inhibits 
IFN-initiated JAK-STAT signaling. ORF3 also induces SIRP-α that subsequently blocks IRF3 
phosphorylation. At the same time, however, ORF3 enhances innate immune responses by a direct 
interaction with RIG-I.  
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TNFα and NF-κB signaling pathway 
Genetic polymorphisms in the promoter regions of the TNFα gene are associated with 
human susceptibility to HEV.31 A significantly higher level of TNFα was found in HEV-infected 
pregnant women and was associated with severe outcomes.32 
Transcriptional analysis of HEV-infected lung epithelial cell lines revealed upregulation of 
pro-inflammataory cytokines, including interleukin 6 (IL-6), IL-8 and TNFα.17 TNFα treatment 
moderately inhibits HEV replication, and the combination of TNFα and IFNα produces 
synergistic anti-HEV effects.33 Interestingly, TNFα can independently induce ISG expression 
via NF-κB complex, the key downstream component, explaining the possible mechanism of 
enhancing the antiviral effect of IFN.33 Consistently, patients treated with anti-TNFα 
triggered exacerbation of HEV34, indicating its important role in controlling HEV. 
On the other hand, HEV has a capacity to subvert NF-κB signaling. The P2 domain of ORF3 
inhibits TLR3- and TLR4-induced NF-κB signaling. Consequently, the production of pro-
inflammatory cytokines, including TNFα, IL-8 and IL-1β, is significantly reduced.35,36 
Mechanistic studies revealed that these events are mediated via inhibition of TNF receptor 
1-associated death domain protein (TRADD) and reduction of receptor-interacting protein 
kinase 1 (RIP1) ubiquitination.35 Intriguingly, the P2 domain has also been reported to block 
TNFα-induced NF-κB signaling via stimulation of TNFα-induced protein 3 (TNFAIP3, also 
known as A20), a negative regulator of NF-κB signaling.37 In addition, ORF2 protein impedes 
NF-κB signaling by preventing IκBα degradation.38,39 Thus, HEV has also evolved effective 
strategies to block TLR- and TNFα-induced NF-κB signaling pathway. 
The role of innate immune cells 
Although cellular innate immunity has been extensively investigated in HEV infection, the 
role of different types of innate immune cells has been rarely studied in the context of HEV 
infection. The frequencies of natural killer (NK) and natural killer T (NKT) cells in the 
peripheral blood of acute HEV patients are lower than in healthy controls.40 However, a 
considerably higher proportion of those cells express activation markers in acute HEV 
patients. During the convalescent phases, these changes become normalized.40 It is not clear 
whether the reduced frequency of NK and NKT cells in the blood is the consequence of their 
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migration into the inflamed liver, and their function in this context remains unknown. Thus, 
furture reseach is required to delineate the role of these innate immune cells in HEV 
infection, in particular on dendritic cells (DC) that are the key players of innate immunity 
against viral and bacterial infections.  
Adaptive Immunity against HEV 
Understanding of the importance of adaptive immunity in HEV elimination primarily derives 
from organ transplant patients receiving immunosuppressive therapy. These medications 
are aimed to prevent organ rejection mainly by inhibiting T cells. The majority of these 
patients fails to spontaneuosly clear HEV infection and develop chronic infection.3,41 The use 
of tacrolimus has been associated with chronic progression, probably due to the potent 
immunosuppressive effect.41,42 Furthermore, viral clearance was achieved after dose 
reduction of immunosuppressants in a subset of patients, confirming the essential role of 
host immunity in HEV clearance.42  
Humoral immune responses 
Studies in non-human primates indicated that anti-HEV specific antibodies, whether due to 
prior infection or after passive and active immunization, protected the animals against 
subsequent challenges with HEV.43-47 It is well-known that HEV infection can induce the 
development of specific antibodies early during infection that play a role in the clinical 
outcome of acute HEV infection in humans.48 In a typical acute HEV infection, anti-HEV IgM 
reaches a maximum level at 6-8 weeks after infection and becomes undetectable after 5-6 
months. A gradual increase of anti-HEV IgG is shown during the acute and convalescent 
phases and may persist for life to provide immunity to the host.1  
As a non-enveloped virus, the ORF2-encoded capsid is the main target of anti-HEV 
neutralizing antibodies and a number of immunodominant epitopes have been identified in 
this region.49,50 However, a quasi-enveloped virion is identified in HEV-infected patients. HEV 
virions found in bile and feces are non-enveloped, while those in the blood and culture 
supernatant are associated with lipids derived from the cellular membrane, thus resembling 
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enveloped viruses.51 These lipid-associated HEV virions are more resistant to anti-HEV 
antibodies52, suggesting HEV strategies to evade humoral immune responses. 
The protective role of naturally-acquired antibody responses has been demonstrated in 
outbreak and non-outbreak settings.53-56 Similarly, passive anti-HEV IgG immunization is also 
protective for pregnant women in endemic settings.57 Persistence of anti-HEV IgG has been 
observed at 5-14 years after the occurrence of an outbreak.58,59 However, a gradual 
substantial loss of anti-HEV IgG has been observed in other studies.60,61 This suggests that 
repeated exposure to natural infection maintains herd immunity against HEV. Of note, the 
progressive loss of HEV-specific antibodies may be responsible for repeated outbreaks in the 
same areas.61   
HEV-specific T cell response 
The activation of HEV-specific CD4+ and CD8+ T cell responses has been detected in patients 
acutely infected with HEV. The functionality of these HEV-specific T cell responses has been 
demonstrated in vitro, as characterized by proliferation and cytokine production, including 
TNFα and IFNγ.62-71 Noteworthy, the frequency as well as the overall strength and breadth of 
these responses vary between studies, reflecting the different assays and HEV-derived 
proteins (peptides) used for in vitro stimulation.  
A longitudinal analysis of acute-resolving HEV patients demonstrated a rapid decline of HEV-
specific T cell responses during the first few weeks after primary infection.64,72 Importantly, 
HEV-specific T cell responses have been detected years after HEV clearance both in humans 
and chimpanzee, indicating the successful generation of long-lived HEV-specific memory T 
cells.63,68,72,73 
Infiltration of HEV-specific T cells into the liver could also contribute to the liver damage due 
to their cytotoxic (perforin and granzyme) activity. Indeed, a prominent infiltration of CD8+ T 
cells was found in the liver biopsy from HEV-induced acute liver failure.74 Similarly, 
infiltration of CD8+ T cells has been shown in the liver biopsies of HEV patients dying of 
fulminant hepatic failure.75 In these patients, gene expression profiles demonstrated a 
significant overexpression of genes associated with cytotoxic activity.75 In addition, fewer 
IFNγ- and TNFα-producing CD4+ T cells were found in HEV-induced fulminant hepatic failure 
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compared to acute-resolving HEV patients.65 However, it is not clear whether these weaker 
responses are the causes or consequences of disease progression. Collectively, these results 
suggest that T cell responses are associated with HEV immunopathogenesis in the infected 
liver.  
Several studies mapped the dominant epitopes eliciting T cell responses in HEV-infected 
patients. Specific regions in ORF2 are commonly targeted by HEV-specific T cells.63,66,68,72,76 
These targeted epitopes are mostly located at relatively conserved regions of the HEV 
genome.72 However, HEV-specific T cells against ORF1 have also been demonstrated.71 
Interestingly, HEV genotype 3-infected patients mount detectable responses upon 
stimulation with genotype 1-derived peptides and vice versa, suggesting cross-genotype 
protection.68,72 The generation of HEV-specific B and T cell responses, along with anti-HEV 
treatments, likely exert a selective pressure towards HEV genome variability, leading to an 
increased virus quasispecies and subsequently influence HEV adaptation and 
pathogenesis.77-79  
T cell exhaustion in chronic hepatitis E 
A continuously high antigen stimulation may lead to T cell exhaustion, as characterized by 
impaired proliferation, cytokine production and cyototoxic activity. This phenomenon has 
been well described in several chronic viral infections, including hepatitis B virus (HBV), HCV 
and human immunodeficiency virus (HIV).80 Several factors contribute to the dysfunctional 
state of T cells in chronic viral infections, such as negative regulation by regulatory T cells 
(Treg) and IL10 as well as upregulation of inhibitory receptors, i.e. PD-1 and CTLA-4. T cell 
exhaustion may limit immunopathology in the infected host, however, it favours viral growth 
and facilitates viral persistence.81  
Dysfunctional HEV-specific T cell responses have been found in chronic HEV-infected 
patients and are associated with high HEV-antigen levels.71,73 It needs to be further 
investigated whether these dysfunctional HEV-specific T cell responses were specifically due 
to chronic HEV or due to immunosuppressive therapy in general. In contrast, a detectable 
proliferation and IFNγ production of HEV-specific T cell responses were observed in those 
who resolved the HEV infection.73 Interestingly, in chronic HEV patients who achieved viral 
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clearance, these T cell responses were improved73, even though this phenomenon was not 
observed in another study.71 These phenomena were probably associated with different 
treatments received by these patients, including dose-reduction of immunosuppressive 
medications and antiviral RBV therapy. 
Following PBMC stimulation with HEV-derived pools, higher IL-10 production was observed 
in HEV-infected organ transplant recipients who progressed into chronic HEV, as compared 
to those who cleared the infection73, suggesting a role for IL-10 in regulation of T cell 
function. An increased frequency of CD4+ CD25+ Foxp3+ and an elevated level of IL-10 were 
found in the peripheral blood of acute HEV patients.82 Future studies are encouraged to 
further investigate the role of negative regulation by Treg and IL-10 in acute and chronic HEV 
patients.  
Development of HEV Vaccines  
The protective role of HEV-specific antibodies provides the foundation for vaccine 
development. A safe and efficacious vaccine is crucial in public health community to reduce 
the burden of HEV diseases globally. It has been successfully demonstrated in clinical trials 
that anti-HEV antibodies can be induced by vaccination. In a large phase III clinical trial in 
China, virus-like particles (VLP) HEV239 vaccine (Hecolin®), which is derived from aa. 368-
606 pORF2 of genotype 1, showed a high efficacy to prevent HEV infection.83 Follow up 
studies have demonstrated that this high efficacy is maintained to effectively protect the 
population against HEV infection.84 It is predicted that HEV239 vaccine-induced IgG is 
detectable to provide protection for nearly a lifetime.85,86 Interestingly, the study area is 
endemic for HEV genotype 4, suggesting that the vaccine-induced antibodies conferred 
cross-genotype protection, consistent with the findings from the previous animal 
studies.46,87 This vaccine has now been approved by the China Food and Drug 
Administration.88 Another vaccine candidate, a genotype 1 recombinant protein (rHEV), is 
also efficacious against HEV in a phase II clinical trial conducted in Nepal.89 In addition, some 
novel HEV vaccines, including genotype 4-derived peptide vaccines, are now in different 
stages of development.90-93 
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Exploiting the role of HEV-specific CD4+ and CD8+ T cells in HEV clearance should contribute 
to the development of either prophylactic or therapeutic HEV vaccines. Since Hecolin® 
mainly induce humoral responses, there is no evidence of the involvement of HEV-specific T 
cells in Hecolin®-induced protective immunity. Therefore, it would be valuable to carefully 
examine HEV-specific T cell responses in Hecolin®-vaccinated individuals. 
In fact, only one single serotype of HEV is recognized despite the presence of different 
genotypes. However, since there is no definitive evidence that Hecolin® could confer 
protection against HEV genotypes 2 or 3, further studies are required to assess the vaccine 
efficacy in different endemic areas. In addition, it is important to study the safety and 
efficacy of HEV vaccine in pregnant women94, the population in which a high case fatality 
rate was observed during many HEV outbreaks. The trial is currently conducted in a rural 
area in Bangladesh, involving more than 20,000 women of childbearing age by 
administration of Hecolin® at day 0, 1 month and 6 month (NCT02759991). 
Large and prolonged HEV outbreaks are frequently seen in Asian and African countries.2 It 
has been suggested that Hecolin® could be valuable in preventing severe morbidity and 
mortality in this epidemic setting, such as in a recent outbreak in Nepal.95,96 However, the 
effectiveness of HEV vaccine is not known to provide a quick protection for the exposed 
populations during HEV outbreaks. Therefore, other HEV experts argue against its usefulness 
for mass vaccination during HEV outbreaks.97 
Immune-based Therapies for HEV  
IFN treatment  
In cell culture, the response of HEV infection to IFN treatment is moderate.14,19,24,98,99 Only 
IFNα exerts a considerable anti-HEV effect24,100; whereas other types, including IFNβ, IFNγ, 
IFNλ1, IFNλ2, and IFNλ3, do not show clear antiviral activity against HEV.24 HEV blocks IFNα-
induced ISG expression via inhibition of STAT1 phosphorylation mediated by ORF3 protein.98 
Interestingly, recent studies in humanized mice models have documented a rapid clearance 
of HEV genotype 1 and 3 upon pegylated IFNα (PEG-IFNα) treatment.101 
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In the clinic, several retrospective case series and case reports have documented an efficacy 
of PEG-IFNα to treat chronic HEV patients.4,24,102 However, it is associated with severe 
adverse events, including graft rejection and thrombocytopenia. Therefore, PEG-IFNα is not 
recommended as the first-line therapy in chronic HEV patients.4,103  
Novel immune-based therapeutic strategies  
Dissecting immune responses responsible for HEV clearance provides proof-of-concept for 
designing novel anti-HEV therapy, which ideally should circumvent the limitations of IFNα 
treatment.4 The identification of specific anti-HEV ISGs, i.e. RIG-I, potentially guides the 
development of new effective antiviral therapies against HEV with limited side effects.28 A 
number of RIG-I agonists are currently in various phases of clinical trials to treat viral 
infections104, deserving its evaluation as novel anti-HEV therapies. 
Importantly, manipulation of T cell immunity is a potential strategy for immune-based 
interventions in chronic viral infections.81 It has been shown that restoration of HEV-specific 
T cells is achieved by blocking inhibitory pathways through PD-1 and CTLA-4.73 However, the 
responses to individual inhibitory receptor blockade are patient-specific and therefore 
challenges the development of personalized immunotherapy by manipulating inhibitory 
receptor pathway.73 
Another way to induce a powerful immune response is via T cell-based vaccines. Several 
strategies have been developed to induce specific T cell responses, including peptide-based 
CD8+ T cell vaccines or CD4+ helper T cell-targeted vaccines.105,106 Such approaches have 
been employed for treating cancer and chronic HBV infection.105-107 Identification and 
optimization of the target epitopes are essential in designing peptide-based T cell vaccines 
against HEV.68,71,72 These vaccine strategies may be useful for chronic HEV patients. However, 
the major drawback of their application in HEV is currently limited understanding of T cell 
responses against HEV as well as a limited interest in developing novel anti-HEV therapy by 
pharmaceutical industries. 
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Conclusions and Future Perspective 
Significant progress has been achieved in understanding innate and adaptive immunity to 
HEV infection, but many gaps remain. Future studies to improve our insight of HEV 
immunopathogenesis in association with HEV clearance and distinct clinical outcomes are 
encouraged. Characterisation of cellular innate immunity, including NK cells, DC and 
macrophages, is highly important since these cells are the key effectors that initiate immune 
responses against HEV and govern the establishment of antiviral B and T cell immunity.  
Previous studies on T cell immunity were predominantly performed in the peripheral blood 
of HEV-infected patients. However, HEV is a hepatotropic virus and its clinical progression is 
determined by immune-mediated liver pathology. It is highly possible that the liver 
microenvironment will determine the strength and quality of immune responses against HEV. 
Therefore, the immune responses to HEV in the liver should be comprehensively studied.  
Although a commercial vaccine for HEV prevention is currently availabe in China, the limited 
availability restrains its potential role to reduce the global burden of HEV infection.108 
Therefore, further development and particularly implementation of HEV vaccines as well as 
novel antiviral stratergies are essential for better control of the disease.  
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Dear Editor,  
Sofosbuvir (SOF), the direct-acting anti-hepatitis C virus (HCV) drug (targeting HCV RdRp; 
RNA-dependent RNA polymerase), has been recently reported to be a potential anti-HEV 
drug candidate.1 However, some debates emerged whether SOF is a promising drug 
candidate for treating hepatitis E.2 Given the important potential clinical implications, this 
study has comparatively assessed the antiviral efficacy of SOF in both HCV and HEV models. 
We believe that the anti-HEV and anti-HCV potency of SOF should be comparatively assessed, 
before proposing its clinical application for treating HEV-infected patients.  
In our study, the potential anti-HEV effect of SOF was investigated in HEV replication models 
with concentrations ranging from 0.01 μΜ to 10 μΜ (Supplementary Figure 1A), which is 
comparable to the previous study.1 In this model, human hepatoma Huh7 cells were 
transfected with a subgenomic construct of HEV coding sequence derived from genotype 1 
(Sar55/S17/luc) and genotype 3 (Kernow-C1, p6-luc), in which the 5’ portion of open reading 
frame 2 (ORF2) coding sequence was replaced with a gene encoding a secreted form of 
Gaussia luciferase. To normalize for non-specific effects of SOF on luciferase signals, Huh7 
cells stably expressing a non-secreted firefly luciferase under control of the human 
phosphoglycerate kinase (PGK) promotor (PGK-Luc) was used. In addition, Huh7 cells 
harboring a subgenomic HCV bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET; Huh7-ET) was 
used as control of anti-HCV activity.3 We demonstrated that SOF significantly reduced and 
even eliminated HCV-driven luciferase activity at 24 and 48 hours of treatments, but did not 
affect the PGK-driven luciferase activity. However, an antiviral effect of SOF was not 
observed in both HEV genotype 1- and genotype 3-based subgenomic replicon either at 24 
and 48 hours of treatment (Figure 1A).  
We further evaluated the anti-HEV effect of SOF in the full-length (Kernow-C1, p6) infectious 
models of HEV genotype 3. The infectious HCV model, containing full-length JFH1-derived 
genome, was used as the control of antiviral activity.4 In this model, only a modest effect 
was observed after the treatment of SOF at the highest concentration (10 μM) for 48 hours 
(Figure 1B). In contrast, SOF strongly inhibited HCV infection. At concentration of 1 μM, SOF 
completely eliminated HCV RNA (Figure 1B). These results showed the highly specific effect 
of SOF against HCV replication.  
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Figure 1. The antiviral effect of SOF was investigated on various HEV and HCV models. (A) In the 
Huh7 cell-based subgenomic HCV replicon, treatment with SOF dose-dependently decreased and 
even eliminated HCV replication-related luciferase activity. While SOF exerted no effects on HEV 
replication in both HEV genotype 1- and 3-based subgenomic replicon either at 24 and 48 hours of 
treatment. PGK-Luc was used to assess non-specific effects of SOF on luciferase signals (n = 3 
independent experiments with 2–3 replicates each). (B) SOF strongly inhibited HCV in Huh7 based 
full-length JFH1-infectious model, while a modest effect on HEV was observed in the full-length  p6 
infectious models after the treatment of SOF at the highest concentration (10 μM) for 48 hours (n = 2 
independent experiments with 2 replicates each). (C) Huh7 cell-based subgenomic HCV replicon was 
infected with infectious HEV p6 particles. SOF exerted no significant anti-HEV effect, while retained 
its strong effect against HCV replication (measured at 48 hours) (n = 4). (D) Huh7 cells were 
coinfected with both infectious HEV (p6) and HCV (JFH.1) particles. SOF led to the elimination of HCV 
at the concentration of 1 μM, while exerting no significant effect on HEV (measured at 48 hours) (n = 
4).  
 
We then examined whether SOF could directly inhibit the activity of HEV RdRp enzyme using 
an in vitro RdRp assay.5 Huh7 purified RdRp-Flag was used in the presence of increasing dose 
of SOF. As template, an in vitro transcribed RNA containing 130 bases from 5’-end and 210 
bases from 3’-end of HEV genotype 1 was employed. Addition of SOF at any of the 
concentrations tested did not inhibit HEV RdRp activity as measured by the level of double 
stranded RNA intermediate level (680 bases) (Supplementary Figure 1B). 
Acute and chronic HEV patients may develop extra-hepatic manifestations such as 
neurological and kidney complications.6 Therefore, we established HEV genotype 3-based 
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infectious and replication models in human embryonic kidney epithelial cell line HEK 293T 
cells and human glioblastoma cell line U-87 MG cells. In line with the results observed in 
Huh7-based HEV replication model, we did not observe any effect of SOF on both HEK 293T 
and U-87 MG based HEV replication models (Supplementary Figure 1C). Furthermore, in 
both HEK 293T cell and U-87 MG cell based HEV infectious models, only a moderate effect 
was observed after the treatment of SOF at the highest concentration (10 μM) for 48 hours 
(Supplementary Figure 1D). This is consistent with the result in Huh7 based HEV infectious 
model. The similar results we obtained from both hepatic and extra-hepatic cell lines further 
emphasized the highly specific effect of SOF against HCV relative to HEV. 
In clinical settings, coinfection of HCV and HEV could be found.7 To clarify whether SOF could 
inhibit viral replication of both viruses in this specific setting, Huh7-ET cells infected with 
infectious HEV particles (Kernow-C1, p6) were used as an in vitro HCV and HEV coinfection 
model. Surprisingly, SOF lost its modest effect on HEV, while retained its strong antiviral viral 
effect against HCV replication (Figure 1C). This observation was further supported by the 
coinfection of both infectious HEV (Kernow-C1, p6) and HCV particles (JFH.1) in Huh7 cells. In 
this model, SOF led to the elimination of HCV virus at the concentration of 1 μM/mL, while 
exerting no significant effect on HEV even at the concentration of 10 μM (Figure 1D). This 
results underscored the highly specific anti-viral effect of SOF againts HCV.  
Based on evaluation in chronic HCV patients, the geometric mean steady state of SOF 
concentration was 828 ng•hr/mL when coadministered with ribavirin.8 The concentration 
was much lower than the concentration of SOF we used in vitro at which SOF showed 
modest effect on HEV (10 μΜ of SOV is equivalent to 5294.5 ng/mL). Therefore, we suggest 
that SOF is likely not valuable to be used in the clinical settings for treating HEV-infected 
patients. Nevertheless, targeting HEV polymerase is a potential strategy to develop new 
antiviral drugs against HEV. 
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Supplementary Materials and Methods  
 
Anti-viral Agents 
Sofosbuvir (SOF) was purchased from Selleckchem (Houston, TX). Stocks of SOF were 
dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10 mM. 
Cell Culture 
Human hepatoma cell line Huh7, human embryonic kidney epithelial cell line HEK 293T cells, 
and human glioblastoma cell line U-87 MG cells were cultured in Dulbecco’s modified Eagle 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 IU/mL 
penicillin and 100 IU/mL streptomycin.  
Stable luciferase expressing cells were generated by transducing naïve Huh7 with a lentiviral 
vector expressing the firefly luciferase gene under control of the human phosphoglycerate 
kinase (PGK) promotor (LV-PGK-Luc). LV-PGK-Luc was used as household luciferase activity 
for normalization and to determine the specific effects on viral replication-related luciferase 
activity. 
Hepatitis E Virus (HEV) Cell Culture Models 
A plasmid construct containing the full-length HEV genome (Kernow-C1 p6 clone, GenBank 
Accession Number JQ679013) and a construct containing subgenomic HEV sequence coupled 
with a Gaussia luciferase reporter gene (p6-Luc) were used to generate HEV genomic RNA by 
using the Ambion mMESSAGE mMACHINE in vitro RNA transcription Kit (Life Technologies 
Corporation, Carlsbad, CA). For HEV genotype 1, we used Sar55/S17/luc subgenomic 
replicons coupled with a Gaussia luciferase reporter gene.  
The Huh7 cells, HEK 293T cells, and U-87 MG cells were collected and centrifuged for 5 min, 
1500 rpm, 4 oC. Supernatant was removed and washed with 4 mL Optimem by centrifuging 
for 5 min, 1500 rpm, 4 oC. The cell pellet was re-suspended in 100 μL Optimem and mixed 
with p6 full-length HEV RNA or p6-Luc subgenomic RNA. Electroporation was performed to 
generate infectious or replication models, respectively.  
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Hepatitis C Virus (HCV) Cell Culture Models 
HCV subgenomic replicon model (Huh7-ET) was based on Huh7 cells containing a 
subgenomic HCV bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET) which contains the non-
structural coding  sequence of HCV and the firefly luciferase gene. Huh7-ET cells were 
cultured in the presence of 250 μg/mL G418 (Sigma). As an infectious model, Huh7 cells 
harboring the full-length JFH-1 derived HCV genome was used. 
Measurement of Luciferase Activity 
To quantify the HEV replication models, the activity of secreted gaussia luciferase in the cell 
culture medium was measured using BioLux Gaussia Luciferase Flex Assay Kit (New England 
Biolabs, Ipswich, MA). Huh7-ET and PGK-Luc firefly luciferase activity was quantified by 
adding luciferin potassium salt (100 mM, Sigma) to the cells and then incubating for 30 
minutes at 37 oC. Both gaussia and firefly luciferase activities were quantified with a 
LumiStar Optima luminescence counter (BMG labTech, Offenburg, Germany). 
Quantitative Real-Time Polymerase Chain Reaction 
RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was prepared from total 
RNA using a cDNA Synthesis Kit (Takara Bio Inc). The cDNA of HEV, HCV, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and human retinitis pigmentosa 2 (RP2) were amplified 
by 50 cycles and quantified with a SYBRGreen-based real-time PCR (MJ Research Opticon, 
Hercules, CA, USA) according to the manufacturer’s instructions. GAPDH and RP2 were 
considered as reference genes to normalize gene expression. The qPCR primer sequences 
listed as follows: HEV-F 5’-ATTGGCCAGAAGTTGGTTTTCAC-3’; HEV-R 5’-
CCGTGGCTATAATTGTGGTCT-3’; HCV-F  5’-GTCTAGCCATGGCGTTAGTATGAG-3’; HCV-R 5’-
AGATGTTCAGGCACTTGGCGG-3’; GAPDH-F 5’-TGTCCCCACCCCCAATGTATC-3’; GAPDH-R 5’-
CTCCGATGCCTGCTTCACTACCTT-3’; RP2-F 5’-GTCAGAGACAGAAGAGCAGCGA-3’; RP2-R 5’- 
GGACACTTCCTTTGTCTGAACTAG-3’ 
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MTT assays 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to cells seeded in 96-well plates. The cells was incubated at 37 0C with 5% CO2 for 3 h. 
The culture medium was then removed and 100 μl of DMSO was added to each well. The 
absorbance of each well was read on the microplate absorbance readers (BIO-RAD) at 
wavelength of 490 nm. All measurements were performed in triplicates. 
HEV RNA-dependent RNA-polymerase (RdRp) Assay 
HEV RdRp assay was performed as described previously (see reference no. 5 in the main 
document). SOF was added to the reaction mixture at the indicated final concentrations (1, 
10, 100 μM). 
Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-Whitney 
test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values <.05 were 
considered statistically significant. 
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Supplementary figure 1. The antiviral effect of SOF was evaluated on extra-hepatic cell based HEV 
models. (A) The effects of SOF on hepatic and extra-hepatic cell lines were determined by MTT assay. 
SOF showed relatively strong cytotoxicity at the concentration of 100 μΜ. (B) Effect of SOF on HEV 
RdRp activity in vitro. RdRp assay was performed using purified HEV RdRp and a 340 base HEV RNA 
template. Schematic illustrates the position of ds RNA (+,-) and ss RNA. (C) SOF exerted no antiviral 
effect on both HEK 293T and U-87 MG based HEV replication models (n = 3 independent experiments 
with 2–3 replicates each). (D) In both HEK 293T cell and U-87 MG cell based HEV infectious models, a 
moderate anti-HEV effect was observed after the treatment of SOF for 48 hours (n = 2 independent 
experiments with 2 replicates each). 
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Abstract 
Hepatitis E virus (HEV) infection is a major cause of acute hepatitis but also provokes chronic 
infection in immunocompromised patients. Although the pathogenesis and treatment 
outcome involve complex interplay between the virus and host, the nature of adaptive 
responses of HEV to the host immune system remain obscure at best. In this study, we 
employed large-scale proteomic bioinformatics to profile characteristic mutations in human 
HEV isolates associated to ribavirin treatment failure, chronic hepatitis, hepatic failure or 
altered immunoreactivity. The prevalence of specific mutations was examined in a large 
number of protein sequences of ORF1 and ORF2 regions of the three major human-derived 
HEV genotypes (1, 3 and 4). By analyzing potential B, CD4⁺ and CD8⁺ T cell epitopes, we 
found that many of these mutations overlap with the predicted epitopes and are frequently 
present among the three HEV genotypes. These overlapping mutations mediate reduced 
antigenicity. Finally, by delineation of diversification and evolution of the underlying 
epitopes, we observe that most of these variants apparently evolved earlier in genotype 1 
when compared to genotypes 3 and 4. These results indicate that HEV is under substantial 
evolutionary pressure to develop mutations enabling evasion of the host immune response 
and resistance to antiviral treatment. This indicates the existence of an ongoing evolutionary 
arms race between human immunity, antiviral medication and HEV.  
 
Key words: B and T cells; epitope; evolution; hepatitis E virus; mutation  
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Introduction 
Hepatitis E virus (HEV) is a non-enveloped, single-stranded positive sense RNA virus which 
mainly infects the liver.1 It causes over three million acute cases and 57,000 deaths every 
year.2 Although eight HEV genotypes are now recognized, there are 4 well-defined 
genotypes infecting humans, including genotype 1, 2, 3 and 4. Genotypes 1 and 2 are found 
only in humans and are responsible for most cases of infection in the developing countries. 
Genotypes 3 and 4 circulate in several animals (e.g. pigs, wild boars and deer) and are the 
main cause of sporadic infection in the developed countries.3, 4 Although no FDA-approved 
treatment is available, pegylated interferon-α (PEG-IFN-α) or ribavirin has been used as off-
label treatment for some cases of HEV infection.5, 6  
As an RNA virus, HEV possesses a high mutation rate. It was indirectly estimated from clinical 
isolates that the mutation rate of HEV was ~1.5 base substitutions per site per year, which is 
quite similar to that reported for hepatitis C virus (HCV).7 The viral RNA-dependent RNA 
polymerase (RdRp), which lacks the proof-reading capacity, is an important factor 
contributing to the high rate of mutations in the HEV genome.8 Furthermore, the selection 
pressure imposed by the host immune responses may also contribute to the variability of 
HEV genome. Recently, studies have hinted at the acquisition by the HEV genome of certain 
mutations associated with ribavirin treatment failure, chronic hepatitis, hepatic failure and 
reduced immunoreactivity.9 The observation that different mutations change the HEV 
proteome with respect to not only the therapeutic response but also the immunoreactivity 
highlights the importance of studying HEV mutations and their effects on the host immune 
responses. 
Only limited knowledge is available on the contribution of HEV genome variants towards 
susceptibility, pathogenesis and therapeutic responses. To elucidate these processes, we 
have used a large-scale proteomic bioinformatics to profile human HEV characteristic 
mutations. In the present study, we have comprehensively investigated the proteomic 
variation of the open reading frame 1 (ORF1) and ORF2 regions among the major HEV 
genotypes 1, 3 and 4, by retrieving a large dataset of HEV sequences. We first mapped the 
presence and abundance of the mutations related to ribavirin treatment failure, chronic 
hepatitis, hepatic failure or reduced immunoreactivity. Furthermore, we examined the 
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overlap of these mutations with predicted B cell, CD4+ and CD8+ T cell epitopes, and 
assessed their antigenicity. Interestingly, we have observed that these overlapped mutations 
evolved earlier in genotype 1 when compared with genotype 3 and 4. Thus, the acquisition 
and evolution of these characteristic mutations may help the virus to evade host immune 
response, develop resistance to antiviral treatment, and facilitate its adaptation in human 
population.  
Results 
Identification of HEV characteristic mutations 
Several HEV variants were previously reported both in vitro and in vivo. Using a combination 
of phrases/keywords in PubMed (Table S1), we explored clinical and in vitro data reporting 
mutations within the ORF1 and ORF2 of HEV. In our analysis, 20 mutations (Table S2) were 
identified in these regions, 17 in ORF1 and 3 in ORF2 (Figure 1). Among these mutations, one 
was related to chronic hepatitis, nine with hepatic failure, eight with ribavirin treatment 
failure, and two with altered immunoreactivity (Table S2). 
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Figure 1. (A). Identified mutations of ORF1 and ORF2 regions of HEV. The number within the box 
represents the amino acid position; the letter(s) above the box refer to the wild type amino acid, and 
the letter below the box are relevant mutations reported in previous studies. (Met: 
methyltransferase; Y: Y-domain; HVR: hypervariable regions; Hel: RNA helicase; RdRP: RNA-
dependent RNA polymerase; C: capsid protein) (B). The prevalence of mutations within HEV 
genotype 1 (n = 81), 3 (n = 182) and 4 (n = 143). Amino acid diversity was measured as the proportion 
of sequences that varies from the consensus sequence.  
Frequency of mutations within ORF1 and ORF2 
To evaluate the relevance of these reported characteristic mutations, we first evaluated 
their presence in the circulating strains based on the HEV sequences deposited in the 
GenBank. We have searched the 4 main genotypes identified from the human host. 
However, limited sequences are available for genotype 2. Thus, we retrieved 57 ORF1, 51 
ORF2 (genotype 1), 131 ORF1, 131 ORF2 (genotype 3) and 99 ORF1, 96 ORF2 (genotype 4) of 
HEV sequences (retrieved in January 2017). The selected sequences represent all major 
genotypes (1, 3 and 4). The full-length sequences used in this study based on each ORF and 
genotype are provided in Table S3. 
After removal of closely related and redundant sequences, 406 full length ORF1 and ORF2 
sequences were finally selected for further analysis. Table 1, Table S4 and Figure 1 show the 
number of all possible and experimentally confirmed amino acid variants and frequency of 
their variation for each HEV genotype. The number of variants found in ORF1 region was 
higher (17 variants) than that of ORF2 region (three variants). Out of 17 variants in ORF1, 
eight were related to hepatic failure; one with chronic hepatitis; and eight with ribavirin 
treatment failure. While in ORF2, one variation was associated with hepatic failure and two 
with immunoreactivity. When analyzing HEV genotypes, it was revealed that genotype 1 
possesses a higher number of mutations (eight) with considerable frequency when 
compared with genotype 3 and 4 which possesses only six and three mutations, respectively 
(Table 1 and Figure 1B). This observation further suggests the high level of polymorphism in 
HEV genotype 1. 
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Table 1. All possible and experimentally confirmed (in vivo and in vitro) mutations and their 
prevalence in the major HEV genotypes (1, 3, 4). Different colors indicate the mutations related to 
ribavirin treatment failure (yellow), chronic hepatitis (purple), hepatic failure (red) or altered 
immunoreactivity (blue). 
Mutations within genotype 1, 3 and 4 
In genotype 1, nine out of 17 reported mutations (V1213A, Y1320H, K1383N, D1384G, 
K1398N, C1483W, N1530T, Y1587F, G1634R) in ORF1 and one (P259S) out of three in ORF2, 
were found to be conserved (i.e. not present in our analyzed sequences), while others have 
shown considerable variations (Table 1). Among these variable mutations, T735I and 
G1634R/K were observed to be frequent among all selected genotype (1, 3 and 4). Another 
mutation (A317T) was found in two genotypes (1 and 3). Four mutations (ORF1 = 2; ORF2 = 2) 
reached the frequency of >90% (Table 1, Figure 1B). Among these, two mutations were 
O
RF
1 
Mutations Percentage 
GT1 ORF1 
(57) 
GT3 ORF1 
(131) 
GT4 ORF1 
(99) 
F179S 16 (28%) 0 0 
A317T 28 (49%) 128 (98%) 0 
T735I 26 (46%) 60 (46%) 43 (43%) 
L1110F 35 (61%) 0 0 
V1120I 38 (67%) 0 0 
V1213A  0 125 (95%) 93 (93%) 
Y1320H 0 0 0 
K1383N 0 0 0 
D1384G 0 0 0 
K1398N 0 0 0 
F1439Y 9 (16%) 0 0 
V1479I 54 (95%) 0 0 
C1483W 0 0 0 
N1530T 0 0 0 
Y1587F 0 0 96 (97%) 
G1634R 0 128 (98%) 96 (97%) 
G1634K 54 (95%) 0 0 
 GT1 ORF2 
(51) 
GT3 ORF2 
(131) 
GT4 ORF2 
(96) 
O
RF
2 
P259S 0 0 0 
L477T 46 (90%) 127 (97%) 0 
L613T 46 (90%) 125 (95%) 
 
0 
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related to ribavirin treatment failure (G1634K and V1479I) and two were associated with 
altered immunoreactivity [L477T (ORF2; genotype 1, 3) and L613T (ORF2; genotype 1, 3)]. 
In genotype 3, we found that the reported mutation sites [13 in ORF1 (F179S, L1110F, 
V1120I, Y1320H, K1383N, D1384G, K1398N, F1439Y, V1479I, C1483W, N1530T, Y1587F, 
G1634K) and one (P259S) in ORF2] were conserved (i.e. not present in our analyzed 
sequences) (Table 1, Figure 1B). Mutations of ORF1, i.e. V1213A and G1634R, were found 
with a considerable frequency in genotypes 3 and 4. The most important variants were 
A317T, V1213A and G1634R which showed a high prevalence in genotype 3. Five mutations 
approached a frequency of >90%, where one was related to chronic hepatitis (V1213A), one 
with hepatic failure (A317T), one with ribavirin treatment failure (G1634R) and two with 
immunoreactivity (L477T, L613T) (Table 1, Figure 1B). 
In genotype 4, 13 sites in ORF1 (F179S, A317T, L1110F, V1120I, V1213A, Y1320H, K1383N, 
K1398N, D1384G, F1439Y, V1479I, C1483W, N1530T) and three in ORF2 (P259S, L477T, 
L613T) were found to be conserved. Mutation Y1587F was frequent in genotype 4. Two 
mutations reached the frequency of >90% (Y1587F, G1634R) (Table 1, Figure 1B). Both 
mutations have been reported to be related to ribavirin treatment failure (Y1587F, G1634R). 
Mutations as a missense SNPs and their effects on protein structural stability 
In our analysis, four in silico SNP prediction algorithms were employed to predict the 
selected mutations as neutral or deleterious. According to predicted results, most of the 
selected mutations with high prevalence in HEV infected population are deleterious (Table 
S5). Next, most of these mutations are predicted to cause destabilization of the protein as 
calculated using three web servers (Table S6), suggesting the importance of these mutations. 
Because the crystal structure of HEV ORF2 (2ZTN-amino acid 129-606) is available (Figure 
3A), we have modeled the effect of two mutations that are located within this region on 
structural stability of the protein. We found that both P259S (Figure 3B) and L477T (Figure 
3C) are predicted to cause destabilization of ORF2 protein.  
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Figure 2. Antigenicity difference between wild-type and mutated T cell (MHCI and MHCII) (A) and B 
cell epitopes (B).  
Overlap of characteristic mutations within the predicted B cell, CD4+ and 
CD8+ T cell epitopes 
The consensus sequence of ORF1 and ORF2 of genotypes 1, 3 and 4 (respectively) was used 
to predict B cells, major histocompatibility complex class I (MHCI) and class II (MHCII) T cell 
epitopes using IEDB, ProPred-1 and ProPred, respectively.10-12 In case of MHCI and II, 
epitope’s binding to maximum number of alleles and binding capacity of <500 mM were 
selected. The predicted epitopes were further confirmed by BLASTp13 to avoid considering 
the epitopes that have a homology with human proteins. 
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The predicted epitopes were then evaluated for the presence or absence of the reported 
mutations (Table 1). We found that many of these characteristic mutations reported in ORF1 
and ORF2 regions overlap with the predicted epitopes and were also frequently observed 
among selected HEV genotypes (1, 3 and 4) (Table 2 and Table 3). In our analysis, all 
epitopes possessing mutations that are present in our analysed HEV sequences were 
considered. Table 2 and Table 3 show mutations in the predicted epitopes of ORF1 and 
ORF2 (consensus genotype 1, 3 and 4) against B cells, MHC-I and MHC-II T cells. It was 
observed that ORF1 and ORF2 of genotype 1 possess more epitopes with reported 
mutations when compared with genotype 3 and 4 (Table 2 and 3). Most of these overlapped 
mutations were related to hepatic failure (HF), followed by ribavirin treatment failure (RTF), 
altered immunoreactivity (AI) and chronic hepatitis (CH) (HF>RTF>AI>CH). 
Alteration of epitope antigenicity by characteristic mutations 
We hypothesize that HEV may alter its epitopes by acquiring mutations to evade the 
immune recognition by both B and T cells.14 The online tool VaxiJen15 was used to detect the 
effect of each mutation on the antigenicity of the epitopes (wild type and mutation 
containing epitopes) (Table 2 and Table 3). Interestingly, in many cases, mutated epitopes 
have a reduced antigenicity when compared to the wild-type epitope (Table 2, Table 3, and 
Figure 2). Some mutated epitopes have a sustained antigenicity, while only few mutated 
epitopes have an increased antigenicity. These findings suggest that most of the reported 
mutations within predicted epitopes have a reduced antigenicity. Consequently, they are 
less recognized by both B and T cells and thus, decreasing the effective roles of the adaptive 
immune cells to clear the infections. 
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Figure 3. The effects of mutations (P259S, L477T) on the structural stability of ORF2 region of HEV 
predicted by DUET web server. Mutations are shown in blue color ribbon. (A) Crystal struture 
without mutation of ORF2 (2ZTN-amino acid 129-606). (B). P259S; feature: destabilizing; secondary 
structure: loop or irregular. (C). L477T; feature: destabilizing; secondary structure: extended beta-
strand. 
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Table 2. Antigenicity evaluation of wild-type and mutated epitopes. The effect of mutations on the 
antigenicity (threshold level = 0.4) of predicted T cell epitopes (MHCI and MHCII). Bold letters (one-
letter amino acid code) represent mutations within the predicted epitopes. 
 
 
 
 
 
Region/ 
Genotype 
Epitopes 
name 
Position Wild-type 
epitope 
Antigenicity Mutated epitope Antigenicity 
 MHCI 
ORF1/GT1 T1 F179S MFRHGMTRL 0.1 MF/SRHGMTRL 0.2 
 T2 T735I ATPTPAAPL 0.2 ATPT/IPAAPL 0.2 
 T3 L1110F TTSRVLRSL 0.4 TTSRVL/FRSL -0.6 
 T4 F1439Y FYGDAFDDT 0.2 FYGDAF/YDDT 0.2 
 T5 G1634K AVSDFLRGL 0.4 AVSDFLRG/KL -0.6 
ORF2/GT1 T6 L613T SALALLEDL 0.3 SALALLEDL/T 0.5 
 MHCII 
ORF1/GT1 T7 A317T FHAVPAHIW 0.5 FHAVPA/THIW -0.7 
 T8 T735I IPSRAATPT 0.2 IPSRAATPT/I 1 
 T9 V1120I FWGEPAVGQ 0.2 FWGEPAV/IGQ 0.2 
 T10 V1479I LGLECAVME 0.8 LGLECAV/IME 0.7 
 T11 G1634K LRGLTNVAQ 0.7 LRG/KLTNVAQ 0.7 
ORF2/GT1 T12 L477T WLSLLAAEY 1.1 WLSLL/TAAEY 1.7 
 MHCI 
ORF1/GT3 T13 V1213A VIVNNFFLV 0.1 VIVNNFFLV/A -0.1 
 T14 G1634R LGLAVCDFL 0.2 LG/RLAVCDFL -0.3 
 MHCII 
ORF1/GT3 T15 V1213A LVGGEVGHH 1.1 LV/AGGEVGHH 1 
 T16 G1634R LGLAVCDFL 0.2 LG/RLAVCDFL -0.3 
ORF2/GT3 T17 L477T WLSLLAAEY 1.1 WLSLL/TAAEY 1.7 
 T18 L613T VLEDLIDYP 0.4 VLEDL/TIDYP -0.17 
 MHCI 
ORF1/GT4 T19 T735I AEADTPVAV 0.2 AEADT/IPVAV 0.1 
 T20 V1213A REVGISDAI 0.8 REVGISDV/AI 0.7 
 T21 G1634R SERAEQLRL  0.3 SEG/RAEQLRL 0.3 
 MHCII 
ORF1/GT4 T22 T735I VATDVPPPA 0.4 VAT/IDVPPPA 0.1 
 T23 V1213A VIVNNFFLS 0.03 V/AIVNNFFLS 0.02 
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Region/ 
Genotype 
Epitopes 
name 
Position Wild-type B 
cell epitopes 
Antigenicity Mutated B cell 
epitopes 
Antigenicity 
ORF1/GT1 B1 F179S FRHGMTRLY 0.1 F/SRHGMTRLY 0.1 
 B2 T735I TPAAPLPPP 0.1 T/IPAAPLPPP 0.1 
 B3 L1110F TTSRVLRSL 0.1 TTSRVL/FRSL 0.01 
 B4 V1120I WGEPAVGQK 0.8 WGEPAV/IGQK 1 
 B5 F1439Y FYGDAFDDT 0.2 FYGDAF/YDDT 0.2 
 B6 G1634K SDFLRKLTN 0.1 SDFLRG/KLTN -0.1 
ORF2/GT1 B7 L477T SLTAAEYDQ 1.1 SLL/TAAEYDQ 1.0 
 B8 L613T LLDYPARAH 0.4 L/TLDYPARAH 0.4 
ORF1/GT3 B9 T735I LPHPTPPVS 0.5 LPHPT/IPPVS 0.6 
 B10 G1632R ERAEQLRLA 0.1 ERAEQLG/RLA 0.1 
ORF2/GT3 B11 L477T SLTAAEYDQ 1.1 SLL/TAAEYDQ 0.5 
 B12 L613T LIDYPARAH 0.5 L/TIDYPARAH 0.4 
ORF1/GT4 B13 V735I TPVAVDVPP 0.5 TPVAV/IDVPP 0.6 
 B14 Y1587F CGLKLKVDY 0.7 CGLKLKVDY/F 1.7 
 B15 G1634R KNWGPGSEG 1.8 KNWGPGSEG/R 1.7 
 
Table 3. Antigenicity evaluation of wild-type and mutated epitopes.  The effect of mutations on the 
antigenicity (threshold level = 0.4) of predicted B cells epitopes. Bold letters (one-letter amino acid 
code) represent mutations within the predicted epitopes. 
Evolution of the characteristic mutations 
To visualize the mutation evolution within the predicted epitopes of each genotype, a heat 
map was generated for each reported mutation (Figure 4). The concept of evolving 
mutations among the HEV genotypes within antigenic area will be helpful in determining 
their role in both immune and therapeutic responses. Different trends of evolving mutations 
have been observed in our analysis. The mutations A317T, T735I, L1110F, V1120I, V1479I 
and G1634K which were frequently observed in genotype 1 ORF1 have an evolving period of 
3 years (1998-2001), 6 years (1998-2003), 8 years (1992-1999) 7 years (1992-1998), 5 years 
(1983-1987) and 4 years (1983-1986), respectively (Figure 4 and Figure 5). A commonly 
observed variation in all selected genotypes (1, 3 and 4), i.e. T735I, was found to be evolved 
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earlier in ORF1 of genotype 1 (1998-2003) when compared with genotype 3 and 4. Another 
common variation G1634K/R evolved earlier in ORF1 of genotype 1 (1983-1986) as 
compared to genotype 3 (1993-1997) and genotype 4 (1995-1998) (Figure 4 and Figure 5). 
Similarly, the mutations in ORF2 (L477T and L613T) appear to evolve earlier in genotype 1 
compared to genotype 3 (Figure 4 and Figure 5). These data collectively indicate an earlier 
acquisition of several characteristic mutations in genotype 1 as compared to genotype 3 and 
4. 
Discussion 
Ribavirin monotherapy has been widely used for treatment of chronic hepatitis E.5 It is in 
general very effective. However, for a subset of patients, ribavirin treatment fails.16, 17 
Mutations in the viral polymerase have been noted before or during therapy in these 
patients.18 Furthermore, many mutations related to hepatic failure, chronic hepatitis and 
immunoreactivity have also been reported, conferring the importance of these mutations in 
HEV pathogenesis and treatment responses. In support of this, several studies have shown 
that proteomic variations in certain epitopes that are associated with these mutations can 
critically influence the outcome of the immune responses.19 These antigenic variations have 
been observed among HEV strains using genotype- and strain-specific monoclonal 
antibodies.20 Even though a number of studies have reported frequencies of mutations in 
the HEV genome, the global prevalence of these characteristic mutations has not been 
comprehensively studied. Thus, this study has evaluated the HEV ORF1 and ORF2 variability 
in major genotypes (1, 3 and 4) by a systematic retrieval of human-derived HEV sequences. 
Furthermore, important co-occurrence of B and T cell (CD4+ and CD8+) epitope mutations 
was revealed, suggesting adaptation of viruses to escape immune surveillance.  
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Figure 4. A heat map showing the evolvement of mutations with years. Mutations 1 = F179S, 2 = 
A317T, 3 = T735I, 4 = L1110F, 5 = V1120I, 6 = V1213A, 7 = Y1320H, 8 = K1383N, 9 = D1384G, 10 = 
K1398N, 11 = F1439Y, 12 = V1479I, 13 = C1483W, 14 = N1530T, 15 = Y1587F, 16 = G1634R, 17 = 
G1634K, 18 = P259S, 19 = L477T, 20 = L613T. Each box represents the sequence of ORF 1 or ORF2, 
from genotype 1, 3 or 4 in a particular year. Red colored boxes represent the mutations related to 
hepatic failure mutations; purple to chronic hepatitis; yellow to ribavirin treatment failure; and blue 
to altered immunoreactivity. The year of deposition of each sequence is mentioned in the arrow 
below the heat map. 
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Figure 5. Evolution period of overlapped mutations. Each bar represents the evolving period (years ) 
of each mutations. 
By exploring the intra-genotypic diversity from representative human HEV genotypes, we 
have demonstrated that genotype 1 produces the largest number of intra-genotypic variants 
(Table 1). These variants were found to be evolved with a period of on average ~4 years but 
varied from 3 to 5 years in the human population (Figure 4 and Figure 5). Surprisingly, some 
reported mutations, including Y1320H, K1383N, D1384G and K1398N (related to ribavirin 
treatment failure) and C1483W, N1530T and P259S (related to hepatic failure), were hardly 
present in our retrieved large set of sequences, suggesting their insignificance. In contrast, 
two mutations T735I (related to hepatic failure) and G1634R (related to ribavirin treatment 
failure) were found in all selected genotypes (1, 3 and 4) with a considerably high frequency. 
Among these mutations, G1634R/K was identified in patients as a baseline mutation that 
affects ribavirin treatment response.21 This mutation was also observed in a patient with 
chronic hepatitis E, experiencing ribavirin treatment failure with a completely resistant 
phenotype.16 However, the exact clinical relevance of such mutations in ribavirin treatment 
failure is uncertain since findings from in vitro studies show that some of these mutations 
facilitate HEV replication but paradoxically seem to increase ribavirin sensitivity,16 thus 
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requiring further investigation. Furthermore, effective new antiviral therapy is needed for 
HEV patients with ribavirin treatment failure.22 Two immunoreactivity-related mutations 
(L477T and L613T) were mainly found in genotype 1 and 3 highlighting the role of such 
mutations in affecting host immune response (Table 1).  
To investigate the implication of these characteristic mutations in the host immune 
response, we have profiled their overlap with predicted B and T cell epitopes. We found that 
the hotspot sites where mutations and predicted epitopes overlap are frequently present 
among many HEV genotypes (Table 1 and Figure 2). The subsequent analysis of these 
mutations showed that this overlap mostly decreases and in few cases, sustains or enhances 
the antigenicity of the mutated epitopes (Table 2, Table 3 and Figure 2). Experimental 
studies have demonstrated that only antibodies recognizing conformational epitopes are 
neutralizing, and the aa residues Leu477 and Leu613 in the capsid protein are important in 
forming a neutralization-sensitive epitope representing the importance of these mutations 
in epitope deformation.23 In patients, HEV-speciﬁc T cells target relatively conserved HEV 
peptides, and those are predominantly located in the ORF2 capsid protein. The T-cell 
responses persist over years after resolution of HEV infection, suggesting the role in both 
clearance of primary infection and protective immune response against secondary 
infection.24 Based on our study, we propose a model of immune evasion by HEV (Figure 6). 
In this model, mutated epitopes will result in escape recognition by B and T cells. 
Furthermore, we have mapped the evolution of these mutations in all selected genotypes. 
We found that most of the overlapped mutations are more abundantly present in genotype 
1 as compared to genotype 3 and 4. Interestingly, the common mutations evolved earlier in 
genotype 1 than genotype 3 and 4. 
In summary, our study represents a comprehensive analysis of the characteristic mutations 
in the major HEV genotypes. Some of these mutations overlap with predicted B and T cell 
epitopes that are expected to affect the antigenicity. We further revealed the evolution of 
these mutations among the three major genotypes. These results indicate that HEV is under 
substantial evolutionary pressure to develop mutations enabling evasion of the host 
immune response and resistance to antiviral treatment. This indicates the existence of an 
ongoing evolutionary arms race between human immunity, antiviral medication and the HEV. 
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Figure 6. Possible mechanisms of immune evasion by hepatitis E virus. Main routes by which HEV 
mutations may result in evasion of the host immune responses. Mutated epitopes presented by 
antigen presenting cells, B and T cells will results in escape recognition of the epitopes. 
Material and Methods 
Data collection 
A database on reported mutations within the ORF1 and ORF2 regions of HEV is currently not 
available. We reviewed earlier studies (through January 2017), using a combination of the 
key words that are listed in Table S1, and evaluated mutations in HEV-infected individuals, 
as well as in HEV replicons. These studies were searched from the PubMed 
(ncbi.nlm.nih.gov/pubmed), EMBASE, and Cochrane Library databases. 
Retrieval of sequences 
We retrieved 57 ORF1, 51 ORF2 (genotype 1), 131 ORF1, 131 ORF2 (genotype 3) and 99 
ORF1, 96 ORF2 (genotype 4) of HEV protein sequences from the GenBank25 (accessed on 
January 2017). The selected protein sequences represent all major genotypes (1, 3 and 4). 
The GenBank accession numbers of HEV protein sequences used in this study against each 
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ORF and genotype are provided in Table S3. The sequences were trimmed manually and 
analyzed using the reference protein sequences of selected genotypes [AF185822 (genotype 
1), AB291960 (genotype 3), AB200239 (genotype 4)]. Different quality control measures 
were performed for the sequences, and many sequences were disqualified for further 
analysis based on the following two conditions: (a) if the sequence derived from a non-
human host; and (b) if the sequence was a clonal sequence from the same patient. 
Sequences were also annotated by the year of sampling. In some cases where the source did 
not provide the sampling year, we used the submission date to the GenBank as the sampling 
year. 
Consensus sequence and mutations analysis 
The HEV ORF1 and ORF2 sequences were aligned using ClustalW, BioEdit and CLC 
Workbench 7 (http://www.clcbio.com). A consensus analysis for each HEV genotype was 
performed to observe the presence or absence of mutation at each site. These mutations 
were selected on the basis of published data reporting all experimentally proven mutations 
(in vitro and in vivo). The prevalence of each mutation was then measured within the 
selected regions (ORF1 and ORF2) of each genotype (1, 3 and 4). 
Analysis of mutations as a missense SNPs and their effects on structural 
stability 
To validate selected mutations as missense SNPs in ORF1 and ORF2 regions of HEV genotype 
1, 3 and 4, computational analysis was performed using four tools PROVEAN (Protein 
Variation Effect Analyzer),26 nsSNP analyser,27 SNPs & GO and PMUT.28 These tools describe 
missense SNPs as damaging or neutral to function and structure. To predict the change in 
protein stability due to these SNPs, DUET,29 I-Mutant version 2.0,30 and STRUM31 web 
servers were used. As an input in I-Mutant and STRUM servers, FASTA sequences of ORF1, 
ORF2 regions of selected genotypes were used. PDB files of 3D structures (2ZTN) of ORF2 
were used as an input in DUET web server. 
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Prediction of the B and T cell epitopes and comparison with the host 
proteome 
Nine-mer B cell epitopes were predicted against HEV genotype (1, 3 and 4) from their 
consensus sequence by using online tool, the Immune Epitope Database (IEDB).32 Similarly, 
nine-mer T cell epitopes (MHC class I and II), following the same criteria as B cell epitopes, 
were predicted by online T cell epitope prediction tools, including ProPred-I (MHCI) and 
ProPred (MHCII).33, 34 ProPred-I and ProPred identify and predict 47 types of MHCI and 57 
types of MHCII allele specific binding peptides in a provided protein, respectively.33, 34 The 
predicted T cell epitopes were also confirmed by IEDB tool.35 The selected epitopes were 
analyzed for comparisons with the human proteome using the Protein Blast program 
(BLASTp).13 This was performed to validate that these epitopes will not trigger an 
autoimmune response. 
Overlapping sites of mutations and predicted epitopes  
A comprehensive exploration was performed to find out any reported mutations positioned 
in a predicted epitope. Predicted B cells and T cells epitopes were mapped to ORF1 and 
ORF2 regions that contain most of the reported mutation sites. Finally, the incidence of 
these overlapped mutations was determined among the selected genotypes (1, 3 and 4) by 
using percentage formula. 
Prediction of antigenicity of epitopes 
To investigate the antigenic properties of epitopes before and after mutations, VaxiJen tool 
was used.15 The analysis was performed to find out whether these mutations lead to 
decreased, enhanced or sustained antigenicity of the specific epitopes. 
Evolutionary analysis of mutations 
To visualize the evolution of amino acid mutation related to chronic hepatitis, hepatic failure, 
ribavirin treatment failure or immunoreactivity within each genotype, a heat map was 
developed by GraphPad Prism version 7 (GraphPad Software, La Jolla California, USA) to 
calculate the number of amino acid and the isolation year differences between three 
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individual genotypes. Isolation years were extracted from the strain-annotated information. 
The difference values were added into a matrix where the y-axis represents the isolation 
year differences and the x-axis represents the amino acid differences. 
Abbreviations 
AI  Altered immunoreactivity  
CH  Chronic hepatitis 
HCV  Hepatitis C virus (HCV) 
HEV  Hepatitis E virus  
HF  Hepatic failure 
MHCI  Major histocompatibility complex class I 
MHCII  Major histocompatibility complex class II 
PEG-IFN-α  Pegylated interferon-α  
ORF  Open reading frame 
RdRp  RNA-dependent RNA polymerase 
RNA  Ribonucleic acid  
RTF  Ribavirin treatment failure  
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Supplementary information  
Table S1. Search terms used in this study. 
 
Organism Mutations Method of 
introducing 
mutations 
Hepatitis E virus Mutations Engineered 
HEV ORF1 Mutagenesis Site directed 
HEV ORF2 Site directed 
mutations 
Wild type 
HEV genotype 1 Transductions Induced 
HEV genotype 3 Mutants  
HEV genotype 4 Codon  
 
Table S2. Schematic illustration of the study. 
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Table S3. The GenBank accession numbers of HEV sequences used in this study. 
Available online: https://www.tandfonline.com/doi/suppl/10.1080/21505594.2017.1358349 
Table S4. HEV mutations analysed in this study. 
A. Twenty main mutations analyzed in the present study. 
Mutations Effect Reference(s) 
Y1320H; G1634R/K, 
K1383N, D1384G; K1398R; 
V1479I; Y1587F 
Ribavirin treatment failure [1-3] 
L477T; L613T Influence the immunoreactivity of HEV by 
affecting the neutralization epitope 
[4] 
F179S, A317T, T735I, 
L1110F, V1120I, F1439Y, 
C1483W, N1530T, P259S 
Fulminant hepatic failure [5-7] 
V1213A Chronic hepatitis [8] 
 
B. Other studies analyzed to see the effect of specific mutations. 
Studies for HEV mutation evaluations Reference(s) 
H443L; C457A; C459A; C471A; C472A; C481A; C483A; H497L; H590L [9, 10] 
Insertion/deletion [11] 
Mutational analysis [12] 
Insertion/deletion of a 24 bp RdRp-derived fragment [1] 
N809A; H812L; G816A/V; G817A/V [13, 14] 
L1110F; V1120I [15] 
Effect of mutagenesis on enzyme activity [16] 
K1383N [1] 
F51L [11, 17] 
T59A [17, 18] 
S390L [17, 18] 
N137Q; N310Q; N311Q [19] 
N562Q/D/P/Y [19] 
A5145C; A5178C; A5190C; G5676T; T5690G [20] 
CGC5148–5150AGA [20] 
A5108Δ; T5109C; C5112U; TCT5116–5118AGC; T5121C [20] 
S80A (V66G) [20] 
G6574C; C6570G; G7106T/A; G7097A; C7144A [21-23] 
C1816, U3148, C5907 [24, 25] 
186 bp insertion [26] 
90 bp insertion [27] 
171 bp insertion [28] 
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174 bp insertion [28] 
117 bp insertion [29] 
246 bp deletion [30] 
Recombination [31] 
Mutations in HEV [32, 33] 
Deletion [34] 
HEV adaptations  [35, 36] 
HEV mutations (review) [37] 
Ribavirin-induced mutagenesis [3] 
Role of asparagine at position 562 [38] 
Role of truncated ORF2 region in immunoreactivity [39] 
HEV pathogenesis in pregnancy [40] 
 
Table S5. Missense SNPs in ORF1 and ORF2 regions of HEV predicted to be deleterious using nsSNP 
Analyzer, PROVEAN, PMUT and SNPs & GO.  
 
Mutations Provean 
PM
U
T 
SN
Ps&
G
o 
nsSN
P 
analyser 
Provean 
PM
U
T 
SN
Ps&
G
o 
nsSN
P 
analyser 
Provean 
PM
U
T 
SN
Ps&
G
o 
nsSN
P 
analyser 
ORF1 GT1 GT3 GT4 
F179S - - - - - - - - - - - - 
A317T - - - - - - - - - - - - 
T735I             
L1110F - - - - - - - - - - - - 
V1120I - - - - - - - - - - - - 
V1213A  - - - - - - - - - - - - 
Y1320H             
K1383N             
D1384G             
K1398N - - - - - - - - - - - - 
F1439Y - - - - - - - - - - - - 
V1479I - - - - - - - - - - - - 
C1483W             
N1530T             
Y1587F             
G1634R - - - - - - - - - - - - 
G1634K -   - -   - -   - 
ORF2             
P259S - - - - - - - - - - - - 
L477T             
L613T - - - - - - - - - - - - 
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Table S6. Stability analysis of the mutations by using I-Mutant web server. Tick mark in the table 
shows that a mutation is found to be destabilizing by the server. 
 
Mutations I-Mutant I-Mutant I-Mutant 
ORF1 GT1 GT3 GT4 
F179S    
A317T    
T735I    
L1110F    
V1120I    
V1213A    
Y1320H    
K1383N    
D1384G    
K1398N    
F1439Y    
V1479I    
C1483W    
N1530T    
Y1587F    
G1634R    
G1634K    
ORF2    
P259S - - - 
L477T    
L613T    
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Abstract 
Rotavirus (RV) primarily infects enterocytes and results in severe diarrhea, particularly in 
children. It is known that the host immune responses determine the outcome of viral 
infections. Following infections, interferons (IFNs) are produced as the first and the main 
anti-viral cytokines to combat the virus. Here we showed that RV predominantly induced 
type III IFNs (IFN-λ1), and to a less extent, type I IFNs (IFN-α and IFN-β) in human intestinal 
cells. However, it did not produce detectable IFN proteins and thus, was not sufficient to 
inhibit RV replication. In contrast, we revealed the essential roles of the basal IFN signaling in 
limiting RV replication by silencing STAT1, STAT2 and IRF9 genes. In addition, exogenous IFN 
treatment demonstrated that RV replication was able to be inhibited by all types of IFNs, 
both in human intestinal Caco2 cell line and in primary intestinal organoids. In these models, 
IFNs significantly upregulated a panel of well-known anti-viral IFN-stimulated genes (ISGs). 
Importantly, inhibition of the JAK-STAT cascade abrogated ISG induction and the anti-RV 
effects of IFNs. Thus, our study shall contribute to better understanding of the complex RV-
host interactions and provide rationale for therapeutic development of IFN-based treatment 
against RV infection.  
 
Keywords: immune responses; interferons; interferon-stimulated genes; JAK-STAT pathway; 
rotavirus 
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Introduction 
Rotavirus (RV) is a member of the Reoviridae family that primarily infects mature 
enterocytes of the small intestinal villi. However, it can spread systemically to cause viremia 
and infection of multiple organs1. RV is the most frequent agent of severe dehydrating 
diarrhea episodes in children under five years of age2. Before introduction of RV vaccines, RV 
caused 9.8 billion of severe diarrhea episodes and 1.9 billion diarrhea-related deaths 
worldwide, with the highest burden in southeast Asian and African countries3. The incidence 
is lower especially in countries that have introduced oral RV vaccination4. 
Intestinal innate immune responses are the first line of defense to battle RV infection5. 
Recognition of RV viral proteins and double-stranded RNA by the host induces the 
production of cytokines, including interferons (IFNs)6. IFNs are potent anti-viral cytokines 
classified into three different groups, type I (IFN-α, IFN-β, IFN-δ, and others), type II (IFN-γ) 
and type III (IFN-λ1, IFN-λ2 and IFN-λ3) IFNs7,8. Some members are widely used in the clinic 
for treating viral infections or malignancy; whereas others are at stages of clinical 
development. Even though they bind to distinct receptors, they signal through a common, 
classical Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway8,9.  
Once activated, STAT1 and STAT2 are phosphorylated and bind IFN regulatory factor 9 (IRF9) 
to form IFN stimulated gene factor 3 complex (ISGF3). ISGF3 subsequently translocates to 
the nuclues, inducing transcription of hundreds IFN-stimulated genes (ISGs) which 
cooperatively establish an anti-viral state that protects against various types of viruses10. 
Furthermore, IFN induction following RV recognition is essential to promote the 
development of adaptive, B-cell-mediated immune responses11. On the other hand, however, 
RV has developed effective strategies to evade the host immune response12. RV can inhibit 
IFN production in the infected cells13 and also block the action of STAT1 and STAT2 proteins14. 
Viral nonstructural protein NSP1-mediated IFN inhibition has been shown to be associated 
with different levels of RV replication in primary mouse cells15. 
Detectable levels of IFN-α16 and IFN-γ17,18 were documented in chidlren with acute RV 
diarrhea, suggesting a role for these INFs in disease pathogenesis. Indeed, early in vitro19-21 
and animal studies in calves22 and piglets23 demonstrated anti-RV effects of both type I and II 
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IFNs. However, in the murine models of homologous RV infection, administration of type I 
(IFN-α and IFN-β) and II (IFN-γ) IFNs failed to protect the mice against RV infection24. In 
addition, mice deficient in type I or II IFN receptor signaling controlled RV infection as well as 
wild-type mice24,25. These results suggest a minor role of type I and II IFNs in controlling RV 
infection in mice. Interestingly, a more prominent function of type III IFNs in constraining 
viral infection was suggested by experimentation in mouse models25,26. Administration of 
IFN-λ conferred better protection against RV infection than IFN-α/β25. 
Because animal models do not always recapitulate the responsiveness in human, we 
therefore comprehensively assessed the role of endogenous and the therapeutic IFNs on RV 
infection in human intestinal cell line and primary intestinal organoids. We found that the 
basal JAK-STAT cascade is effective in restraining RV infection. Furthermore, RV is sensitive 
to inhibition by all three types of IFNs in both models. Our results strengthen the evidence of 
essential roles of IFN pathway in protecting the host against viral infection.  
Results 
RV infection modulates IFN gene expression 
First, we investigated whether RV SA11 modulates the expression of the three types of IFN 
genes. Human intestinal Caco2 cells were infected with RV SA11 for 48 hours. An effective 
replication was shown by an increase in intracellular RNA level as well as secreted rotavirus 
in culture medium (Supplementary Fig. S1). In addition, immunofluorescence staining 
showed VP6-positive Caco2 cells at 48 hours after infection, indicating productive 
replications (Supplementary Fig. S2). 
Relative RNA levels of ifna, ifnb, ifng, il29 (IFN-λ1) and il28 (IFN-λ2/IFN-λ3) genes were 
examined and compared to uninfected cells at 6, 24, 36 and 48 hours post infection. As 
shown in Fig. 1, RV infection had no major effect on the gene expression at 6 and 24 hours 
post-infection. At 36 hours after infection, only il29 gene expression was notably increased 
by 3.4 ± 1.0 (P < 0.05) fold. Importantly, at 48 hours after infection, the expression of ifna 
and ifnb genes were significantly increased by 2.8 ± 0.6 (P < 0.001) and 2.8 ± 0.5 (P < 0.01) 
fold, respectively. A profound upregulation was observed on il29 by 29.6 ± 10.7 fold (P < 
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0.001). No difference was found on il28 gene expression. The expression level of ifng gene 
was undetectable (data not shown). Together, our findings showed that RV SA11 infection 
preferentially induced il29 (IFN-λ1) gene expression in Caco2 cells. 
 
Figure 1. RV infection modulates IFN gene expression in Caco2 cells. Caco2 cells were infected with 
RV SA11. Relative RNA levels of ifna, ifnb, il29 (IFN-λ1) and il28 (IFN-λ2 and IFN-λ3) genes were 
examined at 6, 24, 36 and 48 hours post infection as compared to uninfected cells. Data were 
normalized to GAPDH and presented as means ± SEM. (n = 3 independent experiments with each of 
3-4 replicates; **P < 0.01; ***P < 0.0001)  
The increased expression of IFN genes does not result in production of 
detectable IFN protein and was not sufficient to limit RV SA11 replication 
To examine whether the increased expression of IFN genes result in IFN production in our 
cell culture system, we collected the conditioned medium (supernatant) derived from 
control and SA11-infected Caco2 cells at 48 hours post-infection. Then, we performed IFN 
production bioassay by adding the conditioned medium into two highly IFN sensitive cell 
lines, Huh7-based ISRE-luciferase and HCV-luciferase reporter cell lines. As shown in Fig. 2A, 
the supernatant from SA11-infected Caco2 cells was not capable of stimulating ISRE reporter, 
while as low as 1 U/mL of IFN-α significantly induced ISRE-luc by 1.8 ± 0.2 fold (P < 0.001). 
Consistently, it was not able to diminish HCV replication, although as low as 0.1 IU/mL of 
IFN-α considerably reduced HCV-luc by 40 ± 7% fold (P < 0.001) (Fig. 2B). 
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The induced expression of IFN-α and IFN-λ1 proteins can signal via autocrine and paracrine 
manner to stimulate ISGs expression. Therefore, to confirm our previous findings from ISRE-
luciferase cell lines, we also examined ISG expression in SA11-infected Caco2 cells. Despite a 
clear induction of IFN genes, we observed no upregulation of ISGs, both at 24 and 48 hours 
post-infection. At 48 hours, some ISGs were significantly downregulated by SA11 infection, 
including IRF1, IRF9, MX1 and IFIT3 (Fig. 2C).  
To rule out the possibility that endogenous IFN produced (if any) following RV infection is 
sufficient to restrict RV replication, we investigated whether the inhibition of JAK proteins, 
the downstream elements of IFN receptor, influences RV replication. Treatment of JAK I 
inhibitor at 5 and 10 μM had no effect on RV replication (Fig. 2D). At those concentrations, 
the drug did not influence the cell viability as determined by MTT assay (Fig. 2E). Collectively, 
our results demonstrate that the increased expression of IFN genes during RV infection does 
not result in IFN production and consequently appears relatively unimportant for 
constraining RV replication in intestinal epithelial cells. 
Basal IFN signaling is necessary to restrict RV replication 
As no functional production of IFN is observed following RV infection, we investigated the 
possibility that constitutive ligand-independent IFN signal transduction defends intestinal 
epithelial cells against RV replication. ISGF3 that consists of STAT1, STAT2 and IRF9 is a 
central complex in IFN signal transduction. We have previously reported that in the absence 
of IFN stimulation, unphosphorylated ISGF3 drives constitutive ISG expression in 
homeostatic conditions and is critical to provide immunity against hepatitis C (HCV) and E 
(HEV) virus infections27. It is thus possible that constitutive IFN signal transduction is 
important for counteracting RV in intestinal cells as well. 
To test this possibility we first transduced Caco2 cells with a lentiviral vector expressing 
STAT1- and STAT2-specific shRNA. A successful knockdown is shown in Fig. 3A and 3C. 
Supplementary Fig. S3 shows the quantification of knockdown efficiency. Importantly, 
shRNA-mediated STAT1 and STAT2 knockdown resulted in an increased RV replication by 3.8 
± 0.6 fold (P < 0.01) (Fig. 3B) and 13 ± 4.6 (P < 0.001) (Fig. 3D), respectively. 
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Next we investigated the role of IRF9. Two of three tested IRF9-specific shRNA (sh-2 and sh-3) 
exert a potent gene silencing capacity (Fig. 3E and Supplementary Fig. S3). Consistently, IRF9 
KD led to 4.8 ± 1.0 fold elevation of RV replication as compared to sh-CTR transfected cells (P 
< 0.001) (Fig. 3F). Altogether, these results indicate that the integrity of ISGF3 complex is 
required to provide basal immunity against RV infections. 
 
Figure 2. The increased expression of IFN genes does not result in production of detectable IFN 
protein and was not sufficient to limit RV SA11 replication. IFN production bioassay was performed 
in ISRE-luciferase (A) and HCV-luciferase (B) cell lines which are highly sensitive to IFN treatment. 
Conditioned medium derived from 48 hours post-RV infection on Caco2 cells was used (n = 3 
independent experiments with each 2-3 replicates). (C) Caco2 cells were infected with RV SA11. 
Relative RNA levels of IFN-stimulated genes (ISGs) were examined at 24 and 48 hours post-infection 
as compared to uninfected cells (n = 3 independent experiments with each 2-3 replicates). (D) Pan-
JAK I inhibitor had no effects on RV replication (n = 3 independent experiments with each 2-3 
replicates).  (E) Pan-JAK I inhibitor did not affect cell viability as determined by MTT assay (OD490 
value) at 48 hours of treatment (n = 3 independent experiments with each 2 replicates). Data were 
presented as means ± SEM., **P < 0.01; ***P < 0.001; ns, not significant.  
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RV SA11 is sensitive to IFN treatment in human intestinal Caco2 cells and 
primary intestinal organoids 
Since we did not find a significant role of endogenous IFN in restricting RV replication, we 
then investigated whether RV was sensitive to exogenous IFN treatment (Fig. 4A). Treatment 
of SA11-infected Caco2 cells with 100 and 1000 IU/mL of IFNα resulted in a potent inhibition 
of RV replication by 79 ± 4% (P < 0.001) and 98 ± 0.7% (P < 0.001) as measured in total RNA 
levels. Similarly, IFNβ treatment at 100 and 1000 IU/mL dose-dependently inhibited total 
viral RNA levels by 60 ± 9% (P < 0.01) and 73 ± 7% (P < 0.001). Type II IFNs also strongly 
reduced RV replication, although the effects were not dose-dependent. At concentration of 
100 and 1000 ng/mL, IFNγ restricted RV replication by 81 ± 6% (P < 0.001) and 68 ± 7% (P < 
Figure 3. The key component of ISGF3 
complex is necessary to restrict RV 
replication. (A) STAT1 knockdown by 
lentiviral shRNA vectors. Western blot 
analysis confirms a successful 
knockdown of total STAT1 protein. (B) 
Correspondingly, knockdown of STAT1 
led to a significant increase of RV 
replication (n = 3 independent 
experiments with 3-4 replicates each). 
(C) Knockdwon of STAT2 by lentiviral 
shRNA vectors. Western blot analysis 
shows a potent decrease of total STAT2 
protein level. (D) Similarly, silencing of 
STAT2 resulted in a prominent increase 
of RV RNA level (n = 3 independent 
experiments with 3-4 replicates each). 
(E) IRF9 knockdwon by lentiviral shRNA 
vectors. Western blot analysis shows a 
potent decrease of IRF9 protein level. 
(F) Knockdown of IRF9 led to a notable 
increase of RV replication (n = 3 
independent experiments with 3-4 
replicates each). Data were presented 
as means ± SEM., **P < 0.01; ***P < 
0.001.  
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0.01). Analysis of intra and extracellular RNA levels also demonstrated the inhibition of RV 
replication by type I and II IFNs in Caco2 cells (Supplementary Fig. S4). 
Next, we investigated anti-RV effects of type III IFNs. Treatment of SA11-infected Caco2 cells 
with 100 and 1000 ng/mL of IFNλ1 resulted in a notable restriction of RV replication by 76 ± 
11% (P < 0.01) and 65 ± 6% (P < 0.001). Inhibition of RV replication was also observed with 
IFNλ2 treatment. At a concentration of 100 and 1000 ng/mL, IFNλ2 decreased RV replication 
by 61 ± 17% (P < 0.01) and 50 ± 7% (P < 0.05), respectively. At a similar concentration, IFNλ3 
significantly dimished RV replication by 52 ± 7% (P < 0.05) and 62 ± 6% (P < 0.01). Analysis of 
intra and extracellular RNA levels also demonstrated the effects of type III IFNs in limiting 
rotavirus replication in Caco2 cells (Supplementary Fig. S4).  
To further confirm the effects of various types of IFNs that we observed in the conventional 
2D cell culture system, we employed a 3D culture model of primary intestinal organoids 
derived from one individual (P1) to more closely mimick the physiological situation in vivo 
(Fig. 4B). Treatment of SA11-infected organoid with 1000 IU/mL of IFNα and IFNβ led to a 
significant reduction of intracellular viral RNA levels by 73.9 ± 7.5% (P < 0.05) and 57.8 ± 7.7% 
(P < 0.05), respectively. Surprisingly, the inhibition by IFNγ was more pronounced. Treatment 
of SA11-infected organoid with 1000 ng/mL of IFNγ significantly reduced intracellular viral 
RNA levels by 99.5 ± 0.1% (P < 0.01) (Fig. 4C). Similarly, treatment with 1000 ng/mL of IFNλ1, 
IFNλ2 or IFNλ3 significantly diminished intracellular viral RNA levels by 70.2 ± 7.6% (P < 0.01), 
78.2 ± 4.2% (P < 0.01) and 79.6 ± 3.6% (P < 0.01), respectively (Fig. 4C). Quantification of 
extracellular (secreted) RNA levels also showed a notable reduction of viral production 
(Supplementary Fig. S5). To confirm these findings, we obtained primary intestinal organoids 
from the second individual (P2). Similarly, treatment of SA11-infected organoid with IFNα 
(1000 IU/mL), IFNγ (1000 ng/mL) and IFNλ1 (1000 ng/mL) significantly reduced total viral 
RNA levels by 74.6 ± 5.1% (P < 0.01), 85.5 ± 4.4% (P < 0.01) and 71.4 ± 10.5% (P < 0.01), 
respectively (Supplementary Fig. S6A). Collectively, these results suggest that all type of IFNs 
effectively inhibit RV replication, both in 2D and 3D culture model system. 
Sensitivity of patient-derived RV strains to type I, II and III IFNs 
Next, we evaluated the sensitivity of patient-derived RV strains against different types of 
IFNs. We treated human RV (G1P[8]) with IFNα 100 IU/mL (as representative of type I IFN), 
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IFNγ 100 ng/mL (type II IFN), IFNλ1 and IFNλ3 100 ng/mL (as representative of type III IFN) 
for 48 hours. Three out of four samples were sensitive to the inhibition by IFNα and all 
samples were inhibited by IFNγ (Fig. 5). Interestingly, only one sample which is sensitive to 
type III IFN treatment. Collectively, our data suggest that type I and II IFN more efficiently 
inhibit the replication of human RV strains as compared to type III IFN. 
 
Induction of the known antiviral ISGs by all three types of IFNs 
The observed anti-RV activity of type I, II and III IFNs prompted us to investigate whether all 
types of IFNs effectively induce the expression of known anti-viral ISGs in Caco2 cells and 
organoid. Although there are hundreds of ISGs, only a subset have broad or targeted 
antiviral effects28. We have selectively investigated the expression of those known antiviral 
ISGs. Indeed, treatment of Caco2 cells with recombinant human IFN-α (1000 IU/mL), IFN-γ 
(1000 ng/mL) and IFN-λ1 (1000 ng/mL) for 24 hours induced the expression a panel of ISGs 
Figure 4. Exogenous 
treatment of type I, II and III 
IFNs inhibits RV SA11 
infection. Antiviral activity of 
IFNα, IFNβ, IFNγ, IFNλ1, IFNλ2 
and IFNλ3 treatment against 
RV SA11 infection on (A) 
Caco2 cells (n = 2-3 
independent experiments 
with each of 3-4 replicates) 
and (C) organoids (n = 3 
independent experiments 
with each of 2-3 replicates) at 
48 hours after infection. Data 
were presented as means ± 
SEM., *P < 0.05; **P < 0.01; 
***P < 0.001. (B) A 
representative picture of the 
morphology of human small 
intestinal organoid at day 4 
post embedding in Matrigel. 
The organoid used in this 
experiment was derived from 
one individual (P1). 
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(Fig. 6A). Similarly, they also efficiently induced ISGs in organoids derived from both P1 (Fig. 
6B) and P2 (Supplementary Fig. S6B). Interestingly, we observed a variation of the type and 
extent of ISG induction with different IFN treatment. For example, IRF1 and RTP4 were more 
induced by IFN-γ as compared to IFN-α in Caco2 cells. In contrast, DDX60 and IFI6 were more 
induced by IFN-α as compared to IFN-γ (Fig. 6A). In organoid (P1), several ISGs were more 
efficiently induced by IFN-λ1 as compared to IFN-α and IFN-γ, including OASL, ISG15 and 
OAS1 (Fig. 6B). 
 
Figure 5. Sensitivity of patient-derived RV strains to type I, II and III IFNs. Caco2 cells were infected 
with four different patient-derived RV strains (G1P[8]) and treated with IFNα 100 IU/mL (as 
representative of type I IFN), IFNγ 100 ng/mL (type II IFN), IFNλ1 and IFNλ3 100 ng/mL (as 
representative of type III IFN). Distinct sensitivity was observed among these patient-derived RV 
samples. Human RV RNA levels were quantified by qRT-PCR at 48 hours post-infection and 
normalized to a reference gene GAPDH. The data are derived from an experiment for multiple 
patient-derived RV strains. 
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Inhibition of JAK-STAT signaling abrogates the anti-RV activity of IFN-α and 
IFN-γ 
The ISG induction by type I and III IFNs is mediated via a similar pathway involving ISGF3 
complex. For type II IFN, its signaling pathway involves phosphorylation and dimerization of 
STAT1 to form IFNγ activation factor (GAF)9. To investigate the role of JAK-STAT signaling 
pathway in the anti-RV effects of IFNs, we used JAK I inhibitor that predominantly inhibit 
JAK1 protein, the upstream element that is responsible for STAT1 and STAT2 
phosphorylation. As expected, JAK I inhibitor (10 μM) efficiently blocked IFNα- and IFNγ-
induced ISG expression in Caco2 cells (Supplementary Fig. S7 and S8). Consistently, JAK I 
inhibitor treatment abolished the anti-RV effects of IFN-α and IFNγ in Caco2 cell lines (Fig. 7A 
and 7B, repectively). These data clearly indicate an important role of JAK-STAT pathway in 
mediating the anti-RV effects of IFNs. 
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Figure 6. ISG induction by type I, II and III IFNs on Caco2 cells and organoids. Caco2 cells (A) and 
organoids (B) were stimulated with IFNα 1000 IU/mL (as representative of type I IFN), IFNγ 1000 
ng/mL (type II IFN) and IFNλ1 1000 ng/mL (as representative of type III IFN) for 24 hours. The 
expression levels of several ISGs were measured by qRT-PCR. The organoid used in this experiment 
was derived from one individual (P1). 
 
 
Figure 7. JAK I inhbitor block the anti-RV effects of IFNα and IFNγ. Caco2 cells were first infected 
with RV SA11 for 60 minutes. After four times washing, IFNα or IFNγ and Pan-JAK I inhibitor were 
added simultaneously to SA11-infected Caco2 cells and then cultured for 48 hours. Pan-JAK I 
inhibitor (10 μM) can block the anti-RV effects of IFNα 100 IU/mL (A) and IFNγ 100 ng/mL (B) in 
Caco2 cells. (n = 3 independent experiments with 2-4 replicates each) Data were presented as means 
± SEM., *P < 0.05; **P < 0.01; ns, not significant. 
Discussion 
The in vitro study of RV biology had mainly been based on the conventional two-dimensional 
(2D) cell culture system of intestinal carcinoma-derived cell lines, including Caco2 and HT29 
cell lines14,29-31. They are homogenous immortalized cell lines that can functionally reflect the 
real biological processes in the humans intestinal epithelium However, they are lacking 
three-dimensional (3D) higher order organisation present in the human intestine in vivo32. 
Recently, 3D models of primary intestinal organoids were developed for studying RV biology 
which better recapitulate the architecture and cellular composition of the human intestine33-
35. Intestinal organoids contain heterogenous and non-transformed cell types, including 
enterocytes, enteroendocrine cells, goblet cells, Paneth cells and stem cells35. Therefore, 
they enable us to investigate individual-specific response associated with histo-blood group 
antigen (HBGAs) profiles and microbiome diversity35. 
Transcriptional analysis of SA11-infected Caco2 cells revealed that RV predominantly 
induced type III (IFNλ1) rather than type I (IFNα and IFNβ) IFN responses. In other intestinal 
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epithelial cells, such as HT29, RV infection induces type I IFN response (IFNβ) and 
subsequently regulates ISG expression29,30,36. However, our findings are consistent with 
previous studies in human intestinal enteroids (organoids) infected with human RV strains in 
which predominant type III IFN responses (IFNλ1 and IFNλ2) were observed34. The relatively 
low induction of type I IFNs in these human epithelial cells is also consistent with studies in 
murine RV37. Following murine RV infection, type I IFN response was mainly produced by 
immune (hematopoietic) cells, not epithelial cells37. A predominant type III IFN response was 
also observed in hepatocytes upon HCV38 and HEV infection39. However, both type I and III 
IFN were similarly induced following influenza virus infection in lung epithelial cells40. Thus, 
all these findings suggest that preferential induction of type I and/or type III IFN response is 
virus- and cell type-specific and reflects the complex regulation of type I and III IFN induction 
following viral infections. 
Despite a clear induction of type III IFN responses, our IFN production bioassay found 
undetectable levels of IFN proteins in the (conditioned) culture medium from SA11-infected 
Caco2 cells (Fig. 2A and 2B). Consistently, we did not observe ISG upregulation in SA11-
infected Caco2 cells (Fig. 2C), indicating an absence of secreted IFN to stimulate ISG 
expression in an autocrine and/or paracrine manner. Further analysis by inhibiting 
downstream IFN signaling using JAK inhibitors demonstrated that RV replication levels were 
not altered. In human intestinal enteroids (organoids) infected with human RV strains, type 
III IFN induction was followed by stimulation of type III-dependent ISGs34. These 
discrepancies may be due to different RV strains as well as the different cellular composition 
of both models. However, despite this ISG induction, blockade of type I and III IFN receptor 
had no effects on RV replication34. Altogether, these findings indicate that endogenously 
produced IFNs (if any) were not sufficient to limit RV replication, even though they were able 
to induce ISGs in intestinal organoid models. These findings also suggest the ability of RV to 
subvert innate immune responses. It is known that RV have multiple ways to blunt innate 
IFN responses12. It has been shown that RV nonstructural protein 1 (NSP1) interacts with 
IRF3 to promote its degradation, leading to attenuation of IFN induction41.  
While previous studies mainly focused on the role of STAT1 in RV replication15,42, here we 
highlighted the role of basal IFN signaling in constraining RV infection. Individual knockdown 
of ISGF3 component, i.e. STAT1, STAT2 and IRF9, led to an elevated level of RV replication. 
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Similarly, STAT1 knockout (KO) mice shed a significantly higher titer of RV than wild-type (WT) 
controls42. STAT1 is also shown to protect against lethal challenge of murine norovirus 
infection in mice43. In dengue virus (DENV)-infected mice, STAT2 was essentially required to 
protect against DENV-mediated diseases independently of STAT144. Our findings are also 
consistent with our previous in vitro studies demonstrating that unphosphorylated ISGF3 
complex is responsible for maintaining basal transcription of ISGs in the absence of IFN 
stimulation to provide a “combat-ready” antiviral state in the susceptible host27. Thus, 
constitutive IFN signaling, ligand independent but maintained by background expression of 
its essential component, including STAT1, STAT2 and IRF9, are pivotal to restrict RV 
replication in the intestinal epithelium.  
While endogenous IFN response was not able to reduce RV replication, exogenous IFN 
treatment was effective to limit RV replication. We demonstrated that all three types of IFNs 
have notable antiviral effects against simian RV SA11 both in Caco2 cells and human 
organoids. Patient-specific organoid lines have promising implications for personalized 
medicine. Noteworthy, our study employed organoids derived from only two individuals. In 
this aspect, using organoids derived from several numbers of patients would be much better 
in recapitulating inter-individual variations, including HBGAs profiles, microbime diversity 
and genetic background32,35.  
We have also successfully cultivated four human-derived RV strains from acute diarrhea 
patients. Treatment with representative type I (IFNα), II (IFNγ) and III (IFNλ1 and IFNλ3) IFNs 
showed various sensitivity of human RV to IFNs, in which more pronounced inhibition was 
observed with type I and II rather than type III IFN treatment. In previous studies using 
human organoid models, type I IFN was more effective than type III IFN to suppress human 
RV replication34. However, conflicting results were found from in vivo studies about the 
relative contributions of type I and III IFNs during RV infections25,26,45. Type I IFN response 
plays a functional role to limit extra-intestinal spread in the mesenteric lymph node (MLN)45. 
On the other hand, RV has the capacity to attenuate the antiviral actions of IFNs14. Our study 
therefore suggests that human RV may differentially adapt in homologous host. 
While many previous studies mainly focused on the effects of type I and III IFNs, our study 
highlights the role of type II IFN (IFNγ) in limiting RV replication. Previous studies showed 
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that IFNγ level in the serum was significantly higher in children with RV diarrhea than those 
of control children17. In our study, transcriptional analysis showed that IFNγ mRNA level was 
not detectable from SA11-infected Caco2 cells (data not shown). However, it has been 
shown that IFNγ was produced from human peripheral blood mononuclear cells (PBMCs) 
stimulated with RV46. Consistently, the level of IFNγ gene expression as well as secreted level 
in the supernatant of PBMCs were significantly elevated in children with RV diarrhea as 
compared with controls18,47. These findings suggest that immune cells, and not epithelial 
Caco2 cells, were responsible for IFNγ production upon RV infection.  
RV-specific CD4+ and CD8+ IFNγ+ T cells were detected in the peripheral blood of RV-
infected children and adults48,49. IFNγ producing T cells were also observed following 
experimental vaccines in animals and associated with disease protection21,50,51. It was 
previously shown that IFNγ inhibit RV entry into Caco2 cells20. In our study, we found that 
human IFNγ significantly reduces RV replication, suggesting that IFNγ can inhibit RV infection 
at various steps of the life cycle in the infected cells. In apparent agreement, it was 
suggested that IFNγ responses critically determine the severity of RV diseases in children52.  
ISGs are the ultimate effectors of IFN-mediated antiviral responses. Based on our findings, all 
three types of IFNs effectively induced a panel of well-known anti-viral ISGs both in Caco2 
cells and in human organoids. However, further studies are needed to identify specific anti-
RV ISGs to improve our understanding of immunity against RV infections. In conclusions, our 
study describes the role of both endogenous and exogenous IFN in RV infection, as well as 
the role of both basal and activated IFN signaling in limiting RV infection. These knowledge 
shall contribute to the better understanding of RV-host interactions and therapeutic 
development. 
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Material and Methods 
Reagents 
Type I human recombinant IFN alpha 2a (IFNα; Thermo Scientific) and IFN beta 1a (IFNβ; 
Sigma-Aldrich; Catalog Number 14151); Type II IFN gamma (IFNγ; BioLegend; Catalog# 
570202), and Type III IFNs IL29 (IFNλ1; Abnova), IL28A (IFNλ2; Abnova) and IL28B (IFNλ3; 
Abnova) were dissolved in culture medium. Stocks of Jak inhibitor I (Santa Cruz Biotech, CA) 
was dissolved in DMSO (Sigma-Aldrich, St Louis, MO, USA) with a final concentration of 5 
mg/mL. Anti-STAT1 antibody (#9172) was purchased from Cell Signaling Technology. IRF9 
antibody was obtained from LSBio (Life Span BioSciences, Inc). β-actin and STAT2 (sc-476) 
antibodies were purchased from Santa Cruz Biotechnology. Anti-rabbit or anti-mouse IRDye-
conjugated antibodies were used as secondary antibodies for western blotting (Stressgen, 
Victoria, BC, Canada).  
Viruses 
Simian RV SA11, a broadly used laboratory strains, was employed. SA11 RV used in this study 
was prepared as described previously53. RV genome copy numbers were determined by 
quantitative real-time polymerase chain reaction (qRT-PCR). A plasmid template was used to 
generate a standard curve by plotting the log copy number versus the cycle threshold (CT) as 
previously described 33.  
Human-derived RV strains (G1P[8]) were obtained from fecal samples of four RV patients 
and stored at -80 oC freezer (the Erasmus MC Biobank, Department of Viroscience, Erasmus 
Medical Center, Rotterdam). These samples were collected during diarrhea period and 
tested negative for enterovirus, parechovirus, norovirus genogroup I and II, adenovirus, 
astrovirus and sapovirus by qRT-PCR. The patient characteristics were shown in 
Supplementary Table S1. 
Cell and human primary intestinal organoid culture 
Caco2 cell line (human caucasian colon adenocarcinoma ECACC) was cultured in Dulbecco’s 
modified Eagles’s medium (DMEM; Lonza, Verviers, Belgium) containing 20% (vol/vol) heat-
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inactivated fetal calf serum (FCS; Sigma-Aldrich, St. Louis USA), 100 U/mL penicillin and 
streptomycin (Gibco, Grand Island, USA). The cells were maintained in 5% CO2 at 37 oC in a 
humidified incubator.  
Organoid culture was performed as described previously33. Briefly, intestinal tissues taken 
from biopsy were vigorously shaken in 8 mM EDTA for 15 min at 4 oC. The EDTA solution was 
then discarded. Loosened crypts were collected by pipetting the solution up and down for 8-
10 times through a 10 mL pipette and transferred into a 50 mL tube (Greiner Bioone, the 
Netherlands). The biopsies were repeatedly used for crypts collection (2-3 times). Crypt 
suspensions were pooled and centrifuged at 300 g for 5 min. The crypt pellets were 
resuspended in 2 mL complete medium containing growth factors CMGF-: advanced 
DMEM/F12 supplemented with 1% (vol/vol) GlutaMAX™ Supplement (Gibco, Grand island, 
USA), 10 mM HEPES. The crypts were collected by centrifugation at 130g for 5 min at 4 oC, 
suspended in matrigel (Corning, Bedford, USA) and placed in the center of a 24-well plate (40 
μL per well). After the matrigel had solidified (15 min at 37 OC), organoids were maintained 
in culture medium at 37 oC, 5% CO2. Culture medium was refreshed every 2-3 days, and 
organoids were passaged every 6-7 days. 
Inoculation of SA11 and human-derived RV strains and treatment 
Caco2 cells cultured in T75 flask were suspended and subsequently seeded into 48-well plate 
(5 * 104 cells/well) in DMEM complemented with 20% (vol/vol) FCS and 100 IU/mL penicillin-
streptomycin. After 2-3 days of culture, culture medium was removed when the cell 
confluence was about 80%. The cell layers were then washed twice with 500 μL PBS. Serum-
free DMEM medium (100 μL) containing 5 μg/mL of trypsin (Gibco, Paisley, UK) and SA11 RV 
were added and incubated for 60 min at 37 oC with 5% CO2 to allow efficient infection, 
followed by four times washing with PBS (500 μL each) to remove free virus particles. 
Subsequently, culture medium containing 5 μg/mL of trypsin (and indicated treatments) 
were added to the infected cells and incubated for 24 or 48 hours at 37 oC with 5% CO2. 
For organoid infection, SA11 RV (contain 5000 genome copies) was first activated with 5 
μg/mL of trypsin at 37 oC with 5% CO2 for 30 minutes. Subsequently, organoids were infected 
with the activated SA11 for 60 minutes at 37 oC with 5% CO2, followed by four times washing 
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with PBS to discard the free viruses. Organoids were then aliquoted into 48-well plates that 
have been coated with 20% (vol/vol) Collagen R Solution (SERVA, Heidelberg, Germany) and 
maintained in culture medium containing indicated treatments at 37 oC with 5% CO2. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total, intracellular or extracellular (secreted) RNA was isolated by using the Machery-
NucleoSpin RNA II kit (Bioke, Leiden, The Netherlands) and quantified by a Nanodrop ND-
1000 spectrophotometer (Wilmington, DE, USA). cDNA was made from total RNA using a 
cDNA Synthesis Kit (Takara Bio Inc, Shiga, Japan) with random hexamer primers. qRT-PCR of 
RV RNA and genes of interest were performed with a SYBRGreen-based real-time PCR (MJ 
Research Opticon, Hercules, CA, USA) according to the manufacturer’s instructions with the 
StepOnePlus System (Thermo Fisher Scientific Life Sciences). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene was used as a housekeeping gene to normalize (relative) gene 
expression using the 2-ΔΔCT formula. All primers used in this study are listed in 
Supplementary Table S2. 
Lentiviral vector production and transfection assays  
Lentiviral pLKO knockdown vectors (Sigma–Aldrich) targeting STAT1, STAT2 and IRF9 or 
scrambled control, were obtained from the Erasmus Center of Biomics. All shRNA sequences 
are listed in Supplementary Table S3. The lentiviral vectors were produced in human 
embryonic kidney epithelial cell line HEK 293T cells as previously described54. The shRNA 
vectors exerting optimal gene knockdown were selected. To generate the gene knockdown 
cells, Caco2 cells were transduced with the lentiviral vectors and subsequently selected by 
adding puromycin (8 μg/mL; Sigma) to the culture medium. Knockdown and control Caco2 
cells were infected with RV as previously described. 
IFN production bioassay 
The IFN production bioassay was performed to detect secreted IFN proteins in the culture 
medium as described previously55. Briefly, the culture (conditioned) medium derived from 
control and SA11-infected Caco2 cells (48 hours) were collected and filtered through 0.45 
μm pore size membrane. Two luciferase reporter models which are extremely sensitive to 
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IFN treatments were employed. Huh7.5-ET-Luc luciferase model is a hepatitis C virus (HCV) 
replicon (I389/NS3-3V/LucUbiNeo-ET) in which the HCV-related firefly luciferase activity 
(HCV-luc) can be potently inhibited by a low concentration of IFN-α treatments. Huh7-ISRE-
luc is a luciferase reporter model in which the firefly luciferase gene was driven by multiple 
IFN-stimulated response elements (ISRE) promoter. In this model, the firefly luciferase 
activity can be potently stimulated by a low concentration of IFN-α treatment. Therefore, 
these two luciferase models can be employed to sensitively detect the presence of IFN 
proteins in the conditioned medium. Huh7 HCV-luc and ISRE-luc cells were cultured in 
DMEM supplemented with 10% FCS (vol/vol), 100 U/mL penicillin and streptomycin. For 
Huh7 HCV-luc, 250 μg/mL G418 (Sigma-Aldrich) was added to the culture medium. 
Western blot assay 
Cultured cells were lysed in Laemmli sample buffer containing 0.1 M dithiothreitol (DTT) and 
heated for 5 min at 95°C. Cell lysates were subjected to 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) for 100 min running at 110 V.  The proteins 
were transferred onto polyvinylidene difluoride (PVDF) membrane (Immobilon-FL) for 1.5 
hours with an electric current of 250 mA. Subsequently, the membrane was blocked with a 
mixture of 2.5 ml of blocking buffer (Odyssey) and 2.5 ml of PBS containing 0.05% Tween 20 
for 1 hour at room temperature. This was followed by an overnight incubation with the 
indicated primary antibody (1:1000 dilution) at 4°C. The membrane was then washed three 
times, followed by incubation for 1 hour with IRDye-conjugated secondary antibody (1:5000 
dilution) at room temperature. After washing three times, the protein bands were detected 
with the Odyssey 3.0 Infrared Imaging System. The intensity of the immunoreactive bands of 
blotted proteins was quantified by the Odyssey V3.0 software.  
Immunofluorescence microscope assay 
Caco2 cells were seeded on glass coverslips. After SA11 infection for 48 hours, cells were 
washed with PBS, fixed in 4% PBS-buffered formalin for 10 mins and blocked with tween-
milk-glycine medium (PBS, 0.05% tween, 5g/L skim milk and 1.5g/L glycine). Samples were 
incubated with anti-rotavirus (ab181695) antibody (Abcam) overnight at 4 °C. Subsequently, 
samples were incubated with 1:1000 dilutions of Alexa FluorTM 594 goat anti-mouse 
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secondary antibodies (Invitrogen). Nuclei were stained with DAPI (4,6-diamidino-2-
phenylindole; Invitrogen). Images were detected using immunofluorescence microscope. 
MTT assay 
10 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) was 
added to Caco2 cells seeded in 96-well plates at indicated time points. The cells were 
incubated at 37 0C with 5% CO2 for 3 hours. The culture medium was then removed and 100 
μl of dimethyl sulfoxide (DMSO) was added to each well. The absorbance of each well was 
read on the microplate absorbance readers (BIO-RAD) at wavelength of 490 nm.  
Study Approval 
Human intestinal tissue were obtained during surgical resection. A written informed consent 
was signed by the volunteers or patients who agreed to participate. The study was approved 
by the Medical Ethical Committee of the Erasmus Medical Center (Medisch Ethische 
Toetsings Commissie Erasmus MC), and all experiments were performed in accordance with 
relevant guidelines and regulations. 
Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-Whitney 
test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values <0.05 were 
considered statistically significant. 
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Supplementary Information 
 
 
Supplementary Figure S1.Efficient replication of rotavirus SA11 in Caco2 cells as demonstrated by 
qRT-PCR. Intracellular (A) and secreted (extracellular) levels (B) of rotavirus SA11 were detected and 
quantified by qRT-PCR at 0 (before virus inoculation) as well as at 1, 24 and 48 hours after inoculation. 
For intracellular RNA quantification (A), RV RNA levels were shown as fold increases relative to 1 
hour post infection. GAPDH was used as the housekeeping gene. 
 
 
 
Supplementary Figure S2. Efficient replication of rotavirus SA11 in Caco2 cells as demonstrated by 
immunofluorescence stainings. Representrative immunofluorescence stainings of ab181695 
(targeting VP6 rotavirus protein) (red) after 48 hours infection of Caco2 cells with rotavirus SA11. 
Nuclei were visualized by DAPI (blue).  
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Supplementary Figure S3. Western blot assays showed a successful knockdown of STAT1 (58% 
reduction), STAT2 (69% reduction) and IRF9 proteins (69% and 77% reduction). β-actin served as an 
internal reference. (means ± SEM, n = 3).  
 
Supplementary Figure S4. 
The effects of exogenous 
treatment of type I, II and III 
IFNs on RV SA11 replication 
in Caco2 cells. Antiviral 
activities of IFNα, IFNβ, IFNγ, 
IFNλ1, IFNλ2 and IFNλ3 
treatments against RV SA11 
infection on Caco2 cells were 
determined by quantifying 
intracellular (A) and 
extracellular (secreted) (B) 
RNA levels at 48 hours post-
infection. (n = 2-3 
independent experiment 
with each of 3 replicates) 
Data were presented as 
means ± SEM., *P < 0.05; **P 
< 0.01; ***P < 0.001; ns, not 
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Supplementary Figure S5. The effects of type I, II and III IFNs on the extracellular level of RV SA11 
in human organoids. Antiviral effects of IFNα, IFNβ, IFNγ, IFNλ1, IFNλ2 or IFNλ3 treatment against RV 
SA11 infection in organoids were determined by quantifying extracellular (secreted) RNA levels at 48 
hours post-infection. The organoids were derived from one individual (P1). Data were presented as 
means ± SEM., *P < 0.05; **P < 0.01; ns, not significant. (n = 3 independent experiments with each of 
2-3 replicates). 
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Supplementary Figure S6. (A) Antiviral effects of representative type I (IFNα, 1000 IU/mL), type II 
(IFNγ, 1000 ng/mL), and type III (IFNλ1, 1000 ng/mL) treatment against RV SA11 infection in 
organoids were determined by quantifying total RV RNA levels at 48 hours post-infection. The 
organoid was derived from individual 2 (P2). Data were presented as means ± SEM, **P < 0.01. (n = 3 
independent experiments with each of 1-2 replicates). (B) Organoids (P2) were stimulated with IFNα 
1000 IU/mL, IFNγ 1000 ng/mL and IFNλ1 1000 ng/mL for 24 hours. The expression levels of several 
ISGs were measured by qRT-PCR.   
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Supplementary Figure S7. JAK I inhbitor blocks IFNα-induced ISGs in Caco2 cells. JAK I inhibitor (10 
μM) abrogated IFNα- (100 IU/mL) induced ISG expression as measured by qRT-PCR. Data were 
presented as means ± SEM., *P < 0.05; **P < 0.01; ns, not significant. (n = 3 independent 
experiments with each of 2-3 replicates) 
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Supplementary Figure S8. JAK I inhbitor abolishes IFNγ-induced expression of ISGs in Caco2 cells. 
JAK I inhibitor (10 μM) abrogated IFNγ- (100 ng/mL) induced ISG expression as measured by qRT-PCR. 
Data were presented as means ± SEM., *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant. (n = 3 
independent experiments with each of 2-3 replicates) 
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Supplementary Table S1. Patient characteristics. 
 
 
 
Patient Age 
(years) 
Gender Clinical symptoms  Virus Detection 
Enterovirus Parechovirus Norovirus 
genogroups 
I 
Norovirus 
genogroups 
II 
Adenovirus Astrovirus Sapovirus Rotavirus 
1 74 Female Congestive heart 
failure, myocarditis 
No No No No No No No Yes 
2 27 Female Fever, diarrhea, 
nausea, vomiting 
No No No No No No No Yes 
3 67 Male Fever, stomach 
ache, watery 
diarrhea (Kidney 
transplant) 
No No No No No No No Yes 
4 1.5 Female Vomiting, watery 
diarrhea 
No No No No No No Yes Yes 
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Supplementary Table S2. Primers used in this study.  
Target Genes Sequences (5’ - 3’) 
Viruses  
RV SA11-F TGGTTAAACGCAGGATCGGA 
RV SA11-R AACCTTTCCGCGTCTGGTAG 
Human RV-F ACCATCTACACATGACCCTC 
Human RV-R CACATAACGCCCCTATAGCC 
Human Genes  
IRF1-F GAGGAGGTGAAAGACCAGAGCA 
IRF1-R TAGCATCTCGGCTGGACTTCGA 
DDX58-F CACCTCAGTTGCTGATGAAGGC 
DDX58-R GTCAGAAGGAAGCACTTGCTACC 
IFIH1(MDA5)-F GCTGAAGTAGGAGTCAAAGCCC 
IFIH1(MDA5)-R CCACTGTGGTAGCGATAAGCAG 
IFITM1-F GGCTTCATAGCATTCGCCTACTC 
IFITM1-R AGATGTTCAGGCACTTGGCGGT 
IFITM3-F CTGGGCTTCATAGCATTCGCCT 
IFITM3-R AGATGTTCAGGCACTTGGCGGT 
IRF2-F TAGAGGTGACCACTGAGAGCGA 
IRF2-R CTCTTCATCGCTGGGCACACTA 
IRF7-F CCACGCTATACCATCTACCTGG 
IRF7-R GCTGCTATCCAGGGAAGACACA 
IRF9-F CCACCGAAGTTCCAGGTAACAC 
IRF9-R AGTCTGCTCCAGCAAGTATCGG 
DDX60-F GGTGTTTTCACCAGGGAGTATCG 
DDX60-R CCAGTTTTGGCGATGAGGAGCA 
IFI44L-F TGCACTGAGGCAGATGCTGCG 
IFI44L-R TCATTGCGGCACACCAGTACAG 
OASL-F GTGCCTGAAACAGGACTGTTGC 
OASL-R CCTCTGCTCCACTGTCAAGTGG 
IFI6-F TGATGAGCTGGTCTGCGATCCT 
IFI6-R GTAGCCCATCAGGGCACCAATA 
TREX-F GCATCTGTCAGTGGAGACCACA 
TREX-R CAGTGGTTGTGACAGCAGATGG 
RTP4-F GACGCTGAAGTTGGATGGCAAC 
RTP4-R GTGGCACAGAATCTGCACTTGG 
ADAR-F TCCGTCTCCTGTCCAAAGAAGG 
ADAR-R TTCTTGCTGGGAGCACTCACAC 
FAM46C-F CCTTGAACAGCAGAGGAAGTTGG 
FAM46C-R GGAGATGAGGTTCAGAGTCTGC 
LY6E-F GACCAGGACAACTACTGCGTGA 
LY6E-R AAGCCACACCAACATTGACGCC 
PKR-F GAAGTGGACCTCTACGCTTTGG 
PKR-R TGATGCCATCCCGTAGGTCTGT 
ISG15-F CTCTGAGCATCCTGGTGAGGAA 
ISG15-R AAGGTCAGCCAGAACAGGTCGT 
OAS1-F AGGAAAGGTGCTTCCGAGGTAG 
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OAS1-R GGACTGAGGAAGACAACCAGGT 
OAS3-F CCTGATTCTGCTGGTGAAGCAC 
OAS3-R TCCCAGGCAAAGATGGTGAGGA 
IFI27-F CGTCCTCCATAGCAGCCAAGAT 
IFI27-R ACCCAATGGAGCCCAGGATGAA 
IFIT3-F CCTGGAATGCTTACGGCAAGCT 
IFIT3-R GAGCATCTGAGAGTCTGCCCAA 
IFNαR1-F CGCCTGTGATCCAGGATTATCC 
IFNαR1-R TGGTGTGTGCTCTGGCTTTCAC 
IFNλR1-F CAGCAAGTTCTCTAAGCCCACC 
IFNλR1-R GTCATTCACGGACTCTGGTCTG 
IFNα-F GACTCCATCTTGGCTGTGA 
IFNα-R TGATTTCTGCTCTGACAACCT 
IFNβ1-F CTTGGATTCCTACAAAGAAGCAGC 
IFNβ1-R TCCTCCTTCTGGAACTGCTGCA 
IFN-γ-F GAGTGTGGAGACCATCAAGGAAG 
IFN-γ-R TGCTTTGCGTTGGACATTCAAGTC 
IFNλ1 (IL-29)-F  GGAAGACAGGAGAGCTGCAACT 
IFNλ1 (IL-29)-R AACTGGGAAGGGCTGCCACATT 
IFNλ2/3 (IL-28)-F TCGCTTCTGCTGAAGGACTGCA 
IFNλ2/3 (IL-28)-R CCTCCAGAACCTTCAGCGTCAG 
GAPDH-F TGTCCCCACCCCCAATGTATC 
GAPDH-R CTCCGATGCCTGCTTCACTACCTT  
Supplementary Table S3. Lentiviral sh-RNA sequences used in this study. 
Name Oligo Sequences (5’ - 3’) 
shSTAT1 CCGGCGACAGTATGATGAACACAGTCTCGAGACTGTGTTCATCATACTGTCGTTTTT 
shSTAT2 CCGGGCTGAGCCATAGGTCTAAATACTCGAGTATTTAGACCTATGGCTCAGCTTTTT 
shIRF9-1 CCGGTTCAAGGCCTGGGCAATATTTCTCGAGAAATATTGCCCAGGCCTTGAATTTTTG 
shIRF9-2 CCGGGAGACTTGGTCAGGTACTTTCCTCGAGGAAAGTACCTGACCAAGTCTCTTTTTG 
shIRF9-3 CCGGCTCAGTAGTTGTCCGTGATAACTCGAGTTATCACGGACAACTACTGAGTTTTTG  
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Abstract 
Active virus-host interactions determine the outcome of pathogen invasions. It has been 
shown that in isolated dendritic cells (DCs), rotavirus can induce the expression of tumor 
necrosis factor α (TNF-α), a vital cytokine mediating host immune responses. However, the 
role of TNF-α in rotavirus infection is unknown. In this study, we demonstrated that TNF-α 
has potent anti-rotavirus effects, independent of type I interferon production. Blocking of 
TNF-α by infliximab, a clinically available TNFα antibody, totally abrogated this effect. 
Mechanistic studies revealed that the anti-rotavirus effect of TNF-α was achieved by NFκB-
regulated genes via the activation of classical nuclear factor κB (NF-κB) signaling. Our study 
reveals the pivotal role and the mechanism-of-actions of TNF-α in the host defense against 
rotavirus. Thus, this knowledge may contribute to the better understanding of the 
complexity of rotavirus-host interactions.  
 
Keywords: antiviral; cytokines; NF-κB signaling; rotavirus; TNF-α 
  
Chapter 7 
148 | P a g e  
 
1. Introduction 
Rotavirus is a viral pathogen that causes severe gastroenteritis worldwide, especially in 
children under five years of age (Tate et al., 2012). It is also prevalent in 
immunocompromised patients, such as pediatric and adult organ transplant recipients (Yin 
et al., 2015b). Notably, gastrointestinal infections including rotavirus have been recognized 
as potential cause of exacerbation and induction of flares in inflammatory bowel disease 
(IBD) patients (Masclee et al., 2013). Rotavirus primarily infects mature enterocytes at the 
tips of the intestinal villus, leading to acute diarrhea (Greenberg and Estes, 2009). However, 
systemic infections can occur which involve multiple extra-intestinal organs, including liver, 
kidney and the central nervous system (Chiappini et al., 2005).  
The innate and adaptive immune systems play an essential role in the limitation of rotavirus 
infection in infected hosts (Angel et al., 2012; Holloway and Coulson, 2013). Rotavirus can 
induce the production of interferons (IFNs) and cytokines, including interferon α (IFN-α), IFN-
β, tumor necrosis factor α (TNF-α), interleukin 6 (IL-6) and also IL-8 in dendritic cells (DCs) 
(Deal et al., 2010; Mesa et al., 2007; Rosales-Martinez et al., 2016). Previous studies have 
demonstrated a role for the different types of IFNs in constraining rotavirus infection 
(Hernandez et al., 2015; Lin et al., 2016; Saxena et al., 2017). In addition, we have previously 
shown that rotavirus modulates the expression of interferon-stimulated genes (ISGs) that 
cooperatively mediate an anti-viral state in the infected cells (Yin et al., 2015a). On the other 
hand, rotavirus efficiently develops strategies to counteract these anti-viral responses 
(Arnold et al., 2013; Ding et al., 2016), indicating an active and dynamic virus-host interplay 
following infection. 
TNF-α was first described as a serum factor that mediates killing of tumors in vitro, from 
which it derives its name (Carswell et al., 1975). Further studies discovered that TNF-α is a 
potent and essential mediator of inflammatory responses. Aberrant regulations of TNF-α 
have been associated with many immune-mediated inflammatory diseases, such as 
rheumatoid arthritis (RA) and IBD. This has led to the development of therapeutic agents 
targeting TNF-α that are now successfully used in the clinic (Kalliolias and Ivashkiv, 2016; 
Sedger and McDermott, 2014). However, these TNF-α antagonists are well known to 
increase the risk of severe viral (including rotavirus) and bacterial infections, thus limiting 
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their use in groups of patients (Kim and Solomon, 2010; Sedger and McDermott, 2014). This 
phenomenon highlights the fact that TNF-α has either direct or indirect effects against 
bacterial and viral infections. Indeed, several studies have demonstrated the anti-viral and 
anti-bacterial properties of TNF-α against influenza virus (Seo and Webster, 2002), hepatitis 
C (HCV) and E (HEV) viruses (Wang et al., 2016), poxviruses (Bartee et al., 2009), and 
Mycobacterium tuberculosis (Flynn et al., 1995), either alone or in combination with IFNs. 
However, the potential activity of TNF-α on rotavirus has not yet been described. Here we 
report that TNF-α has potent anti-viral effects against rotavirus. However, its anti-rotavirus 
effect is totally independent of interferon production and the IFN signaling pathway. 
Importantly, these effects are achieved by the induction of NFκB-regulated genes through 
the activation of classical nuclear factor κB (NF-κB) signaling. This study therefore 
strengthens the role of TNF-α production as a host immune response in defending against 
viral infections.  
2. Materials and Methods 
2.1. Reagents 
Recombinant human TNF-α (Peprotech, USA) was dissolved in phosphate-buffered saline 
(PBS) to a final concentration of 100 μg/mL. Human recombinant IL32A (GeneTex), IL8 
(Abnova), CXCL10 (BioLegend), CXCL11 (BioLegend), CCL20 (BioLegend) and CCL2 (BioLegend) 
was dissolved to a final concentration of 10 μg/mL. Stock of JAK I inhibitor (Santa Cruz 
Biotech, CA) was dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO, USA) 
with a final concentration of 5 mM. ReIA (p65) antibody (C22B4, #4764) was purchased from 
Cell Signaling Technology (Leiden, The Netherlands). β-actin and TNFR1 antibody (sc-8436) 
were purchased from Santa Cruz Biotechnology. β-tubulin antibody (ab6046) was purchased 
from Abcam. Anti-VP4 mouse monoclonal antibody (HS-2) was generously provided by 
Professor Harry Greenberg (Standford University School of Medicine, USA). Anti-rabbit or 
anti-mouse IRDye-conjugated antibodies were used as secondary antibodies for western 
blotting (Stressgen, Victoria, BC, Canada).  
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2.2. Rotavirus SA11 and human-derived strain 
A well-characterized and broadly used laboratory strain, simian rotavirus SA11, was 
employed. SA11 rotavirus strain used in this study was prepared as previously described 
(Knipping et al., 2012). Rotavirus genome copy numbers were determined by quantitative 
real-time polymerase chain reaction (qRT-PCR) referring to a plasmid template using a 
standard curve calculation method as described previously (Yin et al., 2015a). A standard 
curve was generated by plotting the log copy number versus the cycle threshold (CT) value 
(Supplementary Figure 1). Human rotavirus (huRV) strains were isolated form rotavirus 
diarrhea patients as described previously (Yin et al., 2015a). 
2.3. Cell culture 
Caco2 cell line (human caucasian colon adenocarcinoma ECACC) was cultured in Dulbecco’s 
modified Eagles’s medium (DMEM; Lonza, Verviers, Belgium) supplemented with 20% 
(vol/vol) heat-inactivated fetal calf serum (FCS; Sigma-Aldrich, St. Louis USA), 100 U/mL 
penicillin and 100 U/mL streptomycin (Gibco, Grand Island, USA). The cells were maintained 
in 5% CO2 at 37 oC in a humidified incubator.  
2.4. Inoculation of SA11 and huRV rotavirus and treatment 
Caco2 cell lines (not differentiated) maintained in T75 flasks were suspended and 
subsequently seeded into 48-well plates (5 * 104 cells/well) in DMEM containing 20% 
(vol/vol) FCS and 100 U/mL penicillin-streptomycin. When the cell confluence was 
approximately 80% after 2-3 days of culture, culture medium was discarded. The cell 
monolayer was then washed twice with PBS. 100 μL of serum-free DMEM medium 
containing 5 μg/mL of trypsin (Gibco, Paisley, UK) and SA11 rotavirus (MOI 0.7) were added 
and incubated at 37 oC with 5% CO2 for 60 min for infection, followed by three times washing 
with PBS to remove free, uninfecting virus particles. Subsequently, the cells were added with 
serum-free culture medium containing 5 μg/mL of trypsin (and indicated treatments) and 
incubated at 37 oC with 5% CO2 for 48 hours. Inoculation protocol of huRV strains is similar 
to to inoculation of SA11 rotavirus. 
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2.5. Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA was isolated with a Machery-NucleoSpin RNA II kit (Bioke, Leiden, The 
Netherlands) and quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). cDNA was 
prepared from total RNA using a cDNA Synthesis Kit (Takara Bio Inc) with random hexamer 
primers. qRT-PCR was performed with a SYBRGreen-based real-time PCR (MJ Research 
Opticon, Hercules, CA, USA) according to the manufacturer’s instructions. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was considered as a reference gene to normalize 
gene expression. Relative gene expressions were normalized to GAPDH using the formula 2-
ΔΔCT (ΔΔCTsample – ΔΔCTcontrol). The SA11 rotavirus sense and anti-sense primers target 564-
585 and 719-699 of the VP6 segment of SA11 genome, respectively. All primers used in this 
study are listed in Supplementary Table 1. 
2.6. IFN production bioassay 
The IFN production bioassay was performed to detect secreted IFN proteins in the culture 
medium as described previously (Xu et al., 2016). Caco2 cells were seeded into 48-well 
plates and stimulated with TNF-α 10 ng/mL. After 24 hours, medium was removed and the 
cell monolayer was washed three times with PBS. Subsequently, the medium was refreshed 
and cultured for another 24 hours to let the produced IFNs secreted into the medium. The 
culture (conditioned) medium were then collected and filtered through 0.45 μm pore size 
membrane. To detect the presence of IFNs, Huh7-ISRE-luc reporter cell lines was used. 
Huh7-ISRE-luc is a luciferase reporter model in which the firefly luciferase gene was driven 
by multiple IFN-stimulated response elements (ISRE) promoter. In this model, the firefly 
luciferase activity can be potently stimulated by a low concentration of IFN-α treatment. 
Huh7-ISRE-luc cells were cultured in DMEM supplemented with 10% FCS (vol/vol), 100 U/mL 
penicillin and streptomycin.  
2.7. Gene knockdown using lentiviral vectors  
Lentiviral pLKO knockdown vectors (Sigma-Aldrich) targeting TNFR1 and ReIA (p65) or 
scrambled control, were obtained from the Erasmus Center of Biomics and produced in 
human embryonic kidney epithelial cell line HEK 293T cells as described previously (Pan et al., 
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2009). After a pilot study, the shRNA vectors exerting optimal gene knockdown were 
selected. All shRNA sequences are listed in Supplementary Table 2. As the lentiviral vectors 
also encode a puromycin resistance gene, transduced cells were subsequently selected by 
adding puromycin (8 μg/mL; Sigma) to the cell culture medium. Knockdown and control 
Caco2 cells were infected with rotavirus SA11 as previously described. 
2.8. Caco2-based NF-κB and AP-1 luciferase reporter cell lines and 
measurement of luciferase activity 
NF-κB and AP-1 luciferase reporter cells were generated by transducing Caco2 cells with 
lentiviral vectors expressing the firefly luciferase gene under the control of the promoters 
containing the NF-κB and AP-1 motifs, respectively (System Biosciences).  
To measure the luciferase activity, luciferin potassium salt (100 mM; Sigma) was added to 
the cells and incubated for 20 minutes at 37 0C. The luciferase activity was quantified with a 
LumiStar Optima luminescence counter (BMG Lab Tech, Offenburg, Germany). 
2.9. Western blot assay 
After discarding the culture medium (supernatants), cultured cells were lysed in Laemmli 
sample buffer containing 0.1 M DTT and heated for 5 minutes at 95 °C, followed by loading 
onto a 10% sodium dodecyl sulfate polyacrylamide gel and separation by electrophoresis 
(SDS-PAGE). After 90 mins running at 120 V, proteins were electrophoretically transferred 
onto a polyvinylidene difluoride (PVDF) membrane (Immobilon-FL) for 1.5 hours with an 
electric current of 250 mA. Subsequently, the membrane was blocked with a mixture of 2.5 
ml blocking buffer (Odyssey) and 2.5 ml PBS containing 0.05% Tween 20, followed by 
overnight incubation with primary antibodies (1:1000) at 4 °C. The membrane was then 
washed 3 times, followed by incubation for 1 hour with IRDye-conjugated secondary 
antibody (1:5000). After washing 3 times, protein bands were detected with the Odyssey 3.0 
Infrared Imaging System. 
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2.10. Enzyme-linked immunosorbent assay (ELISA) 
Serum samples were collected from Crohn’s disease patients and stored at -80 °C. Serum 
TNF-α levels were measured by an ELISA kit (eBioscience, USA) according to the 
manufacturer’s instructions. The absorbance value was measured at 450 nm in an automatic 
microplate reader. The results were calculated based on a standard curve. 
2.11. MTT assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) (10 mM) was 
added to Caco2 cells cultured in 96-well plates at indicated time points (24 and 48 hours) 
following TNF-α and cytokine treatments. The cells were then incubated at 37 0C with 5% 
CO2 for 3 hours. Subsequently, the culture medium was removed and 100 μl of dimethyl 
sulfoxide (DMSO) was added to each well. The absorbance of each well was measured on 
the microplate absorbance readers (BIO-RAD) at the wavelength of 490 nm.  
2.12. Immunofluorescence and confocal microscope assay 
Caco2 cells were seeded on glass coverslips in 6-well plates. Then, Caco2 cells were infected 
with SA11 for 48 hours. Subsequently, cells were washed with PBS, fixed in 4% PBS-buffered 
formalin for 10 mins and blocked with tween-milk-glycine medium (PBS, 0.05% tween, 5g/L 
skim milk and 1.5g/L glycine). Samples were incubated with 1:500 dilution of anti-rotavirus 
(ab181695) antibody (Abcam) overnight at 4 °C. Subsequently, samples were incubated with 
1:1000 dilution of Alexa FluorTM 594 goat anti-mouse secondary antibodies (Invitrogen). 
Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole; Invitrogen). Finally, the 
images were detected using immunofluorescence microscope. 
For analysis of ReIA protein, Caco2 cells on glass coverslips in 6-well plates were infected 
with either mock, SA11, huRV 1 and huRV 2 rotavirus for 8 hours. Subsequently, cells were 
washed twice with PBS. The mock- or rotavirus-infected cells were then stimulated with 
TNF-α (100 ng/mL) for 1 hour. Fixed and permeabilized cells were stained with antibodies to 
ReIA (C22B4, #4764, Cell Signaling Technology, Leiden, The Netherlands), followed by anti-
rabbit IgG(H+L),F(ab') 2 Fragment (Alexa Fluor 488 conjugate) secondary antibodies. The 
ReIA proteins were visualized with confocal microscopy. Nuclei were stained by DAPI (blue). 
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2.13. Statistical Analysis 
Statistical analysis was performed using the nonpaired, nonparametric test (Mann-Whitney 
test; GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). P values <0.05 were 
considered statistically significant. 
2.14. Ethical Statement  
The use of serum samples from IBD patients was approved by the Medical Ethical 
Committee of the Erasmus Medical Center (Medisch Ethische Toetsings Commissie Erasmus 
MC). Informed consents were signed by the volunteers or patients who agreed to participate. 
3. Results 
3.1. TNF-α has potent anti-viral activity against rotavirus 
TNF-α serves as a host immune response against a variety of pathogen invasions. It has been 
previously reported that virus infection, such as influenza virus, induces TNF-α expression in 
lung epithelial cells, which subsequently inhibits influenza virus replication (Seo and Webster, 
2002). To investigate whether rotavirus infection can also induce tnfa gene transcription, we 
employed the widely used Caco2 intestinal epithelium cell line. Infection of these cells with 
SA11 rotavirus did not trigger transcription of tnfa gene at 6, 24, 36 and 48 hours post-
infection (Supplementary Figure 2A). In addition, analysis of IL1B and IL8 gene expression 
levels showed that there were no changes of these genes upon rotavirus infection in Caco2 
cells (Supplementary Figure 2B and 2C). This finding, which is in agreement with previous 
studies (Cuadras et al., 2002), suggests that in in our experimental system, Caco2 cells cells 
do not produce TNF-α upon rotavirus infection. 
Since rotavirus does not stimulate tnfa gene transcription in Caco2 cells, we next 
investigated the effects of exogenous TNF-α treatment on rotavirus replication. Treatment 
of SA11 rotavirus-infected Caco2 cells with human recombinant TNF-α for 24 and 48 hours 
significantly inhibited viral RNA levels. At concentrations of 10 and 100 ng/mL for 24 hours, 
TNF-α decreased total viral RNA levels by 41 ± 8% (P < 0.05) and 61 ± 4% (P < 0.01), 
respectively (Figure 1A). The inhibitions were more pronounced at 48 hours after infections, 
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where TNF-α decreased total viral RNA levels by 67 ± 5% (P < 0.01) and 71 ± 4% (P < 0.01) at 
concentrations of 10 and 100 ng/mL, respectively (Figure 1A). In addition, intracellular viral 
RNA levels quantified at 48 hours post-infections were significantly reduced by 92 ± 0.3% (P 
< 0.001) and 92 ± 2% (P < 0.001) at 10 and 100 ng/mL, respectively (Figure 1B). These 
inhibitions were also more potent than those at 24 hours, where TNF-α inhibited 55 ± 7% (P 
< 0.01) and 70 ± 4% (P < 0.001) of intracellular viral RNA levels at concentrations of 10 and 
100 ng/mL, respectively (Figure 1B). Consistently, human TNF-α significantly reduced 
rotavirus secretion by the infected Caco2 cells as shown in viral titer quantification (Figure 
1C). A notable reduction was also shown in the western blot analysis of VP4 protein (Figure 
1D) and immunofluorescence analysis of VP6 protein of SA11-infected Caco2 cells (Figure 1E). 
Importantly, MTT assay demonstrated that TNF-α did not exert cytotoxicity to Caco2 cells 
(Supplementary Figure 3A). 
It is well known that TNF-α is involved in IBD pathogenesis and is associated with the 
disease’s activity. TNF-α may influence the expression of pro-inflammatory genes in IBD 
patients (Slebioda and Kmiec, 2014). To get further insight about the role of TNF-α in 
rotavirus infection, we collected serum samples from anti-TNF-α naïve Crohn’s disease 
patients. The serum TNF-α levels were measured by ELISA and 4 serum samples with 
relatively high TNF-α levels were selected (Supplementary Figure 4A). Notably, all selected 
serum samples exerted anti-rotavirus effect (as determined by total viral RNA levels) as 
compared to the control serum (Supplementary Figure 4B). These results suggest that TNF-α 
may indirectly influence rotavirus infection. 
3.2. Anti-rotavirus effect of TNF-α is independent of interferon production and 
JAK-STAT pathway activity 
Since TNF-α can induce type I IFNs in several cell lines, we first investigated the 
straightforward possibility that TNF-α merely induces IFN-α and IFN-β expression to mediate 
its anti-rotavirus effect in Caco2 cells. As demonstrated by qRT-PCR, basal constitutive 
expression of IFN-α and IFN-β is low, compared to the reference genes GAPDH (Figure 2A). In 
addition, TNF-α treatment for 48 hours did not significantly increase IFN-α and IFN-β1 
(Figure 2B) gene expression. To further confirm the absence of IFN production in our 
experimental systems, the conditioned medium from the TNFα-stimulated cells were 
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collected and were used to perform an IFN production bioassay.  We used Huh7-ISRE-
luciferase reporter cell lines, in which the firefly luciferase gene expression is driven by 
multiple IFN-stimulated response elements (ISRE) promoter. As shown in Figure 2C, the 
conditioned medium was not able to stimulate IFN response and confirmed the absence of 
IFN proteins secreted in the culture medium. 
Type I IFNs signal through activation of the Janus Kinases (JAKs) protein which leads to 
phosphorylation of Signal Transducers and Activators of Transcription (STAT) family of 
proteins. This JAK-STAT signaling ultimately promotes expression of IFN-stimulated genes 
(ISGs) as the ultimate anti-viral effector molecules (Wang et al., 2017). To further rule out 
the possibility of JAK-STAT pathway involvement, we combined TNF-α with pan-JAK I 
inhibitors which potently block JAK-STAT signaling (Wang et al., 2016). Consistently, addition 
of JAK I inhibitor (5 μM) did not abolish the anti-rotavirus effects of TNF-α (Figure 2D).  
  
Figure 1. Anti-rotavirus effects of 
TNF-α. TNF-α treatment (10 and 
100 ng/mL) significantly inhibits 
rotavirus replication as measured by 
total (A), intracellular (B) and 
extracellular (secreted) (C) rotavirus 
RNA levels in Caco2 cells both at 24 
and 48 hours post-infections (n = 6-
8, means ± SEM; (*P < 0.05; **P < 
0.01; ***P < 0.001; Mann-Whitney 
test). (D) Western blot analysis of 
VP4 protein indicates inhibitory 
effect of 10 and 100 ng/mL TNF-α 
against rotavirus at 24 and 48 hours 
post-infections. (E) 
Immunofluorescence staining of 
VP6 rotavirus protein (red) after 48 
hours infection of Caco2 cells with 
rotavirus SA11. Nuclei were 
visualized by DAPI (blue). 
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Figure 2. Anti-rotavirus effect of TNF-α is independent of interferon and the JAK-STAT signaling. (A) 
The relative basal IFN-α and IFN-β1 gene expression levels of Caco2 cell lines were determined by 
qRT-PCR. GAPDH served as a reference gene. (B) IFN-α and IFN-β1 gene expression levels in Caco2 
cells were not induced following 10 ng/mL TNF-α stimulation for 48 hours as quantified by qRT-PCR 
(n = 12). (C) ISRE firefly luciferase activity in Huh7-ISRE-luc model treated with the conditioned 
medium for 48 hours (n = 11). (D) JAK I inhibitor (5 μM) did not abolish the anti-rotavirus effects of 
TNF-α at 48 hours post-infections (n = 6). Data are presented as means ± SEM (*P < 0.05; ***P < 
0.001; ns, not significant; Mann-Whitney test). 
3.3. TNF receptor 1 is essential for TNF-α induced anti-rotavirus effect 
TNF-α exerts its biological effect through interaction with two different receptors expressed 
in the target cells, TNF receptor 1 (TNFR1) and TNFR2. TNFR1 is ubiquitously expressed by 
almost all human tissues and can be activated by both soluble and transmembrane TNF-α. In 
contrast, TNFR2 expression is limited to certain cell types, such as immune cells, 
mesenchymal stem cells and endothelial cells (Kalliolias and Ivashkiv, 2016). In addition, it is 
suggested that TNFR2 can only be activated by transmembrane TNF-α. Thus, TNFR1 serves 
as the major signaling component for soluble TNF-α in vivo (Kalliolias and Ivashkiv, 2016). 
Therefore, this encouraged us to investigate whether anti-rotavirus effects of TNF-α was 
mediated via TNFR1.  
First, Caco2 cells were transduced with integrating lentiviral vectors expressing shRNA that 
specifically target TNFR1. Among three tested shRNA vectors, sh-96 vector showed the most 
potent gene silencing capacity, as determined by qRT-PCR (Figure 3A) and western blot 
analysis (Figure 3B). As expected, TNFα-induced CXCL10 expression was abolished in TNFR1 
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knockdown cells which was examined at 6 hours following TNF-α stimulation (Figure 3C). 
Caco2 cells with sh-96 TNFR1 knockdown and scrambled sh-RNA (sh-CTR) as control were 
subsequently infected with SA11 rotavirus. In sh-CTR transfected cells, treatment with 10 
ng/mL TNF-α significantly reduced viral RNA levels (80 ± 2.4% inhibition; P < 0.001). However, 
the anti-rotavirus effect of TNF-α was abolished upon TNFR1 silencing (Figure 3D). To 
validate these results, the clinically used anti-TNFα antibody, infliximab (Remicade®), was 
used. Infliximab binds specifically to TNF-α and blocks its interaction with TNF receptors 
(Sedger and McDermott, 2014). As expected, infliximab efficiently abrogated TNFα-induced 
CXCL10 expression at 6 hours after stimulation (Figure 3E). Consistently, combining TNF-α 
with infliximab completely blocked the anti-rotavirus effects of TNF-α at 48 hours after 
infections (Figure 3F).  
 
 
 
Figure 3. Anti-rotavirus effect of 
TNF-α is mediated via TNF 
receptor 1 (TNFR1). (A) qRT-PCR 
(n = 4) and (B) western blot 
analysis of TNFR1 knockdown by 
lentiviral sh-RNA vectors in 
Caco2 cells. (C) TNFR1 
knockdown (sh-96) abolished 
TNFα-induced CXCL10 expression 
at 6 hours following stimulation 
(n = 6). (D) TNFR1 knockdown 
(sh-96) led to the blockade of 
TNFα-induced anti-rotavirus 
activity at 48 hours post-
infections (n = 6). (E) The TNF-α 
inhibitor (Infliximab) (500 μg/mL) 
abrogated the induction of 
CXCL10 gene following TNF-α 
stimulation (10 ng/mL) for 6 
hours (n = 5). (F) Infliximab (500 
μg/mL) blocked anti-rotavirus 
effects of 10 ng/mL TNF-α as 
measured by qRT-PCR at 48 
hours post infection (n = 6). Data 
are presented as means ± SEM 
(*P < 0.05; **P < 0.01; ***P < 
0.001; Mann-Whitney test). 
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3.4. TNF-α mediates anti-rotavirus activity through NF-κB signaling 
At the cellular level, binding of TNF-α to TNFR1 activates downstream c-JUN N-terminal 
kinase (JNK), leading to the transcription of AP-1 target genes. Additionally, TNFR1 activates 
NF-κB, resulting in induced expression of NF-κB target genes (Cabal-Hierro and Lazo, 2012). 
To dissect whether the anti-rotavirus effects of TNF-α are mediated via the AP-1 or NF-κB 
pathway, we first constructed Caco2-based stable NF-κB and AP-1 driven luciferase reporter 
cell lines. As shown in figure 4A, TNF-α stimulation resulted in profound induction NF-κB 
driven luciferase activity in a dose-dependent manner at 12, 24 and 48 hours after 
stimulation, yet no effect on AP-1 driven luciferase activity was observed. Noteworthy, the 
maximum induction of NF-κB driven luciferase activity was observed at 12 hours after 
stimulation (Figure 4A). Based on these results, we hypothesized that the anti-rotavirus 
effects of TNF-α on Caco2 cells are mediated via the classical NF-κB signaling pathway, 
rather than the AP-1 pathway. 
The endpoint of TNF-α signaling is activation of the heterodimeric NF-κB complex, consisting 
of the ReIA (p65) and p50 (Cabal-Hierro and Lazo, 2012). To examine the role of this ReIA 
(p65)-p50 complex in mediating anti-rotavirus effects of TNF-α, Caco2 cells were transduced 
with integrating lentiviral shRNA vectors to silence ReIA. Two of the three tested shRNA 
vectors targeting ReIA profoundly downregulate ReIA both at mRNA and protein level 
(Figure 4B and 4C). Importantly, ReIA knockdown promoted SA11 rotavirus replication by 2.2 
± 0.3 fold (P < 0.01) (Figure 4D), supporting its importance in the control of rotavirus 
infection. In ReIA knockdown cells, induction of CXCL10 expression was efficiently blocked 
following TNF-α (10 ng/mL) stimulation for 6 hours (Figure 4E). Next, Caco2 cells with sh-10 
ReIA knockdown and scrambled sh-RNA as control (sh-CTR) were infected with SA11 
rotavirus with and without treatment of 10 ng/mL of TNF-α. As before, treatment of sh-CTR 
transfected cells with 10 ng/mL TNF-α significantly decreased viral RNA levels (60 ± 6.5% 
inhibition; P < 0.001). However, this anti-rotavirus effect was abrogated in ReIA knockdown 
cells (Figure 4F), demonstrating that NF-κB signaling pathway is essential to mediate anti-
rotavirus effects of TNF-α.  
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3.5. TNFα-induced cytokines are the downstream effectors to exert anti-
rotavirus activity 
Following TNF-α stimulation, the activated p65:p50 NF-κB complex translocates to the 
nucleus where it binds to specific DNA motifs located in the promoter region of its target 
genes. This event will regulate, either induce or suppress, the expression of TNFα-modulated 
genes in a cell-type-specific manner (Kalliolias and Ivashkiv, 2016). These NFκB-regulated 
genes play an essential role in the host immune response such as pro-inflammatory cytokine 
and chemokine regulation. Therefore, we examined a panel of cytokines and chemokines 
which may be induced by human TNF-α in Caco2 cell lines.  
Figure 4. Anti-rotavirus effect of 
TNF-α is mediated via NF-κB 
signaling. (A) In Caco2-based NF-
κB reporter cell lines, TNF-α 
induced activation of NF-κB-
related luciferase signals in a 
dose-dependent manner as 
measured at 12, 24 and 48 hours, 
while AP1-related luciferase 
signals were not affected (n = 4-
6). qRT-PCR (n = 4) (B) and 
western blot (C) analysis of ReIA 
(p65) knockdown by lentiviral sh-
RNA vectors in Caco2 cells. (D) 
ReIA (p65) knockdown (sh-10) 
promoted rotavirus replication as 
quantified by total RNA levels in 
Caco2 cells at 48 hours post-
infections (n = 8). (E) ReIA (p65) 
knockdown (sh-10) led to the 
blockade of TNFα-induced 
CXCL10 expression at 6 hours 
post-stimulations (n = 6). (F) ReIA 
knockdown (sh-10) resulted in 
the blockade of TNFα-induced 
anti-rotavirus activity at 48 hours 
post-infections (n = 6-8). Data 
are presented as means ± SEM 
(*P < 0.05; **P < 0.01; ***P < 
0.001; ns, not significant; Mann-
Whitney test). 
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As shown in figure 5A, 10 ng/mL TNF-α stimulation for 6 and 24 hours led to increased 
transcription of the genes encoding IL-8, IL-32, CCL2, CCL20, CXCL10 and CXCL11 genes in 
Caco2 cells. To dissect whether these TNFα-induced cytokines could inhibit rotavirus 
infection, we treated SA11-infected Caco2 cells with those cytokines at a concentration of 10 
ng/mL. As shown in figure 5B, treatment with IL32, IL8, CXCL11 and CCL20 potently inhibited 
rotavirus replication as measured by qRT-PCR. Western blot analysis of VP4 protein 
confirmed these results (Figure 5C). Importantly, MTT assay revealed that these cytokines 
did not affect cell growth and cytotoxicity to Caco2 cells (Supplementary Figure 5). These 
results collectively show that TNFα-induced cytokines exert a powerful anti-rotavirus activity. 
3.6. Sensitivity of human rotavirus (huRV) derived from clinical strains to TNF-
α treatment. 
Previous studies have indicated that several rotavirus strains, including Wa (human), RRV 
(simian), and OSU (porcine), have different mechanisms of antagonizing NF-κB activation. 
Those mechanisms include degradation of β-TrCP and inhibition the nuclear translocation of 
NF-κB (Graff et al., 2009; Holloway et al., 2009). To extend our results, we employed human 
rotavirus (huRV)-derived clinical strains isolated from two diarrhea patients (Yin et al., 
2015a). Caco2 cells infected with two huRV-derived clinical strains were treated with TNF-α 
100 ng/mL for 48 hours. As shown in Figure 6, huRV strain 1 replication was notably 
inhibited by TNF-α treatment (70 ± 6% inhibition; P < 0.01), in contrast to huRV strain 2 
which was resistant to TNF-α treatment. These results suggest that huRV strains have 
different sensitivity to TNF-α treatment. 
To further investigate the different sensitivity of rotavirus strains against TNF-α treatment 
observed in our study, we analyzed the ability of different rotavirus strains to block 
translocation of ReIA to the nucleus (Supplementary Figure 5). In mock-infected Caco2 cells, 
the ReIA protein level in the nucleus was increased following TNF-α stimulation (100 ng/mL) 
for 1 hour, compared with mock-infected unstimulated cells.  Unexpectedly, in SA11-, huRV 
1- and huRV2-infected Caco2 cells, the nuclear accumulation of ReIA was also elevated 
following TNF-α stimulation (Supplementary Figure 5).  
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4. Discussion 
TNF-α was first known for its anti-cancer activity in vitro (Carswell et al., 1975). The 
subsequent development of recombinant technology allowed the dissection of the multiple 
roles of TNF-α in the human body, which includes inflammatory responses, immune 
Figure 5. TNFα-induced 
cytokines exert anti-rotavirus 
activity. (A) Expression profile of 
33 cytokines in Caco2 cells as 
quantified by qRT-PCR analysis. 
Some cytokines were up-
regulated with 10 ng/mL TNF-α 
stimulation of Caco2 cells for 6 
and 24 hours (n = 6). (B) IL32A, 
IL8, CXCL10, CXCL11, CCL20 and 
CCL2 significantly inhibited 
rotavirus replication as 
quantified by qRT-PCR of total 
RNA levels, both at 24 and 48 
hours (n = 6-8). (C) Western blot 
analysis of VP4 protein indicates 
the inhibitory effect of 10 ng/mL 
of IL32, IL8, CXCL11 and CCL20 
against rotavirus at 48 hours 
post-infections. Data are 
presented as means ± SEM (*P < 
0.05; **P < 0.01; ***P < 0.001; 
ns, not significant; Mann-
Whitney test). 
 
Figure 6. Sensitivity of human 
rotavirus (huRV) clinical strains to 
TNF-α treatment. TNF-α treatment 
for 48 hours (100 ng/mL) 
significantly inhibits replication of 
huRV clinical strain 1 (huRV 1) as 
measured by total rotavirus RNA 
levels in Caco2 cells; while 
replication of huRV clinical strain 2 
(huRV 2) was not affected. (n = 3, 
means ± SEM, **P < 0.01, Mann-
Whitney test). 
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regulatory functions, and anti-microbial immunity (Sedger and McDermott, 2014). 
Inappropriate regulation of TNF-α has been implicated in various human diseases, leading to 
the use of TNF-α inhibitors in the clinic to treat these TNFα-related diseases. The subsequent 
increased of viral and bacterial infections in these patients suggests that TNF-α plays an 
essential role in anti-viral and anti-microbial immunity (Kim and Solomon, 2010). 
Timely and rapid immune responses against invading viral pathogens are critical for the host 
to clear such infections. These early responses mainly depend on anti-viral immunity 
mediated by innate immune cells that produce various cytokines, such as IFNs, interleukins 
and TNF-α that act directly to eliminate infections and indirectly by promoting subsequent 
development of a more specific adaptive immunity (Holloway and Coulson, 2013). In 
infected children, increased levels of IFN-α were detected in the blood, and related to the 
clinical outcome (De Boissieu et al., 1993). Thus, investigating innate responses is crucial for 
understanding virus-host pathogenesis during rotavirus infections (Arnold et al., 2013). 
Previous studies have shown the increased production of TNF-α by DCs (Deal et al., 2010) 
and macrophages (Mohanty et al., 2010) upon rotavirus stimulation. Elevated levels of TNF-
α were found in children with rotavirus diarrhea as compared to healthy controls (Azim et al., 
1999). Furthermore, in children with rotavirus diarrhea, a significantly higher level of TNF-α 
was found in serum of those who developed fever and had more frequent episodes of 
diarrhea (Jiang et al., 2003). It is probably associated with the effect of TNF-α on ion 
secretion in human intestinal epithelial cells (Oprins et al., 2000). This suggests that TNF-α 
may contribute to the immunity and the disease pathogenesis. However, the exact role of 
TNF-α in rotavirus infection has not yet been extensively studied. Here we demonstrated 
that TNF-α has a strong anti-rotavirus effect both at intracellular and extracellular (excreted) 
levels. We also showed that the clinically used TNF-α inhibitors (infliximab) can completely 
block this effect, supporting caution of the use of these treatments in patients with latent or 
active viral infections. 
In several cell lines, TNF-α induces the production of type I IFNs (IFN-β) (Ahrens et al., 1990; 
Hughes et al., 1988; Jacobsen et al., 1989; Yarilina et al., 2008). Thus, we first hypothesized a 
straightforward explanation that anti-rotavirus effect of TNF-α is merely mediated via type I 
IFN and consequently, classical IFN-signaling (JAK-STAT pathway activation). However, 
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treatment of Caco2 cells with TNF-α did not significantly increase ifna and ifnb1 gene 
expression levels, and consequently did not result in IFN production (Fig. 2B and 2C). In 
addition, combination treatment with TNF-α and the pan-JAK I inhibitor did not abolish the 
anti-rotavirus effect of TNF-α. Thus, we conclude that the anti-rotavirus effect of TNF-α is 
independent of IFN production and the JAK-STAT pathway. 
TNF-α signals mainly through TNFR1 receptor and stimulates downstream signaling 
pathways that ultimately activates two major transcription factors, NF-κB (classical NF-κB 
pathway) and c-Jun (AP-1 pathway) (Cabal-Hierro and Lazo, 2012; Kalliolias and Ivashkiv, 
2016). Our experiments using Caco2-based NF-κB and AP-1 reporter cell lines showed that 
TNF-α signals via NF-κB and not via AP-1. NF-κB is activated following rotavirus infection and 
is involved in the regulation of cytokine productions (Rollo et al., 1999), indicating its 
importance in the host defense against rotavirus. Indeed, the following loss-of-function 
assays by knocking down ReIA (p65), one of the main components of the NF-κB protein 
complex, led to an increase of rotavirus replication. Furthermore, knockdown of ReIA 
abrogates anti-rotavirus effect of TNF-α. This indicates the importance of NF-κB in restricting 
rotavirus infection and also in mediating anti-rotavirus effects of TNF-α. 
It is important to note that several studies have reported that other rotavirus strains can 
inhibit NF-κB activation (Graff et al., 2009) or its TNFα-induced translocation to the nucleus 
(Holloway et al., 2009). Noteworthy, the NSP1 protein of rotavirus contains a conserved C-
terminal phosphodegron-like (PDL) motif which disrupts NF-κB activation by interfering with 
IκB degradation (Morelli et al., 2015). However, our data suggested that translocation of 
ReIA to the nucleus was not blocked by SA11 as well as both human rotavirus strains 1 and 2, 
as demonstrated by confocal microscopy analysis (Fig. S5). Other mechanisms, including 
blocking of ReIA binding to its promoter, may be involved. Collectively, our results showed 
that anti-rotavirus effect of TNF-α is mediated via TNFR1 receptor and classical NF-κB 
signaling. 
Several cytokines are induced following exposure of dendritic cells to rotavirus, such as IL-6, 
IL-8, CXCL-10 and CCL5 (Deal et al., 2010; Rosales-Martinez et al., 2016). Several cytokines 
have been associated with clinical symptoms in rotavirus diarrheal children (Jiang et al., 
2003). Surprisingly, we found that TNFα-induced cytokines, such as IL-8, CXCL10, CXCL11, 
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have potent anti-rotavirus effects. Further experiments are therefore required to clarify 
their mechanism of action in inhibiting rotavirus infection. Noteworthy, anti-TNFα treatment 
in Crohn’s disease patients is associated with modulation of pro-inflammatory genes, 
including IL1B and CXCL11 (Leal et al., 2015). Accordingly, our results from patients’ samples 
suggest that a high level of TNF-α in serum may modulate rotavirus infection indirectly by 
affecting cytokine levels in these patients’ sera.   
It is important to note that under inflammatory conditions, infected cells are continuously 
exposed to various cytokines. The effect of these cytokines could be influenced by the 
presence of other cytokines (Bartee et al., 2008). Several studies have shown a synergistic 
anti-viral effect of TNF-α and type I IFNs (IFN-α and IFN-β) in the setting of HCV, HEV (Wang 
et al., 2016), respiratory virus (Fink et al., 2013) and poxvirus infections (Bartee et al., 2009). 
TNF-α can also synergize with type II IFNs (IFN-γ) in the setting of cytomegalovirus (CMV) 
infection (Lucin et al., 1994). Therefore, it is interesting to further investigate whether these 
combined effects can be observed in rotavirus infections.  
5. Conclusion 
We demonstrate a novel role of TNF-α in inhibiting rotavirus replication. This anti-rotavirus 
effect is mediated via the classical NF-κB signaling pathway, independent of IFN production 
and JAK-STAT pathway activity. Furthermore, this finding elucidates the increased risk of 
viral infection upon TNF-α inhibitor treatments used in the clinic. Thus, this knowledge may 
contribute to a better clinical management of these patients. 
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Supplementary Figures 
 
 
 
Supplementary Figure 1. 
Standard curve for quantifying 
rotavirus genome copy 
numbers. An SA11 amplicon was 
first cloned into the pCR2.1-
TOPO vector. The isolated 
plasmid was diluted from 10-2 to 
10-10 dilution and then amplified 
and quantified by qRT-PCR. A 
standard curve was generated by 
plotting the cycle threshold (CT) 
value with regard to the log copy 
number value.   
 
Supplementary Figure 2. A. SA11 
rotavirus infection did not 
modulate tnfa, IL1B and IL8 
gene expression levels in Caco2 
cells at 6, 24, 36 and 48 hours 
post-infection. Caco2 cells were 
infected with rotavirus SA11. 
Relative RNA levels of tnfa (A), 
IL1B (B) and IL8 (C) genes were 
examined at 6, 24, 36 and 48 
hours post infection and 
compared to uninfected cells. 
Data were normalized to GAPDH 
and presented as means ± SEM 
(n = 9). 
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Supplementary Figure 4. (A) TNF-α levels in serum samples from anti-TNF-α treatment naïve 
Crohn’s disease patients were quantified by ELISA. (B) All patient serum samples showed 
anti-rotavirus activity as compared to the control serum sample as quantified by qRT-PCR at 
48 hours post-infections. 
 
  
Supplementary Figure 3. The 
effects of TNF-α and cytokines 
on cell viability. TNF-α (10 and 
100 ng/mL) (A) and several 
cytokines (10 ng/mL of IL32A, 
IL8, CXCL10, CXCL11, CCL20, 
CCL2) (B) did not affect cell 
viability as determined by MTT 
assay (OD490 value) at 24 and 48 
hours of treatment (n = 6-8). 
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Supplementary Figure 5. 
Rotavirus infection did not 
inhibit TNFα-induced nuclear 
accumulation of ReIA. Caco2 
cells were infected with either 
mock, SA11, huRV 1 and huRV 2 
rotavirus for 8 hours. 
Subsequently, the mock- or 
rotavirus-infected cells were 
stimulated with TNF-α (100 
ng/mL) for 1 hour. Fixed and 
permeabilized cells were stained 
with antibodies to ReIA (green), 
and visualized with confocal 
microscopy. Nuclei were 
visualized by DAPI (blue). 
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Supplementary Tables  
Supplementary Table 1. Primers used in the study 
Sequence of SA11 rotavirus primers (targeting VP6 gene segment) 
Primers Sequences 
Sense  TGGTTAAACGCAGGATCGGA 
Anti-sense AACCTTTCCGCGTCTGGTAG 
Sequence of human-derived rotavirus primers (targeting NSP3 gene segment) 
Primers Sequences 
Sense  ACCATCTACACATGACCCTC 
Anti-sense CACATAACGCCCCTATAGCC 
Primer sequences of human genes  
Primers Sequences 
GAPDH-F GTCTCCTCTGACTTCAACAGCG 
GAPDH-R ACCACCCTGTTGCTGTAGTAGCCAA 
TNFα-F CTCTTCTGCCTGCTGCACTTTG  
 TNFα-R ATGGGCTACAGGCTTGTCACTC 
 IL8-F CACTGCGCCAACACAGAAATTA 
IL8-R ACTTCTCCACAACCCTCTGCAC 
IL1B-F CCCTAAACAGATGAAGTGCTCCTT 
IL1B-R GTAGCTGGATGCCGCCAT 
IFNα-F GACTCCATCTTGGCTGTGA 
IFNα-R TGATTTCTGCTCTGACAACCT 
IFNβ1-F CTTGGATTCCTACAAAGAAGCAGC 
IFNβ1-R TCCTCCTTCTGGAACTGCTGCA 
TNFR1-F CCGCTTCAGAAAACCACCTCAG 
TNFR1-R ATGCCGGTACTGGTTCTTCCTG 
ReIA-F TGAACCGAAACTCTGGCAGCTG 
ReIA-R CATCAGCTTGCGAAAAGGAGCC 
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Supplementary Table 2. shRNA sequences  
Name Oligo Sequences 
shTNFR1-94 CCGGCATTGGTTTAATGTATCGCTACTCGAGTAGCGATACATTAAACCAATGTT
TTTG 
shTNFR1-95 CCGGACCGGCATTATTGGAGTGAAACTCGAGTTTCACTCCAATAATGCCGGTT
TTTTG 
shTNFR1-96 CCGGTCCTGTAGTAACTGTAAGAAACTCGAGTTTCTTACAGTTACTACAGGATT
TTTG 
shRelA-08 CCGGGCAGGCTATCAGTCAGCGCATCTCGAGATGCGCTGACTGATAGCCTGCT
TTTT 
shRelA-09 CCGGCACCATCAACTATGATGAGTTCTCGAGAACTCATCATAGTTGATGGTGT
TTTT 
shRelA-10 CCGGCCTGAGGCTATAACTCGCCTACTCGAGTAGGCGAGTTATAGCCTCAGGT
TTTT 
 
 
 
 
 

                                                                                                                                                                                                                                          
175 | P a g e  
 
Chapter 8 
 
 
6-thioguanine inhibits rotavirus replication through suppression of 
Rac1 GDP/GTP cycling 
Yuebang Yin,1,2,3‡ Sunrui Chen,2‡ Mohamad S. Hakim,2,4‡ Wenshi Wang,2 Lei Xu,2 Wen Dang,2 
Changbo Qu,2 Auke P. Verhaar,2 Junhong Su,1,2,5 Gwenny M. Fuhler,2 Maikel P. 
Peppelenbosch,2 and Qiuwei Pan2 
 
1  Center for Biomedical Research, Northwest Minzu University, Lanzhou, China 
2  Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 
Rotterdam, The Netherlands. 
3 Institute of Subtropical Agriculture, Chinese Academic of Sciences, Changsha 410125, 
China 
4 Department of Microbiology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, 
Indonesia 
5  Medical Faculty, Kunming University of Science and Technology, Kunming, PR China 
‡  These authors contributed equally to this work.  
 
 
Antiviral Research 2018; 156: 92-101. 
 
 
 
  
  
Chapter 8                                                                                                        
177 | P a g e  
 
Abstract 
Rotavirus infection has emerged as an important cause of complications in organ 
transplantation recipients and might play a role in the pathogenesis of inflammatory bowel 
disease (IBD). 6-thioguanine (6-TG) has been widely used as an immunosuppressive drug for 
organ recipients and treatment of IBD in the clinic. This study aims to investigate the effects 
and mode-of-action of 6-TG on rotavirus replication. Human intestinal Caco2 cell line, 3D 
model of human primary intestinal organoids, laboratory rotavirus strain (SA11) and patient-
derived rotavirus isolates were used. We have demonstrated that 6-TG significantly inhibits 
rotavirus replication in these intestinal epithelium models. Importantly, gene knockdown or 
knockout of Rac1, the cellular target of 6-TG, significantly inhibited rotavirus replication, 
indicating the supportive role of Rac1 for rotavirus infection. We have further demonstrated 
that 6-TG can effectively inhibit the active form of Rac1 (GTP-Rac1), which essentially 
mediates the anti-rotavirus effect of 6-TG. Consistently, ectopic over-expression of GTP-Rac1 
facilitates, but an inactive Rac1 (N17) or a specific Rac1 inhibitor (NSC23766) inhibits 
rotavirus replication. In conclusion, we have identified 6-TG as an effective inhibitor of 
rotavirus replication via the inhibition of Rac1 activation. Thus, for transplantation patients 
or IBD patients infected with rotavirus or at risk of rotavirus infection, the choice of 6-TG as a 
treatment appears rational. 
 
Keywords: intestinal organoids; Rac1; rotavirus; 6-thioguanine  
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Introduction 
Rotavirus, a double stranded RNA (dsRNA) virus in the Reoviridae family, is a major cause of 
gastroenteritis, particularly in children younger than 5 years of age. As a major global health 
problem, this virus causes 114 million diarrhea episodes, 2.4 million hospitalizations, and an 
estimated 215,000 deaths worldwide annually (Grimwood and Buttery, 2007; Tate et al., 
2016). Although rotavirus infection mainly occurs in developing countries, it also results in 
over 200 deaths and more than 87,000 hospital admissions in infants in European Union 
(Vesikari et al., 2007). Besides young children, organ transplantation patients are also 
susceptible to rotavirus infection irrespective of their age, causing long-term diarrhea and 
even death due to graft failure (Yin et al., 2015b). Although two global licensed rotavirus 
vaccines have been launched, no specific antiviral treatment is available.  
A thio analogue of the naturally occurring purine base guanine, 6-thioguanine (6-TG), has 
been used in the clinic since the early 1950s (Munshi et al., 2014). 6-TG was initially 
developed to treat cancer; whereas currently it is widely used as an immunosuppressive 
agent in organ transplantation. It is also used as treatment for acute lymphoblastic leukemia 
in children and for autoimmune diseases (Bourgine et al., 2011). In particular, 6-TG is often 
used to treat inflammatory bowel disease (IBD) (de Boer et al., 2006). IBD including Crohn’s 
disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) represent a heavy burden in 
Western countries (Kolho et al., 2012). Although the causes of exacerbations of IBD remain 
poorly characterized, gastrointestinal infections including rotavirus might induce flares in IBD 
(Masclee et al., 2013). Thus, preventing or treating rotavirus infection in these patients is of 
importance.  
Upon ingestion, 6-TG is first metabolized into 6-thioguanosine monophosphate (6-TGMP), 
and subsequently into 6-thioguanosine diphosphate (6-TGDP), and finally into 6-
thioguanosine triphosphate (6-TGTP) (Chouchana et al., 2012). Among these metabolites, 6-
TGDP and 6-TGTP are able to compete with endogenous guanosine phosphates for Rac1 
binding and to form 6-TGNP•Rac1 complexes. These complexes are in turn incapable to 
support the formation of the active configuration of Rac1, a process that Rac1 interacts with 
GTP. Thus, 6-TG indirectly provokes inhibition of Rac1-dependent signaling (Shin et al., 2016), 
which has substantial consequences for cellular physiology. As a member of the Ras 
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superfamily of Rho GTPases, GTP-bound Rac1 mediates a myriad of cellular processes 
including actin reorganization and gene transcription. Intriguingly, IBD is characterized by 
hyperactivation of Rac1 in the phagocyte compartment. This is associated with reduced 
effector function of Rac1, which is sensitive to 6-TG treatment (Parikh et al., 2014). The 
inhibition of Rac1 resulting from 6-TG treatment restores innate immune functionality of 
phagocytes in IBD patients, contributing to disease remission (Parikh et al., 2014). Thus, Rac1 
hyperactivation appears an important immunosuppressive effector in human 
pathophysiology, at least in the phagocyte compartment.  
Given the clinical relevance and the potential in revealing mechanistic insight, we have 
investigated the effects and mechanism-of-action of 6-TG on rotavirus replication. To this 
end, we have demonstrated that 6-TG effectively combats rotavirus replication through 
inhibition of Rac1 activation.  
Materials and Methods 
Viruses and reagents 
Simian rotavirus SA11 strain and patient-derived rotavirus isolates (G1P[8]) were prepared 
as previously described (Yin et al., 2015a; Yin et al., 2016).  
Stocks (0.1 mg/mL) of 6-TG (Sigma-Aldrich) were dissolved in alkali solution (1 M NaOH, 50 
mg/ml), and NSC23766 (Merck Millipore) was dissolved in H2O (2 mM). All chemicals were 
stored in 25 µL aliquots and frozen at -80 °C.  
Conventional enterocyte culture and human primary intestinal organoid 
culture 
Human colon cancer cell line Caco2 and human embryonic kidney cell line 293T (HEK 293T) 
cells were grown in Dulbecco's modified Eagle medium (DMEM) (Invitrogen-Gibco, Breda, 
The Netherlands) supplemented with 20% (vol/vol) heat-inactivated fetal calve serum (FCS) 
(Hyclone, Lonan, Utah) and penicillin (100 IU/mL)/streptomycin (100 mg/mL) (Invitrogen-
Gibco) at 37°C in a humidified 5% CO2 incubator. Rac1 knockout mouse embryonic fibroblast 
(MEF) cells were cultured in DMEM supplemented with 10% FCS, Penicillin (100 
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IU/mL)/streptomycin (100 mg/mL), L-Glutamine (Gibco® by Life Technologies), non-essential 
amino acids (Gibco® by Life Technologies) and sodium-pyruvate (Gibco® by Life Technologies). 
Caco2 cells with stable knockdown of Rac1 were generated by transduction of lentiviral 
shRNA (produced in HEK293T cells) targeting Rac1 and selected with puromycin (6 µg/mL) as 
described previously (Yin et al., 2016). The shRNA targeting sequences used in this study 
were listed in Table S1.  
3D culture of human intestinal organoids was performed as previously described (Yin et al., 
2015a).  
Rotavirus inoculation and drug treatment 
Inoculation and treatment of Caco2 cells and human intestinal organoids with SA11 and 
patient-derived rotavirus were performed as previously described (Yin et al., 2016).  
Viability assay of cells or organoids 
The viability of cells or organoids was determined by 3-(4, 5-Dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay. Briefly, Caco2 cells (1x104 cells/well) or organoids 
were seeded into a 96-well culture plate and incubated with various concentrations of 6-TG 
or NSC23766 for 48 h, followed by adding 500 µg/mL of MTT solution to each well and 
incubation at 37 °C for 3 hrs. Subsequently, the medium was removed, and replaced with 
100 µL DMSO and incubated at 37 °C for 50 min. Then, the absorbance was measured at 490 
nm in an enzyme-linked immunosorbent assay reader (BIO-RAD). The effects of 6-TG, 
NSC294002, IFNα and ribavirin on host cell viability were determined by MTT assay (Fig. S1).  
Transfection of plasmids  
A constitutively active Rac1V12 and dominant inactive Rac1N17 plasmids were prepared as 
previously described (Apolloni et al., 2013). HEK 293 cells were seeded into 6-well plates for 
Rac activation assay or 48-well plates for infection assay with ~70% confluence. The cells 
were washed with PBS, followed by adding 500 µL of Opti-MEM® reduced serum medium 
with 2 µg Rac1V12 or Rac1N17 plasmids and 10 µg polyethylenimine (PEI) per well of a 6-
well plate, or 100 µL of Opti-MEM® reduced serum medium (Thermo Fisher Scientific) with 
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0.25 µg Rac1V12 or Rac1N17 plasmids and 1.25 µg polyethylenimine (PEI) (Sigma-Aldrich) 
per well of a 48-well plate. After 4 to 5 hrs of incubation, 2 mL or 0.5 mL of DMEM 
containing 10% FCS was added to each well of 6-well plate or 48-well plate, respectively. 
Transfected cells were infected with rotavirus for 24 hrs.  
Quantitative real-time PCR (qRT-PCR) 
Total cellular RNA was isolated using a NucleoSpin® RNA kit (MACHEREY-NAGEL, Düren, 
Germany) following the manufacturer’s protocol, and quantified with a Nanodrop ND-1000 
(Wilmington, DE, USA). cDNA was synthesized using the reverse transcription system from 
TAKARA according to manufacturer’s instructions (TAKARA BIO INC). The resulting cDNA was 
diluted 1:10, and 2 µL of the diluted cDNA was used for qRT-PCR with primers listed in Table 
S1. All qRT-PCR experiments were performed by SYBR-Green-based (Applied Biosystems 
SYBR Green PCR Master Mix; Thermo Fisher Scientific Life Science) real-time PCR with the 
StepOnePlus System (Thermo Fisher Scientific Life Sciences). The expression of target mRNA 
was normalized to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. Gene 
expression analysis was performed by the ΔΔCT method (Yin et al., 2015a; Yin et al., 2016).  
Rac activation assay 
The levels of Rac1-bound GTP were detected using Rac interactive binding (CRIB) domain of 
PAK (aa56-272) as described previously (Fuhler et al., 2008). In brief, GST-PAKcrib protein 
was pre-coupled to glutathione-sepharose beads (Sigma-Aldrich) for 45 min at 4 °C. Caco2 
cells treated with various concentrations of 6-TG or NSC23766 (48 h, seeded in 6-well-plate) 
were lysed for 10 min in lysis buffer (50 mM Tris, pH 7.4, 10% glycerol, 200mM NaCl, 1% NP-
40, 2mM MgCl2, 2 mM sodium orthovanadate, and protease inhibitors). Cell lysates were 
incubated with pre-coupled beads for 45 min. Then, agarose beads were washed 3 times 
with 1x lysis buffer, followed by boiling in Laemmli buffer, and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE, 15%) analysis.  
Western blotting 
Cell lysates were subjected to SDS-PAGE, and proteins were transferred to PVDF membrane 
(Immobilon-FL). Rac1 monoclonal antibody (1:1000, rabbit; cell signaling) and SA11 rotavirus 
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VP4 [1:1000, HS-2, a mouse monoclonal antibody (provided by Professor Harry Greenberg, 
Stanford University School of Medicine, USA)] were detected by Western blotting analysis. 
Detection of β-actin was served as loading control (1:1000, mouse monoclonal; Santa Cruz) 
as previously described (Versteeg et al., 2002).  
Serial passaging of rotavirus with 6-TG treatment  
To investigate whether rotavirus can develop resistance to 6-TG treatment, viruses were 
passaged in both MA104 and Caco2 cells in the absence of drug (vehicle control) or in the 
presence of gradually increasing concentrations of the drug (1000 ng/mL of 6-TG for passage 
1-10 and 2000 ng/mL of 6-TG for passage 11-20). In brief, MA104 or Caco2 cells in 24-well 
plate were inoculated with 200 µL virus (MOI=0.7) at 37 °C for 1 hr, followed by adding 6-TG 
or without drug (as control). After 48 hrs, both cells and supernatant were harvested, 
subsequently frozen, thawed once, and centrifuged. The supernatant containing passaged 
viruses was stored at -80 °C until used for the next passage. Viruses were serially passaged 
by using 1 aliquot of viral stock from the preceding passage to infect fresh MA104 or Caco2 
cells. The effect of each passage of virus (same titer) was quantified by qRT-PCR.  
IC50 and CC50 calculation  
IC50 and CC50 calculation were described previously (Yin et al., 2016).  
Statistics 
Data are presented as means, and statistical comparison between different groups was 
performed by Mann-Whitney test (two-tailed) using GraphPad Prism 5. Error bars represent 
the SEM, and P value <0.05 was considered statistically significant.  
Results 
6-TG remarkably inhibits rotavirus replication 
To assess the effects of 6-TG on rotavirus replication, we treated SA11 rotavirus-infected 
Caco2 cells with various concentrations (0.001 – 10000 ng/mL) of 6-TG for 48 hrs. This 
resulted in dose-dependent inhibition of rotavirus RNA replication (Fig. 1A, n = 3-17, *P<0.05, 
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***P<0.001). The IC50 value of 6-TG against SA11 rotavirus was 3.0×10-13 M, which is 
substantially below the concentrations reached in patients undergoing 6-TG or azathioprine 
therapy. CC50 of 6-TG to Caco2 cells was 9.8×10-6 M and selectivity index (SI, CC50/IC50) was 
3.3×107 (Table S2). This was further confirmed at the infectious virus production levels and 
protein levels of the rotavirus VP4 protein (Fig. 1B and 1C). To further verify the effect of 6-
TG on rotavirus replication, SA11 rotavirus-infected Caco2 cells were treated with 6-TG at 
different time points (6, 12, 24 and 48 hrs), demonstrating that 6-TG significantly inhibited 
rotavirus RNA replication in time-dependent Manner (Fig. 1D, n = 4-8, *P<0.05, **P<0.01). 
These results were substantiated by experiments in human primary intestinal organoids, a 
model system that recapitulates many aspects of the intestinal epithelium, including the 
presence of a villus domain and a crypt domain (Fig. 1E) (Sato and Clevers, 2013). 6-TG 
significantly inhibited SA11 rotavirus replication and virus production in these organoids (Fig. 
1F and G, n = 6, *P<0.05, **P<0.01). Our results were essentially repeated using five patient-
derived rotavirus isolates in Caco2 cells but also in human intestinal organoids (Table S3). 
Treatment with 100 ng/mL 6-TG inhibited patient-derived isolates in both Caco2 cells (Fig. 
1H) and human intestinal organoids (Fig. 1I). Hence, 6-TG significantly counteracts rotavirus 
replication at clinically relevant concentrations.  
Development of resistance to 6-TG is uncommon for rotavirus 
Rotavirus was serially passaged in the presence of escalating concentrations of 6-TG to 
assess the potential of drug resistance development. As a control, wild-type SA11 rotavirus 
was passaged in the absence of the drug. During the initial ten passages, infected cultures 
were exposed to 1000 ng/mL of 6-TG; whereas the drug concentration was increased to 
2000 ng/mL at the subsequent later passages. After 20 passages, the effects of 6-TG (100 
ng/mL) on each representative passage (both drug treated and untreated) of rotavirus was 
quantified by qRT-PCR. Our results indicate that rotavirus remains sensitive to 6-TG 
treatment in MA104 cells (Fig. 2A) and Caco2 cells (Fig. 2B). Therefore, rotavirus does not 
easily develop 6-TG resistance, suggesting that the antiviral effects of 6-TG likely depend on 
a cellular target but not a direct interaction with the virus itself.  
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Rac1, the cellular target of 6-TG, sustains rotavirus replication 
Although initially characterized as a nucleotide synthesis inhibitor, in the last decade it has 
become clear that many of the effects of 6-TG, at least in gastrointestinal pathophysiology, 
depend on its potency to inhibit Rac1 (Shin et al., 2016). Thus, we investigated the potential 
role of Rac1 on rotavirus replication. To this end, we performed a lentiviral RNAi-mediated 
loss-of-function assay to silence the Rac1 gene. Two (no. 9689 and 9691) out of five RNAi 
vectors showed potent knockdown of the target gene (Fig. 3A). Importantly, these two RNAi 
vectors resulted in 65.0 ± 0.1% (n = 10, P < 0.001) and 61.8 ± 0.2% (n = 6, P < 0.05) reduction 
of SA11 rotavirus viral RNA, respectively (Fig. 3B). In apparent agreement, we obtained Rac1 
knockout mouse embryonic fibroblasts cells (MEFs), and their status as a bona fide knockout 
was confirmed by western blot assay (Fig. 3C). Rotavirus replication in Rac1 knockout MEFs 
(-/-) was significantly less efficient (62.4 ± 0.2%; n = 4; P < 0.05), compared with the 
replication in wild type MEF (lf/lf) (Fig. 3D). Thus, decreased Rac1 levels correlate with 
increased resistance towards rotavirus replication. 
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Fig. 1. 6-TG effectively inhibits rotavirus replication. (A) Treatment with 6-TG (48 hrs) significantly 
inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells (MOI = 0.7) in a dose-dependent 
manner (n = 6-17, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test, A.U. denotes artificial 
unit). (B) Effects of 6-TG on the production of infectious viral particles determined by TCID50 method. 
Each bar represents the TCID50/mL (mean ± SEM) (n = 3, P < 0.05, Mann-Whitney test). (C) Treatment 
with 6-TG (48 h) significantly inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a 
dose-dependent manner (the densitometric analysis of immunoreactive bans in western bots was 
quantified by ImageJ software, and the ratio of VP4/β-actin was expressed in arbitrary units). (D) 
Treatment with 6-TG (6 - 48 hrs) significantly inhibited viral genomic RNA in SA11 rotavirus infected 
Caco2 cells (MOI = 0.7) in a time-dependent manner (n = 4-8, means ± SEM, *P < 0.05, **P < 0.01, 
Mann-Whitney test, p.i.h denotes hour of post infection). (E) The morphology of human primary 
small intestinal organoids with clear villus domain and crypt domain. (F) Treatment with 6-TG (48 hrs) 
significantly inhibited genomic RNA in SA11 rotavirus (MOI = 7) infected human intestinal organoids 
(n = 6, means ± SEM, *P < 0.05, Mann-Whitney test). (G) Treatment with 6-TG (48 hrs) significantly 
inhibited viral production in SA11 rotavirus infected human intestinal organoids (n = 6, means ± SEM, 
**P < 0.01, Mann-Whitney test). (H) Treatment with 100 ng/mL of 6-TG (48 hrs) inhibited viral RNA of 
patient-derived rotavirus isolates in Caco2 cells. (I) Treatment with 100 ng/mL of 6-TG (48 hrs) 
inhibited viral RNA of patient-derived rotavirus isolates in human intestinal organoids. 
 
  
Chapter 8 
186 | P a g e  
 
  
Fig. 2. 6-TG has a high barrier to drug resistance development. Rotavirus was serially passaged in 
MA104 or Caco2 cells exposed to no 6-TG (as control) and increasing concentrations of 6-TG until 20 
passages (infected cultures were exposed to 1000 ng/mL of 6-TG in passage 1-10; whereas the drug 
concentration was increased to 2000 ng/mL at the subsequent later passages). The effect of 6-TG 
(100 ng/mL) on passage 5, 10, 15 and 20 (the drug treated and untreated) of rotavirus was quantified 
using qRT-PCR. 6-TG retained its anti-rotavirus activity even with continuous exposure to 6-TG for 20 
passages in MA104 cells (A) and Caco2 cells (B). ng/mL at the subsequent later passages). 
The effect of 6-TG (100 ng/mL) on passage 5, 10, 15 and 20 (the drug treated and 
untreated) of rotavirus was quantified using qRT-PCR  6-TG retained its anti-rotavirus 
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Fig. 3. Rac1, the drug target of 6-TG, sustains rotavirus replication. (A) Western blot assay detected 
Rac1 in transduced Caco2 cells transduced lentiviral RNAi vectors against Rac1 (The ratio of Rac1/β-
actin was expressed in arbitrary units). (B) Three (No. 9687, 9689 and 9691) out of five lentiviral 
shRNA vectors inhibited rotavirus genomic RNA (n = 6-10, means ± SEM, *P < 0.05, ***P < 0.001, 
Mann-Whitney test). (C) Western blot assay confirmed knockout of Rac1 in Rac1 knockout (-/-) MEF 
cells. (D) SA11 rotavirus replication was significantly attenuated in Rac1 knockout (-/-) MEF cells (n = 
4, means ± SEM, *P < 0.05, Mann-Whitney test).  
Efficient rotavirus replication requires Rac1 activation 
Rac1 acts as binary switch in cellular biochemistry, and it is only capable of provoking 
signaling in the active GTP-bound form (Shin et al., 2016). NSC23766, a specific GTP-Rac1 
inhibitor was able to effectively inhibit GTP-Rac1 accumulation in Caco2 cells, as evident 
when tested in GTP-Rac1 specific pull-down assay (Fig. 4A and B). Importantly, treatment 
with either 5 or 25 µM NSC23766 for 48 hrs resulted in 58.8 ± 0.1% (n = 8; P < 0.05) and 
77.48 ± 0.1% (n = 10; P < 0.001) reduction on viral RNA levels, respectively (Fig. 4C). The IC50 
value of NSC23766 against SA11 rotavirus was 1.1×10-8 M, the CC50 of NSC23766 to Caco2 
cells was 3.1×10-4 M, and the SI was 2.8 ×104 (Table. S2). The inhibitory effect of NSC23766 
on the rotavirus infectious was further verified by a western blot assay, revealing that 
treatment with either 1, 5 or 25 µM NSC23766 significantly inhibits rotavirus VP4 protein 
synthesis in Caco2 cells (Fig. 4D). The effect of this drug was further confirmed by 
experiments in human primary intestinal organoids, which indicated 91.1 ± 0.1% (n = 6; P < 
0.05) reduction of viral RNA in the organoids (Fig. 4E) following treatment with NSC23766.  
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Next, we tested the effects of constitutively active and dominant negative forms of Rac1 on 
rotavirus replication. This was done by transfection of the active Rac1V12 plasmid or the 
dominant negative Rac1N17 plasmid. Expression of both plasmids was successful when 
tested by flow cytometry (Fig. 4F). Accordingly, Rac1V12-transfected cells displayed 
abundant GTP-Rac1, which in contrast is low in Rac1N17-transfected cells, as determined in 
a Rac pull-down assay (Fig. 4G). These results were confirmed by analyzing abundance of 
phospho-PAK2 status (Fig. 4H). Importantly, Rac1V12 promoted, but Rac1N17 inhibited 
rotavirus replication (Fig. 4I). Taken together, activation of Rac1 supports rotavirus 
replication.  
6-TG inhibits rotavirus via suppression of Rac1 GDP/GTP cycling 
The inhibition of the activation of Rac1 by 6-TG was reported in many cell types (Fuhler et al., 
2008; Shin et al., 2016; Tiede et al., 2003). Employing the Rac1 pull-down assay (Fig. 4A), we 
observed that 6-TG potently inhibited GTP-Rac1 accumulation; whereas corresponding 
western blots did not show reduced overall Rac1 levels in Caco2 cells following 6-TG 
treatment (Fig. 5A). Functional studies using Rac1 knockdown Caco2 cells (Fig. 5B and 5C) 
were performed to demonstrate that both 6-TG and NSC23766 require Rac1 to combat 
rotavirus replication. In agreement, pharmacological Rac1 inhibitors did not inhibit rotavirus 
replication in Rac1 knockout MEF cells (Fig. 5D). Thus 6-TG inhibits rotavirus via suppression 
of Rac1 activation. 
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Fig. 4. The activated form of Rac1 is required for supporting rotavirus replication. (A) Schematic 
depicting the pull-down assay. (B) NSC23766 inhibited GTP-Rac1 as detected by pulldown assay (The 
ratio of GTP-Rac1/Rac was expressed in arbitrary units). (C) Treatment with NSC23766 (48 hrs) 
significantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells in a dose-dependent 
manner (n = 8-10, means ± SEM, *P < 0.05, ***P < 0.001, Mann-Whitney test). (D) Treatment with 
NSC23766 (48 hrs) significantly inhibited viral VP4 protein in SA11 rotavirus infected Caco2 cells in a 
dose-dependent manner (The ratio of VP4/β-actin was expressed in arbitrary units). (E) Treatment 
with NSC23766 (48 hrs) significantly inhibited viral RNA in SA11 rotavirus infected human intestinal 
organoids (n = 6, means ± SEM, *P < 0.05, Mann-Whitney test). (F) Flow cytometric analysis of green 
fluorescence indicated the percentages of transduced cells with Rac1V12 and Rac1N17 plasmids. 
Median fluorescence identity (MFIs) of control, N17 and V12 are 3.43, 35.5 and 84.3, respectively. (G) 
Pull-down and western blot assays showed higher level of GTP-Rac1 with transduction of Rac1V12 
but lower level of GTP-Rac1 with Rac1N17 plasmids (The ratio of GTP-Rac1/Rac was expressed in 
arbitrary units). (H) Detection of phospho-PAK2 indicated successful transduction of Rac1V12 and 
Rac1N17 plasmids. (I) Rac1V12 transduction facilitates but Rac1N17 inhibits rotavirus replication (n = 
10, means ± SEM, *P < 0.05, Mann-Whitney test). 
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6-TG has no combination effect with IFNα, but moderately antagonistic effect 
with ribavirin on rotavirus replication 
Interferon-alpha (IFNα) and ribavirin are widely used as general antivirals, being confirmed 
to significantly inhibit rotavirus replication in vitro (Yin et al., 2015a). Consistently, we again 
demonstrated the inhibitory effects of IFNα and ribavirin on rotavirus RNA (Fig. 6A, and 6E) 
and viral protein (Fig. 6B and 6F) in a dose-dependent manner. The IC50 value of IFNα against 
SA11 rotavirus was 3.1×10-5 IU, CC50 of IFNα to Caco2 cells was 18706 IU, and SI was 6.0×108 
(Table S2). The IC50 value of ribavirin against SA11 rotavirus was 1.6×10-7 M, CC50 of ribavirin 
to Caco2 cells was 3.02×10-2 M and SI was 1.9×105 (Table S2). Next, we assessed the 
combinatory antiviral effects of 6-TG with IFNα or ribavirin. The combination of 6-TG and 
IFNα resulted in no combination (no synergy or antagonism) antiviral effect, with a synergy 
volume of -2.8 µM2% (Fig. 6C and 6D). However, the combination of 6-TG and ribavirin 
resulted in moderately antagonistic antiviral effect, with a synergy volume of -26.02 µM2% 
(Fig. 6G and 6H). 
 
Fig. 5. 6-TG inhibits rotavirus via suppression of Rac1 activation. (A) 6-TG inhibited GTP-Rac1 as 
detected by pull-down assay. (B) Anti-rotavirus effect of 6-TG (100 ng/mL) was attenuated in Rac1 
knockdown Caco2 cells. (C) Anti-rotavirus effect of NSC23766 (25 μg ng/mL) was attenuated in Rac1 
knockdown Caco2 cells. (D) The anti-rotavirus effect of 6-TG (100 ng/mL) was attenuated in Rac1 
knockout (-/-) MEF cells (n = 6-8, means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney test). 
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Fig. 6. The effects of the combination of 6-TG with IFNα, or ribavirin on rotavirus replication. (A) 
Treatment with IFNα (48 hrs) significantly inhibited viral genomic RNA in SA11 rotavirus infected 
Caco2 cells in a dose-dependent manner (n = 4, means ± SEM, **P < 0.01, Mann-Whitney test). (B) 
Treatment with IFNα (48 hrs) remarkably inhibited viral VP4 protein in SA11 rotavirus infected Caco2 
cells in a dose-dependent manner (The ratio of VP4/β-actin was expressed in arbitrary units). (C) 
Effect of the combination of various concentrations of 6-TG and IFNα on rotavirus replication in 
Caco2 cells. (D) Synergy plot representing the percentage of antiviral activity above/below the 
expected activity for the 6-TG-IFNα combination based on the data shown in C. (E) Treatment with 
ribavirin (48 hrs) significantly inhibited viral genomic RNA in SA11 rotavirus infected Caco2 cells in a 
dose-dependent manner (n = 4-7, means ± SEM, *P < 0.05, **P < 0.01, Mann-Whitney test). (F) 
Treatment with ribavirin (48 hrs) remarkably inhibited viral VP4 protein in SA11 rotavirus infected 
Caco2 cells in a dose-dependent manner (The ratio of VP4/β-actin was expressed in arbitrary units). 
(G) Effect of the combination of various concentrations of 6-TG and ribavirin on rotavirus replication 
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in Caco2 cells. (H) Synergy plot representing the percentage of antiviral activity above/below the 
expected activity for the 6-TG-ribavirin combination based on the data shown in G. 
Discussion 
In this study, we have demonstrated that 6-TG effectively inhibits rotavirus replication via 
inhibition of the Rac1 activity. This is particularly interesting in view that rotavirus replication 
is especially an issue in organ transplantation recipients and in patients with IBD. 6-TG is a 
therapeutic option for both groups of patients. Based on the findings presented in the 
current study, the choice of 6-TG for these patients appears rational, in particular when they 
are at risk of rotavirus infection (Yin et al., 2015b). 
Our results fit well with the momentum of studies that document antiviral activity of 6-TG. 
For instance, it has been reported that 6-TG can combat Middle East respiratory syndrome 
coronavirus infection by augmenting interferon responses (Cheng et al., 2015) and it has also 
been reported that Simian virus 40 DNA replication is antagonized by 6-TG (Maybaum et al., 
1987). Interestingly, it was reported that vaccinated IBD patients had lower titers of hepatitis 
B surface antibody (HBsAb), which might be influenced by the use of immunosuppressants 
including 6-TG (Watts et al., 2017).  
As a 6-thiopurine (6-TP) prodrug, 6-TG is converted into pharmacologically active deoxy-6-
thioguanosine phosphate (also called 6-thioguanine nucleotide) and 6-thioguanosine 
phosphate (6-TGNP). 6-TGNP can bind to Rac1 to form the 6-TGNP•Rac1 complex 
inactivating Rac1 (Shin et al., 2016). As a major player of the Rho family of small GTPases, 
Rac1 plays a vital role in various cellular signaling pathways to regulate a wide variety of cell 
functions including gene transcription, cell proliferation, apoptosis, motility, and redox 
signaling (D'Ambrosi et al., 2014). The expression of Rac1 is ubiquitous, but it has two 
conformational states including an inactive GDP-bound form and an active GTP-bound form 
(Bosco et al., 2009). It exerts biological functions mainly through activation of Rac1 (i.e. GTP-
bound form) (Bosco et al., 2009). Many viruses interfere with or employ the conformational 
states of Rac1 to regulate their infection. At early stages of African swine fever virus (ASFV) 
infection, Rac1 is activated, and inhibition of Rac1 is able to suppress production of this virus 
(Quetglas et al., 2012). Rac1 is found to be activated during intracellular mature virus (MV) 
of Vaccinia virus entry (Mercer and Helenius, 2008).  
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Although rotavirus replication per se does not affect the activation of Rac1 (Fig. S2), we have 
demonstrated that the loss-of-function of Rac1 by gene knockdown or knockout significantly 
impairs rotavirus replication, which is in line with the previous finding that knockdown Rac1 
could significantly inhibit Enterovirus 1 (EV1) infection (Karjalainen et al., 2008). More 
specifically, the activation of Rac1 is required as shown by the opposing effects of ectopic 
over-expression of the active or inactive forms of Rac1 on rotavirus replication. This 
mechanistically explains the potent anti-rotavirus effects of the GTP-Rac1 inhibitors, 6-TG 
and NSC23766. Of note, NSC23766 has been shown to inhibit the replication of several 
influenza viruses including a human virus strain from the 2009 pandemic and highly 
pathogenic avian virus strains (Dierkes et al., 2014).  
Despite the absence of approved medications for treating rotavirus, the widely used general 
antivirals including ribavirin and IFNα have been studied on rotavirus in experimental models 
(Yin et al., 2015a). Here, we have evaluated the combinatory effects of 6-TG with IFNα or 
ribavirin. Consistently, we confirmed that ribavirin and IFNα inhibit rotavirus replication at 
both RNA and protein levels (Fig. 6A and 6B). We found increased potency of IFNα in the 
presence of 6-TG. However, whether the combination of IFNα and 6-TG could be used to 
treat rotavirus infected patients remains to be further investigated.  
In conclusion, this study has demonstrated that 6-TG effectively inhibits rotavirus replication 
with a high barrier to drug resistance development. We further identified the active form of 
Rac1 as an important host factor supporting rotavirus replication. 6-TG exerts its anti-
rotavirus effects via the specific inhibition of Rac1 activation. Herein, this study provided 
important references for clinicians to optimize medications for organ recipients or IBD 
patients who are infected with rotavirus or at risk of rotavirus replication. These results may 
also help the development of new anti-rotavirus therapies. 
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Supplementary Tables & Figures 
Table S1. Primers and shRNA sequences used in the study. 
Sequence of rotavirus primers 
 SA11 Rotavirus Human Patient Rotavirus 
Sense  TGGTTAAACGCAGGATCGGA ACCATCTACACATGACCCTC 
Anti-sense AACCTTTCCGCGTCTGGTAG CACATAACGCCCCTATAGCC 
 
Primer sequences of GAPDH 
Primers Human Mouse 
GAPDH-F GTCTCCTCTGACTTCAACAGCG TTCCAGTATGACTCCACTCACGG 
GAPDH-R ACCACCCTGTTGCTGTAGTAGCCAA TGAAGACACCAGTAGACTCCACGAC 
 
shRNA targeting sequences of Rac1 
Primers Human Mouse 
GAPDH-F GTCTCCTCTGACTTCAACAGCG TTCCAGTATGACTCCACTCACGG 
GAPDH-R ACCACCCTGTTGCTGTAGTAGCCAA TGAAGACACCAGTAGACTCCACGAC 
 
Table S2. 50% inhibition concentration (IC50) of 6-TG, NSC23766, IFNα and ribavirin against 
SA11 rotavirus, 50% cytotoxic (CC50) of against Caco2 cells, and corresponding selectivity 
index (SI, CC50/IC50).  
Drugs  IC50 against SA11 
rotavirus (M) 
CC50 against Caco2 
cells (M) 
selectivity index 
(SI, CC50/IC50) 
6-TG 3.0×10-13 M 9.8×10-6 M 3.3×107 
NSC23766 1.1×10-8 M 3.1×10-4 M 2.8 ×104 
IFNα 3.1×10-5 IU 18706 IU 6.0×108 
Ribavirin  1.6×10-7 M 3.02×10-2 M 1.9×105 
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Table S3. Patient characteristics. 
 
Patient Age 
(yrs) 
Gender Symptoms  Virus Detection 
Enterovirus Parechovirus Norovirus 
genegroups 
I 
Norovirus 
genegroups 
II 
Adenovirus Astrovirus Sapovirus Rotavirus 
1 3.5 Female Fever  No No No No No No No Yes 
2 74 Female Congestive heart 
failure, myocarditis 
No No No No No No No Yes 
3 27 Female Fever, diarrhea, 
nausea, vomiting 
No No No No No No No Yes 
4 67 Male Fever, stomach ache, 
watery diarrhea 
(Kidney transplant) 
No No No No No No No Yes 
5 28 Female Nausea, stomach 
ache, watery 
diarrhea, fever, 
headache, vomiting 
No No No No Yes No No Yes 
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Supplementary Figures 
 
Fig. S1. Effect of 6-TG (A), NSC23766 (B), IFNα (C) and ribavirin (D) on host cell viability determined by 
MTT assays. Caco2 cells treated with all four drugs for 48 h.  
 
 
 
Fig. S2. The effect of inactive rotavirus by UV treatment, rotavirus and mock infection (1 and 8 h) on 
the expression of GTP-Rac1. (A) Western blot assay detected the expression of GTP-Rac1 after 1 and 
8 h post-infection by inactive rotavirus (UV treatment), rotavirus and mock infection in Caco2 cells. (B) 
Quantification of the intensity of the immunoreactive bands of Rac1 (n = 4, means ± SEM, Mann-
Whitney test) using Odyssey V 3.0 software.  
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Abstract  
Background: Diarrhea significantly contributes to the global burden of diseases, particularly 
in developing countries. Rotavirus and norovirus are the most dominant viral agents 
responsible for diarrheal disease globally. The aim of this review is to conduct a 
comprehensive assessment of rotavirus and norovirus study in Indonesia. 
Data sources: Articles about rotavirus and norovirus surveillance in Indonesia were collected 
from databases, including PubMed and Google Scholar. Manual searching was performed to 
identify additional studies.  Furthermore, relevant articles about norovirus diseases were 
included. 
Results: A national surveillance of rotavirus-associated gastroenteritis has been conducted 
for years, resulting in substantial evidence about the high burden of the diseases in 
Indonesia. In contrast, norovirus infection received relatively lower attention and very 
limited data are available about the incidence and circulating genotypes. Norovirus causes 
sporadic and epidemic gastroenteritis globally. It is also emerging as a health problem in 
immunocompromised individuals. During post-rotavirus vaccination era, norovirus 
potentially emerges as the most frequent cause of diarrheal diseases.  
Conclusions: Our review identifies knowledge gaps in Indonesia about the burden of 
norovirus diseases and the circulating genotypes. Therefore, there is a pressing need to 
conduct national surveillance to raise awareness of the community and national health 
authority about the actual burden of norovirus disease in Indonesia. Continuing rotavirus 
surveillance is also important to assess vaccine effectiveness and to continue tracking any 
substantial changes of circulating rotavirus genotypes. 
 
Keywords: diarrhea; rotavirus; norovirus; Indonesia; surveillance 
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Introduction 
Diarrheal diseases are among the leading causes of global disease burden with significant 
morbidity and mortality, especially in low income developing countries.[1] In 2010, it was 
estimated that there were about 1.7 billion episodes of diarrhea in children aged less than 
five years, of which, 36 million progressed to severe diseases.[1] In Indonesia, the incidence 
of diarrhea in all ages and in children aged less than five years are 3.5% and 10.2% 
respectively.[2] In 2015, 5.0 billion episodes of diarrhea in all age groups are reported, as well 
as 21 diarrhea outbreaks with more than 1200 patients and 30 deaths (Case Fatality Rate 
[CFR] 2.47%).[3] 
Various bacteria, viruses, and parasites have been identified as the causes of diarrhea, 
mainly transmitted through contaminated food or water sources. A systematic review of 
articles published between 1990 and 2011 showed that rotavirus is the most dominant 
cause of diarrhea in children aged less than five years, followed by enteropathogenic 
Escherichia coli (EPEC) and caliciviruses (norovirus and sapovirus).[4] Among pathogens 
commonly transmitted through contaminated food, norovirus is the most common. 
Norovirus causes 677 million diarrheal episodes, resulted in 213 000 deaths in all ages.[5]  
Since rotavirus and norovirus are the main viral pathogens causing diarrhea globally, we 
conducted a comprehensive review of the detection and surveillance of these viruses in 
Indonesia. Based on the available surveillance data, we identified the burden of the diseases 
in Indonesia as well as the circulating genotypes. Finally, we identified gaps in the previous 
surveillance to guide recommendations for improving the surveillance systems of these 
viruses in Indonesia. 
Years of rotavirus surveillance and detection in Indonesia 
Rotavirus is a non-enveloped, double stranded RNA (dsRNA) virus belongs to the Reoviridae 
family. Its genome consists of 11 dsRNA segments encoding six structural proteins (viral 
proteins [VPs]) and six non-structural proteins (NSPs). The viral particle comprises of three 
concentric protein layers. The outer layer is made of two neutralizing antigens, VP7 and VP4 
proteins. These proteins are essential for binary classification of rotavirus into G- and P-
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genotype, respectively.[6] Rotavirus is the most important cause of hospitalization in children 
suffering from diarrhea. In 2013, it was estimated that 215 000 children aged less than five 
years died from rotavirus-associated diarrhea.[7] Rotavirus-associated diseases also emerged 
in immunocompromised patients, including pediatric and adult organ transplant recipients.[8] 
In Indonesia, rotavirus was first visualized using electron microscopy in fecal specimens of 
infants and children with acute diarrhea in Yogyakarta collected during the year 1978-1979.[9] 
Rotavirus was identified in 38% of the collected specimens.[9] Rotavirus was also detected 
from fecal specimens collected from children with diarrhea during August 1979 to 
September 1981 in Jakarta and Medan.[10] Strain characterization was performed by 
electropherotyping.[11] A subsequent study successfully detected the rotavirus serotype by 
using monoclonal antibodies against VP7 protein.[12]  
To further investigate the burden and impact of rotavirus diseases, the Asian Rotavirus 
Surveillance Network (ARSN) was established.[13] As a member of ARSN, the Indonesian 
Rotavirus Surveillance Network (IRSN) conducted a hospital-based surveillance based on 
World Health Organization (WHO) standard protocol.[14-16] Rotavirus surveillance was also 
conducted by other institutions or research laboratories (Table 1).[17-27] Rotavirus detection 
was based on enzyme immunoassay and characterization of rotavirus genotypes was 
performed by reverse transcriptase polymerase chain reaction (RT-PCR).[15, 16]  
These studies indicated a high incidence of rotavirus disease in chidren aged <5 years in 
Indonesia. Rotavirus detection rate in these studies was about 40%-50% (Table 1), in line 
with a recent analysis of worldwide studies from 2000-2013 (37%-40%).[7] It is worth noting 
that the difference of detection rate between studies may be due to the difference of 
detection assays used and the surveillance period. Even though rotavirus was detected year-
round, the incidence tends to be higher from June to August.[14, 15] Rotavirus-positive 
children were at risk of developing severe clinical symptoms such as vomiting and 
dehydration.[15, 23] Outbreaks have been reported from Papua and East Nusa Tenggara[19, 22], 
underlying the urgency to control the diseases. 
Rotavirus genotyping demonstrated that G1P[8], G1P[6] and G2P[4] strains were the most 
predominant strains circulating in Indonesia[15, 16, 25, 26], in line with findings of worldwide 
studies.[28] However, alterations of dominant strains in Indonesia was observed[16], 
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supporting the importance of continuous surveillance in the country. Surveillance in 
Indonesia has identified novel genotypes such as G12 strain.[29] Results of the observation 
highlight the importance of updating genotyping assays to cope with the rapid evolution of 
the virus that might result in typing failure.[30] 
Collectively, the surveillance system provides valuable data about the epidemiology and 
impact of rotavirus disease in Indonesia.[15] Furthermore, it raises awareness about the 
magnitude of rotavirus disease burden. Together with the genotyping studies, government 
and public health experts could assess the prospect of introducing rotavirus vaccine into the 
national program to reduce the burden of diseases in Indonesia. It is expected that inclusion 
of rotavirus vaccines in the National Immunization Program will prevent 480 000 diarrhea 
cases in outpatient clinics, 176 000 hospitalizations and 8000 deaths of Indonesian 
children.[31] 
Decline of rotavirus diarrhea following rotavirus vaccine 
Introduction 
Two commercially available oral rotavirus vaccines, Rotarix and RotaTeq, were licensed in 
2006 and recommended for use by the World Health Organization in all countries, 
particularly those with a high incidence of severe rotavirus-associated gastroenteritis.[32] 
Clinical trials of these vaccines demonstrated high efficacy against severe rotavirus disease 
in developed, high- and upper middle-income countries. However, a lower efficacy was 
observed in developing, lower middle-income countries.[33] 
These vaccines are live-attenuated vaccines that differ in their antigenic composition. 
Rotarix (GlaxoSmithKline Biologicals, Belgium) is a monovalent vaccine (RV1), containing 
G1P[8] strains derived from human rotavirus. RotaTeq (Merck, USA) is a pentavalent 
vaccine (RV5), derived from human-bovine reassortant viruses containing five most 
dominant strains, i.e. G1, G2, G3, G4, and P[8].[34] Both vaccines are available in Indonesia. 
However, they are not included in the National Immunization Program due to financial 
constraints.[35] Currently, there are no available data about the vaccination coverage and 
the impact of rotavirus vaccination in Indonesia. 
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Table 1. Rotavirus (RV) detection and surveillance in Indonesian population. 
No Regions Study periods Types of study Population No of cases 
tested* 
RV positive samples 
(%) 
Methods References 
1 Yogyakarta June 1978 - June 
1979 
Hospital-based 
surveillance 
Children age 0 – 12 years 
hospitalized due to acute 
diarrhea 
334 126 (38%) EM [9] 
2 Jakarta and 
Medan 
August 1979 - 
September 1981 
NS Children with diarrhea.  41 16 (39%) RPH  [10] 
3 Jakarta March 1997 - 
August 1999 
Community- and 
hospital-based 
surveillance 
Pediatric and adults 
patients reporting diarrhea 
539 202 (37.5%) EIA [17] 
4 Jakarta March 1997 - 
June 1999 
Hospital-based 
surveillance 
Inpatient and outpatient 
reporting diarrhea 
402 170 (42.3%) EIA [18] 
5 Yogyakarta 
and Purworejo 
August 2001 - 
April 2004 
Hospital-based 
surveillance 
Children <3 years admitted 
due to diarrhea 
1321 705 (53%) EIA [13, 14] 
6 Kupang, East 
Nusa 
Tenggara 
August 2002 Outbreak 
investigation 
Acute diarrhea cases during 
outbreak period (n=2.600) 
27 13 (48%) EIA [19] 
7 NS February 2004 - 
February 2005 
Hospital-based 
surveillance 
Children <6 years of age 
with acute diarrhea 
1660 755 (45.5%) EIA or RT-PCR [20] 
8 Palembang, 
Jakarta, 
Bandung, 
Yogyakarta, 
Denpasar, 
Mataram 
January - 
December 2006 
Prospective 
surveillance in 6 
teaching 
hospitals 
Children aged <5 years with 
acute diarrhea (inpatient 
and outpatient) 
2240 
(inpatients) 
and 176 
(outpatients) 
1345 (60%) and 73 
(41%) 
EIA [15] 
9 Jakarta, 
Yogyakarta, 
Denpasar, 
Makassar, 
Mataram 
January - April 
2007 
Hospital-based 
surveillance 
Children <5 years old with 
acute diarrhea 
421 257 (61%) RT-PCR [21] 
10 Bandung, 
Yogyakarta, 
Mataram, 
Denpasar 
2006, 2009, 2010 Hospital-based 
surveillance 
Children aged <5 years with 
acute diarrhea 
4235 2220 (52.4%) EIA [16] 
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11 Bintuni Bay, 
Papua 
September - 
October 2008 
Outbreak 
investigation in 
five villages 
242 toddlers admitted to 
hospitals with massive 
diarrhea 
15 10 (67%) or 12 (80%) EIA or RT-PCR, 
respectively. 
[22] 
12 Denpasar April 2009 - 
December 2011 
Hospital-based 
surveillance 
Children aged <5 years with 
acute diarrhea 
656 327 (49.8%) EIA [23] 
13 Bandung April 2009 - 
December 2012 
Hospital-based 
surveillance 
Infants aged ≤6 months 
with acute diarrhea 
134 60 (44.8%) EIA [24] 
14 Surabaya April - December 
2013 
Hospital-based 
surveillance  
Children 1-60 months 
hospitalized due to acute 
diarrhea 
220 88 (40%) IC  [25] 
15 Yogyakarta February - 
August 2009 
Hospital-based 
surveillance 
Children aged <5 years with 
acute diarrhea 
104 57 (54.8%) EIA [26] 
16 Pekanbaru, 
Riau 
January - July 
2015 
Hospital-based 
surveillance 
Children aged 0-60 months 71 42 (59.2%) or 44 
(62.0%) 
EIA or RT-PCR, 
respectively. 
[27] 
*: for case-control studies, only number of tested cases were presented. 
NS: not specified 
IC: immunochromatographic assay 
EIA: enzyme immunoassay 
RT-PCR: reverse transcriptase polymerase chain reaction 
EM: electron microscopy 
RPH: reversed passive hemagglutination kits 
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By the end of 2013, Rotarix and RotaTeq had been included in the national immunization 
programs of more than 50 countries worldwide and showed a significant impact to reduce 
rotavirus diseases.[33] In these countries, rotavirus vaccines proved to be safe and effective in 
reducing rotavirus-associated diarrhea cases, hospitalizations, and deaths.[33] Interestingly, 
following a widespread implementation of rotavirus vaccination, a change in the 
epidemiology of viral gastroenteritis has been observed. With the decline of rotavirus 
disease, human norovirus infection has become more prevalent, especially in countries 
where universal rotavirus vaccination has been introduced. Reports from Bolivia[36], Brazil[37, 
38], Nicaragua[39], Finland[40, 41], and the United States[42, 43] indicated that norovirus has 
become more prevalent than rotavirus in causing gastroenteritis in children. As an example, 
during 2009-2010, norovirus was detected in 21% of young children with acute 
gastroenteritis, while rotavirus was detected in 12% of children at the same period in the 
United States.[43] Although more comprehensive global epidemiological studies are needed, 
these initial reports clearly indicate that norovirus had emerged as the most predominant 
cause of gastroenteritis in children during post-rotavirus vaccination era. 
Norovirus: an emerging and under-recognized human pathogen 
Human norovirus is a linear, single-strand, positive RNA virus that is ∼7.6 kb in length that 
belongs to the family of Caliciviridae. It is classified into at least 6 genogroups (genogroup 1 
[G1] to GVI) and more than 40 genotypes. The prototype of human norovirus, Norwalk virus, 
is designated as GI, genotype 1 (GI.1). Human norovirus GII.4 is the most frequent cause of 
human infection, followed by GI and rarely, GIV. The other genogropus, GIII, GV, and GVI are 
bovine, murine and canine norovirus, respectively.[44, 45] As an RNA virus, norovirus displays a 
great genetic diversity, particularly due to the error-prone nature of RNA dependent RNA 
polymerase (RdRp) and recombination between two related strains.[46] 
Norwalk virus is the first viral agent identified as the cause of gastroenteritis in human. The 
virus was visualized in 1972 from specimens collected during an outbreak of acute 
gastroenteritis in Norwalk, Ohio, the United States, and hence its name.[47] However, its 
significance as human pathogen was under-recognized due to lack of a routine detection 
method.[45] In addition, efforts to develop robust norovirus cell culture models that mimick 
the entire life-cycle in infected cells have been unsuccessful, hampering studies on the 
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molecular biology and development of specific anti-viral drugs.[48] Along with the rapid 
development of diagnostic methodology based on quantitative real time PCR and its wide-
spread availability, understanding of norovirus epidemiology and its disease burden have 
largely improved, particularly in developing countries.[49] 
The global burden of norovirus gastroenteritis 
Norovirus diseases mainly affect children aged less than five years and older adults (greater 
than 65 years) in which it causes a high rate of hospitalization and death.[49] Norovirus can 
infect general population, causing outbreaks and acute sporadic gastroenteritis, and also 
chronic infection in immunocompromised individuals (Fig. 1). 
Figure 1. The global burden of norovirus gastroenteritis. 
Norovirus outbreaks 
Norovirus is the leading cause of acute gastroenteritis outbreaks globally. Indeed, most of 
our recent understandings about molecular epidemiology of norovirus come from the 
analysis of global outbreak samples.[49] Several factors contribute to the high incidence of 
norovirus outbreaks, such as low infectious dose; prolonged fecal shedding that facilitate 
secondary transmission; viral stability in the environment; and lack of cross-protective and 
long-lasting immunity.[45]  
Norovirus is responsible for about 50% of all gastroenteritis outbreaks reported 
worldwide.[50] In some countries, the incidence is even higher. As an example, an analysis of 
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fecal specimens taken from more than 300 outbreaks of nonbacterial gastroenteritis in the 
United States demonstrated that more than 90% of these outbreaks were attributable to 
norovirus.[51, 52] 
In a systematic analysis of norovirus outbreaks, the food service (e.g. restaurant) was the 
most common outbreak setting (35%), followed by health care (e.g. hospitals and long-term 
care facilities) (27%); leisure places (e.g. cruises, hotels and recreational activities) and 
school/daycare facilities (27%).[53] For nosocomial outbreaks, the most frequently reported 
route of transmission was person-to-person transmission (18.5%). However, the majority of 
the transmission route of the nosocomial outbreaks (77.8%) is still unknown.[54] Most 
importantly, a systematic analysis of published hospital outbreaks identified norovirus as the 
most common cause of a hospital wards closure.[55] Altogether, the data underscore that the 
impact of norovirus disease should not be underestimated. Therefore, appropriate 
prevention and control measures are urgently required to prevent the occurrence of any 
future norovirus outbreaks. 
Especially in healthcare settings, a highly virulent GII.4 norovirus strain has been recognized 
as the most common strain responsible for global norovirus outbreaks. The GII.4 strain is 
more likely to be associated with person-to-person transmission.[56, 57] However, some of 
GII.4 outbreaks were attributable to foodborne transmission.[58] A systematic review 
indicates that GII.4 outbreaks were associated with more severe clinical outcomes, 
independent of other factors.[59] New variants of GII.4 strain frequently emerged in cycles of 
two to seven years, replacing the previously dominant variant to cause pandemic.[57] As an 
RNA virus, the high mutation rate facilitates the virus to escape from the host’s immune 
system, leading to a constantly susceptible population and widespread newly emerging 
strains.[46] Interestingly, recent reports from Japan and China identified a novel strain, GII.17 
norovirus, as the major cause of outbreaks and potentially replaces the previously 
dominating GII.4 strain.[60] 
Acute sporadic gastroenteritis 
Beside outbreaks, norovirus is also an important agent of sporadic gastroenteritis. A 
systematic review of published studies between 1990 and 2008 documented that norovirus 
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was responsible for 12% of severe gastroenteritis in children aged less than five years 
worldwide, requiring emergency department visit and hospitalizations. Across all ages, 
norovirus accounted for 12% of mild and moderate diarrhea.[61] More recent estimates 
indicate that it is accounted for 18% cases of acute gastroenteritis in children aged less than 
five years and mixed ages.[62] This estimation suggests that norovirus is the most common 
cause of diarrhea across all ages. In children aged less than five years during pre-rotavirus 
vaccination era, it is the second leading cause of severe diarrhea, following rotavirus.  
Infection in immunocompromised host 
Due to the use of immunosuppressant agents, transplant recipients are at high risk of 
contracting norovirus infection. The prevalence of norovirus-associated diarrhea in 
hematopoietic stem cell transplant (HST) and solid organ transplant (SOT) recipients have 
been reported to be 18%.[63] However, more thorough studies are required to confirm this 
finding. Importantly, norovirus infection in these patients was associated with more severe 
morbidity, such as prolonged viral shedding and recurrences of diarrhea episodes.[63] 
Therefore, a reduction or withdrawal of immunosuppressant agents should be considered 
for transplant patients at risk of norovirus infections in order to enhance the immune 
response in fighting the infection.[64] Patients with primary immunodeficiency, such as 
common variable immune deficiency (CVID), were also highly susceptible to develop chronic 
infections, leading to severe complications such as intestinal villous atrophy and 
malabsorption.[65] Due to a prolonged phase of infection and an increase of viral mutation, 
immunocompromised and transplant patients may serve as potential norovirus reservoirs in 
the human population.[66]  
Relevance of norovirus surveillance in Indonesia 
In contrast to rotavirus, norovirus surveillance and detection in Indonesian population, as 
well as in several other developing countries, are very limited, (Table 2). This suggests that 
norovirus received comparatively less concern than rotavirus, despite its significance in 
global contribution of all acute gastroenteritis cases. We found only four hospital-based 
surveillance identifying norovirus as the cause of acute gastroenteritis in Indonesia with a 
limited surveillance period and a relatively limited number of clinical sample tested. [17, 18, 25, 
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67] Moreover, the surveillances were only conducted in two regions, three of which were 
conducted in the capital city of Jakarta. This is probably due to the requirement of RT-PCR 
for norovirus detection which is not widely available in Indonesia. Therefore, we can 
conclude that nationwide studies focused more on rotavirus diseases rather than any other 
type of viruses.[14-16]  
In these four studies, norovirus prevalence was about 18%-30% (Table 2), in accordance to 
the findings of global studies.[62] One study identified norovirus as co-viral agent with 
rotavirus infection. Seventeen out of 88 rotavirus-infected patients (19.3%) were co-infected 
with human norovirus.[25] Unfortunately, all previous studies (Table 2) did not report the 
genogroup and genotype of the infecting human norovirus. Consequently, genotyping data 
of norovirus circulating in Indonesia are not yet available. These findings clearly 
demonstrated the lack of national studies on the epidemiological burden and genetic 
diversity of human norovirus circulating in Indonesia.  
Some countries have developed surveillance system to monitor norovirus incidence and 
outbreaks. NoroNet, led by the National Institute for Public Health and the Environment of 
the Netherlands (Rijkinstituut voor Volksgezondheid en Milieu, RIVM), is a collaborative 
network of international institutes maintaining a database of norovirus nucleotide 
sequences.[60] In the United States, the Centers for Disease Control and Prevention (CDC) 
established CaliciNet on 2009.[68] Both systems have proven successful in identifying the 
transmission routes and the emergence of norovirus’ new strain variants.[58, 60, 69] A reporting 
system to detect norovirus outbreaks was also established by the United Kingdom 
Department of Health through the Hospital Norovirus Outbreak Reporting System (HNORS). 
In this system, outbreak data are collected and summarized using a standardized paper and 
stored in a web-based database.[70] This system was successful in increasing norovirus 
outbreak reports in hospitals. It also provided data about the burden and economic impact 
of norovirus outbreaks in hospitals.[70] An efficient detection and surveillance system may be 
able to reduce the health and societal cost expenses due to norovirus infections and 
outbreaks.[71] 
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Table 2. Norovirus (NoV) detection and surveillance in Indonesian population. 
No Regions Study periods Types of study Population No of cases 
tested 
NoV positive samples 
(%) 
Methods References 
1 Jakarta March 1997 - 
June 1999 
Hospital-based 
surveillance 
Inpatient and 
outpatient 
reporting diarrhea 
218 45 (20.6%) RT-PCR [18] 
2 Jakarta March 1997 - 
August 1999 
Community- and 
hospital-based 
surveillance 
Pediatric and 
adults patients 
reporting diarrhea 
278 49 (18.0%) RT-PCR [17] 
3 Jakarta October 1997 - 
September 1999 
Hospital-based 
study 
Infants (0-1 year) 
and young 
children (aged 5-
12 years) 
presenting acute 
diarrhea 
102 31 (30%) RT-PCR [67] 
4 Surabaya April - December 
2013 
Hospital-based 
surveillance  
Children 1-60 
months 
hospitalized due 
to acute diarrhea 
88 17 (19.3%)* RT-PCR [25] 
*: as co-infection with rotavirus 
 
 
 
  
Chapter 9 
215 | P a g e  
 
Conclusions 
Continuous surveillance is required to enhance our understanding of the burden and impact 
of rotavirus and norovirus gastroenteritis in Indonesia. During post-rotavirus vaccination era, 
improvement of active surveillance in Indonesia is necessary to assess the effectiveness of 
rotavirus vaccines and to enhance the early detection of any changes of circulating rotavirus 
genotypes.[16] Continuous strain monitoring is pivotal to anticipate the emerging of novel or 
rare genotypes not included in the current vaccines, such as G12.[72] The emergence of these 
genotypes may be due to vaccine-induced selective pressure. Subsequently, it may change 
the epidemiology of circulating rotavirus genotypes and influence the overall impact of 
rotavirus vaccines. The information is therefore useful for rotavirus vaccine development. 
In addition, it is also necessary to include other patients in the surveillance, such as 
immunocompromised patients. In these patients, the incidence of rotavirus infection is 
considerably high and a prolonged diarrheal illness has been observed. These observations 
support the need of surveillance in these patients.[8] 
In contrast to rotavirus surveillance, norovirus surveillance in Indonesia is very limited. With 
the decline of rotavirus diseases following vaccine introduction, norovirus may emerge as a 
major cause of diarrhea in Indonesian children. Therefore, norovirus surveillance is crucial to 
investigate the burden of the disease and to characterize the genotypes. The surveillance 
system is of great importance to anticipate the emergence of novel, potentially pandemic 
strains such as GII.17 viruses.[60] The data of surveillance could serve as the basis for vaccine 
development.[49] 
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Abstract  
Rotavirus and norovirus are the most important viral causes of acute gastroenteritis in 
children. While most previous studies mainly focused on rotavirus, here we investigated the 
burden and epidemiology of norovirus and rotavirus diseases in Indonesia. Hospitalized 
children less than five years of age with acute gastroenteritis were enrolled in this study 
from January - December 2015 at three participating hospitals. Rotavirus was detected by 
enzyme immunoassay (EIA), followed by genotyping with reverse transcription PCR (RT-PCR). 
Norovirus genogroups were determined by TaqMan-based quantitative RT-PCR. Among 406 
enrolled children, 75 (18.47%); 223 (54.93%) and 29 (7.14%) cases were positive for 
norovirus, rotavirus and both viruses (mixed infections), respectively. Most cases clinically 
presented with fever, diarrhea, vomiting and some level of dehydration. Identification of 
norovirus genogroup showed that the majority (n=69/75 [92%]) was genogroup II. Among 35 
samples tested for rotavirus genotype, the most prevalent genotype was G3P[8] (n=30/35 
[85.6%]). Our study suggests that the burden of norovirus diseases in Indonesian children 
should not be underestimated. It also shows the emergence of G3P[8] rotavirus genotype in 
Indonesia. 
 
Keywords: acute gastroenteritis; children; Indonesia; norovirus; rotavirus   
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Introduction  
Acute gastroenteritis (acute diarrhea) is one of the most important global health issues, 
especially in children less than five years of age [49]. It is clinically characterized by acute 
symptoms of fever, abdominal pain, vomiting and diarrhea. The mortality is mainly due to 
severe complications, including dehydration [13]. Control measures of diarrheal disease 
have resulted in a significant progress. The global diarrheal mortality across all ages has 
markedly declined, from an estimated 2.6 million annually in 1990 to about 1.3 million in 
2013 [28]. 
Rotavirus and norovirus are the most common viral agents responsible for acute 
gastroenteritis in children less than five years of age [22]. Rotavirus is a segmented double 
stranded RNA (dsRNA) virus. Based on two outer layer structural proteins VP7 and VP4, it is 
classified into G- and P-genotype, respectively [14]. Our previous national surveillance 
studies found a high incidence of rotavirus diseases and identified G1P[8], G1P[6] and G2P[4] 
as the most common genotype circulating in Indonesia [30, 41, 51]. Reassortment between 
different strains contributes to rotavirus genetic diversity by creating a novel combination of 
G- and P-genotype [11]. Thus, continuous strain monitoring is greatly important to identify 
novel genotypes. 
Norovirus is a positive, single strand RNA virus and considered as the second most common 
cause of severe gastroenteritis in children following rotavirus [33]. Globally, the prevalence 
is about 18% in children aged less than five years and mixed ages with acute gastroenteritis 
[1]. Norovirus genogroup I (GI), II (GII) and IV (GIV) are found to infect humans, with a total 
of more than 30 characterized genotypes within those genogroups. A single genotype, GII.4, 
is the most prevalent globally and responsible for most of norovirus-associated 
gastroenteritis outbreaks [7, 8]. Importantly, norovirus has emerged as the leading cause of 
acute gastroenteritis, especially in countries which have introduced universal rotavirus 
vaccination [21, 34]. 
Despite its importance as the leading cause of severe gastroenteritis, very limited data is 
available on the burden and epidemiology of norovirus diseases in children less than five 
years of age in Indonesia. Norovirus genogroup responsible for acute gastroenteritis cases in 
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hospitalized children in Indonesia is also unknown [15]. Therefore, the objectives of this 
study were to investigate the prevalence, seasonality, clinical characteristics and genotype 
distributions of norovirus and rotavirus infections in hospitalized children less than five years 
of age with acute gastroenteritis in Indonesia. 
Materials and Methods 
Sample and clinical data collection  
This study used stool samples collected from children less than five years of age who were 
hospitalized with acute gastroenteritis in: 1) Mataram General Hospital, Nusa Tenggara 
Barat; 2) Dr. Sardjito General Hospital, Yogyakarta; and 3) Wates General Hospital (Kulon 
Progo District), Yogyakarta, during Indonesian Rotavirus Surveillance Study conducted on 
January - December 2015. Stool samples were collected within the first 48 hours after 
admission according to World Health Organization (WHO) protocol. Stool specimens were 
stored at 4 °C - 8 °C before they were transported to the Department of Microbiology, 
Faculty of Medicine, Universitas Gadjah Mada, Indonesia. The specimens were then 
aliquoted into several tubes and stored at -20 °C. The patients' clinical manifestation such as 
fever, vomiting, dehydration and diarrhea were obtained from the medical histories stored 
at Pediatric Research Office, Dr. Sardjito General Hospital Yogyakarta. 
Severe dehydration was determined by two or more of the following signs: lethargy 
(unconsciousness), unable to drink or drinks poorly, sunken eyes, and skin pinch goes back 
very slowly (>2 seconds). Some dehydration was determined when two or more of the 
following signs were found: restlessness, irritability, sunken eyes, drinks eagerly, thirsty, and 
skin pinch goes back slowly [50].  
Rotavirus detection and genotyping 
All stool samples were examined for the presence of group A rotavirus by enzyme 
immunoassay (EIA) using the IDEIA
TM Rotavirus (DakoCytomation) kit according to the 
manufacturer's instructions. Rotavirus genotyping was performed as we described 
previously [31]. 
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Norovirus genogroup detection  
Norovirus RNA was extracted from stool samples by using QIAamp RNA stool minikit (Qiagen) 
according to the manufacturer's instructions. Determination of norovirus GI and GII were 
performed by TaqMan-based quantitative real time polymerase chain reaction (qRT-PCR) on 
the ABI 7000 (Applied Biosystem) according to  Dung et al [9]. Primers and probes to identify 
norovirus genogroup were listed in Supplementary Table 1. 
qRT-PCR reaction was conducted with a final volume of 25 μl containing 1 μl (10 μM) 
forward primer; 1 μl (10 μM) reverse primer; 0,3 μl (10 μM) probe; 12,5 μl 2X RT-PCR buffer; 
1 μl 25X RT-PCR enzyme mix; 4,2 μl nuclease-free water and 5 μl RNA template. Reverse 
transcription for GI norovirus was performed at 61oC for 3 minutes and followed by an initial 
denaturation temperature of 95oC for 5 minutes; 45 cycles of 95oC for  5 seconds; 57oC for 
45 seconds and 37oC for 60 seconds. Reverse transcription for GII norovirus was performed 
at 61oC for 3 minutes and followed by an initial denaturation temperature of 95oC for 5 
minutes; 45 cycles of 95oC for  5 seconds; 60oC for 45 seconds and 37oC for 60 seconds. 
Statistical analyses  
Data were computed with Stata 13 SE. Characteristics of norovirus, rotavirus and mixed 
infections were presented in frequencies and percentages. Chi-square test was used to 
measure odds ratio and p value of etiology pathogens detected toward clinical 
manifestations of acute gastroenteritis of children less than five years of age in Indonesia.  
Ethical approval  
The research protocol was approved by the Ethical Committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia. Informed consent was provided by the 
parents or guardians of each child before the children were enrolled in the Indonesian 
Rotavirus Surveillance Study 2015.  
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Results 
Study population 
From January to December 2015, there were 406 stool samples collected from children less 
than five years of age hospitalized at three participating hospitals due to acute diarrhea. The 
samples were mostly collected from Mataram General Hospital (68.5%). The age of patients 
ranged from 0 to 59 months (median, 15 months). There were 261 (64.29%) male and 145 
(35.71%) female patients; the sex ratio (male/female) was 1.8. 
Virus detection rates and clinical characteristics 
Of the 406 stool samples collected, 75 (18.47%) and 223 (54.93%) were positive for 
norovirus (as determined by qRT-PCR) and rotavirus (as determined by EIA), respectively. 
Mixed infections of rotavirus and norovirus were identified in 29 (7.14%) patients. Norovirus, 
rotavirus, and mixed infections were most commonly identified in children with acute 
diarrhea at Mataram General Hospital and were more frequently identified in male patients, 
which accounted for 66.7%, 65.5%, and 72.4% of cases, respectively (Table 1).  
Fever, vomiting, diarrhea and dehydration were clinical features commonly observed in 
norovirus and rotavirus infections. Fever was more likely presented in children patients with 
acute diarrhea due to norovirus (OR = 6.78; P = 0.009) and rotavirus (OR = 4.07; P = 0.044) 
infections. Vomiting was only significantly associated with rotavirus infection (OR = 22.32; P 
= <0.001). Diarrhea as well as dehydration were not associated with norovirus, rotavirus or 
mixed infections (Table 2).  
Seasonality and age distribution 
Norovirus and rotavirus were identified in children less than five years of age with acute 
diarrhea throughout the year, following the diarrhea incidence. Norovirus seasonal 
distribution was peaked in January-Febuary and July-August. Meanwhile, rotavirus seasonal 
distribution was mainly peaked during early May to the end of September, with slight 
decrease in July and another peak was identified in January (Figure 1). Although norovirus 
and rotavirus were identified in all age groups, rotavirus infection was clustered in children 
7-24 months of age, while norovirus clustered in children 7-36 months of age (Figure 2). 
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Table 1. Characteristics of children less than five years old hospitalized with acute gastroenteritis 
[n=406].   
 Norovirus + 
(n=75) 
Rotavirus + 
(n=223) 
Mixed 
Infections 
(n=29) 
Detection rate (%) 18.47 54.93 7.14 
Age, month [median (IQR)] 15 (8 – 23) 14 (9 – 24) 21 (13 – 30) 
Sex:    
Male [n (%)] 50 (66.7%) 146 (65.5%) 21 (72.4%) 
Female [n (%)] 25 (33.3%) 77 (34.5%) 8 (27.6%) 
Case detection in each location:    
Dr. Sardjito Hospital Yogyakarta (n=39) 12 (16.0%) 15 (6.73%) 4 (13.8%) 
Wates Hospital Yogyakarta (n=89) 17 (22.7%) 62 (27.8%) 10 (34.5%) 
Mataram Hospital, Nusa Tenggara Barat 
(n=278) 
46 (61.33%) 146 (65.47%) 
 
15 (51.7%) 
 
    
Table 2. Clinical features of norovirus and rotavirus infections among children less than five years old 
hospitalized with acute gastroenteritis [n=406].  
 Norovirus + 
(n=75) 
Rotavirus + 
(n=223) 
Mixed Infections  
(n=29) 
Clinical Features    
Fever [n (%)] 45/75 (60.0%) 170/223 (76.2%) 22/29 (75.(%) 
Diarrhea [n (%)] 74/75 (98.7 %) 222/223 (99.6%) 29/29 (100%) 
Vomiting [n (%)] 66/75 (88.0 %) 209/223 (93.7%) 27/29 (93.1%) 
No dehydration [n (%)] 14/75 (18.7%) 48/223 (21.5%) 5/29 (17.2%) 
Some dehydration [n (%)] 59/75 (78.7%) 168/223 (75.3%) 24/29 (82.8%) 
Severe dehydration [n (%)] 2/75 (2.7%) 7/223 (3.1%) 0/29 (0%) 
The odds ratio of clinical features 
Fever [OR (P)] 6.78 (0.009)* 4.07 (0.044)* 0.21 (0.645) 
Diarrhea [OR (P)] 0.44 (0.506) 0.57 (0.451) 0.23 (0.630) 
Vomiting [OR (P)] 0.19 (0.665) 22.32 (<0.001)* 1.18 (0.277) 
Dehydration [OR (P)] 1.55 (0.462) 1.48 (0.48) 2.03 (0.362) 
*Statistically significant 
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Figure 1. Seasonal distribution of norovirus (NV+) and rotavirus (RV+) infections during January – 
December 2015 [n=406]. 
 
 
Figure 2. Age distribution of hospitalized children with norovirus (NV+) and rotavirus (RV+) infections 
[n=406]. 
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Molecular epidemiology 
Genogrouping of 75 norovirus-positive stool samples identified 6 (8%) and 69 (92%) of GI 
and GII norovirus, respectively. For rotavirus genotyping, G3P[8], G2P[6] and G9P[8] 
genotypes were identified in 30 (85.7%), 1 (2.9%) and 1 (2.9%) of 35 rotavirus-positive stool 
samples. Three of  rotavirus genotypes (8.5%) were unidentified (Table 3). 
Table 3. Genogroup of norovirus and genotypes of rotavirus identified in this study. 
Viral Agent n (%) 
Norovirus (n = 75)  
Norovirus 1 (GI) 6 (8) 
Norovirus 2 (GII) 69 (92) 
Rotavirus (n = 35)  
G2P[6] 1 (2.9) 
G3P[8] 30 (85.7) 
G9P[8] 1 (2.9) 
Untypeable 3 (8.5) 
 
Discussion 
Currently, there is a lack of nationwide studies to assess the burden of norovirus diseases in 
Indonesia, despite its importance as the main agent of acute gastroenteritis outbreaks 
globally [15]. Most of the previous studies have been conducted more than a decade ago in 
only two regions (Jakarta and Surabaya) and in a limited time of surveillance periods [15]. In 
addition, those studies did not characterize the genogroup and genotype of circulating 
norovirus in Indonesia [32, 43-45]. Consequently, there is lacking information about the 
burden of diseases, epidemiology, as well as norovirus diversity in Indonesia, similar with 
other developing countries [23]. 
Our study showed that the prevalence of norovirus in children less than five years of age 
hospitalized with acute gastroenteritis in Indonesia was 18.47%, similar with findings of 
worldwide studies [1]. Since the previous nationwide surveillance of acute gastroenteritis 
was mainly focused on rotavirus [41], we therefore suggest that the burden of norovirus 
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diseases in Indonesia should not be underestimated. In 2015, Ministry of Health [18] 
reported 21 diarrhea outbreaks in Indonesia with more than 1,200 affected patients and 30 
deaths, resulting in a Case Fatality Rate (CFR) of 2.47%. Unfortunately, the etiological causes 
of these outbreaks were not further investigated. It is possible that a proportion of these 
reported outbreaks was attributable to norovirus as the most common cause of diarrhea in 
all ages. In fact, norovirus has been reported in diarrhea outbreaks in neighboring countries 
of Indonesia, including Singapore [29, 39] and Thailand [25, 35].  
Based on our findings, norovirus and rotavirus infections commonly occurred between 7 and 
24 months of age, with a median age of 15 and 14 months, respectively. Maternal antibodies 
could be the protective factor for children early in their life during breastfeeding period [4]. 
Administration of rotavirus vaccines scheduled at 2, 4 and 6 months should therefore reduce 
the prevalence of rotavirus diarrhea at the later ages. The overall clinical characteristics of 
norovirus and rotavirus infections are similar and therefore could not be easily distinguished 
in the clinics.  With regard to seasonality, both viruses were detected throughout the year, 
with exception of norovirus which is not detected in June and September. We found a peak 
of rotavirus positive cases in the cool, dry season in May and June, consistent with our 
previous studies [41, 51]. In temperate countries of northern and southern hemispheres, 
peaks of norovirus and rotavirus cases were observed during winter season [20, 33]. 
Environmental factors, such as temperature and humidity, as well as population dynamics 
such as traveling and food consumption, all contribute to norovirus and rotavirus 
transmission in human. 
We found that GII norovirus was much more prevalent (92%) than GI norovirus (8%). To our 
knowledge, this is the first study that identified norovirus genogroup in hospitalized children 
less than five years of age with acute gastroenteritis in Indonesia. Globally, GII.4 norovirus is 
the most prevalent strain in causing clinical diseases [8]. Interestingly, a recent study in 
Surabaya, Indonesia, reported norovirus shedding in asymptomatic healthy adults [48]. 
Norovirus genotyping found that most of the viruses was GII.2. Norovirus strains associated 
with outbreaks have also been detected, including GII.4 Sydney and GII.17 [48]. GII.4 Sydney 
has been detected in the gastroenteritis outbreaks of 2012-2013 in the United States [3], 
China [53], and Taiwan [52]. While GII.17 norovirus recently emerges as the predominant 
cause of gastroenteritis outbreaks in Japan and China and will potentially replace the 
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previously dominating GII.4 norovirus [5, 8]. Based on all these findings, characterization of 
norovirus genotypes in our patients should be the main focus of our future studies. 
In our study, we did not investigate the source and route of transmission of the infecting 
norovirus. Norovirus genotypes differ in their mode of transmission. GI norovirus is 
associated with waterborne transmission. In contrast, GII.4 genotype is more often 
associated with person-to-person transmission than non GII.4 genotypes [8]. It has been 
previously hypothesized that immunocompromised individuals serve as reservoirs of the 
emerging norovirus strains which are then responsible for large outbreaks [19]. This 
hypothesis was challenged by a recent evidence suggesting that these individuals were 
unlikely to contribute at the epidemic level [10]. Noteworthy, multiple norovirus infections 
have been observed in asymptomatic healthy subjects with a relatively high viral load [48], 
questioning whether healthy asymptomatic individuals could potentially serve as reservoirs 
predisposing to sporadic cases and outbreaks. In nosocomial settings, however, norovirus 
transmission is more likely to occur from symptomatic patients [46, 47]. Therefore, these 
studies suggest that symptomatic individuals are also more likely to contribute in norovirus 
transmission in community settings. Definitely, an improved transmission route 
identification and effective prevention strategies are urgently required to reduce the 
prevalence of norovirus diseases in Indonesia. 
Our study found a high incidence of rotavirus infection in Indonesia, similar with findings of 
our previous national surveillance conducted in 2006, 2009 and 2010 [30, 41]. The 
prevalence of rotavirus infection (54.93%) was indeed higher than norovirus (18.74%). These 
results were not surprising given the fact that rotavirus vaccines are not yet included in the 
National Immunization Program of Indonesia, although the parents can obtain them through 
private health facilities. However, the use of rotavirus vaccines was limited, because of 
limited knowledge of their importance and availability as well as financial constraints of our 
general population [40]. Noteworthy, in several countries where rotavirus vaccines have 
been universally introduced, norovirus infection become more prevalent than rotavirus as 
the cause of acute gastroenteritis in children [16, 21, 34, 37]. 
Rotavirus genotyping demonstrated that G3P[8] was the most common genotype. This 
finding was unexpected since G3P[8] was rarely detected in previous surveillance studies 
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conducted in several regions of Indonesia [30, 31, 36, 38, 41]. Worldwide surveillance data 
from 1996 to 2007 showed that G3P[8] genotype circulates at a lesser extent than G1P[8], 
G9P[8] and G2P[4] genotypes in human [2]. However, its prevalence has increased in the last 
decade in many countries and it has replaced the previously dominating G1P[8] genotype in 
some regions [6, 12, 17, 26, 27, 42]. Whether these changes were associated with mass 
vaccination or were simply the result of natural evolution of rotavirus remain to be 
investigated. Interestingly, G3 genotype has the largest host range among other human 
rotavirus group A. It has been detected in many species, including humans, pig, monkey, 
horse, cat, dog and rabbit [24]. Therefore, further sequence analysis is essential to 
determine the origin and evolution of G3P[8] genotype in Indonesia. These results also 
highlight the importance of continuous strain monitoring to find any alterations of 
circulating genotypes. 
In conclusion, our study describes the considerably high burden of norovirus and rotavirus 
gastroenteritis in Indonesian children less than five years of age. Strengthening collaboration 
between the government, public health experts, virologist and research laboratories is highly 
important to assess the true burden of norovirus diseases in Indonesia, then formulate 
appropriate prevention and control strategies. In addition, norovirus genotyping should be 
performed in our future studies to provide databases of potentially emerging strains and to 
support the development of effective vaccines. 
Acknowledgement 
This study was financially supported by the Indonesia Endowment Fund for Education (LPDP) 
(to Mohamad S. Hakim) and Teuku Jacob Grants, Faculty of Medicine Universitas Gadjah 
Mada (to Hera Nirwati). The authors would like to thank Sri Fatmawati for her technical 
assistance. 
Disclosures 
The authors declare no conflict of interest. 
  
Chapter 10 
234 | P a g e  
 
References 
1. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, Koopmans M, Lopman 
BA (2014) Global prevalence of norovirus in cases of gastroenteritis: a systematic review and 
meta-analysis. Lancet Infect Dis 14:725-730. 
2. Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR, Parashar UD (2012) Systematic 
review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus 
vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 30 
Suppl 1:A122-130. 
3. Centers for Disease C, Prevention (2013) Emergence of new norovirus strain GII.4 Sydney--
United States, 2012. MMWR Morb Mortal Wkly Rep 62:55. 
4. Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, 
Bines JE, Bishop RF, Kirkwood CD, Danchin MD (2011) Maternal antibodies to rotavirus: could 
they interfere with live rotavirus vaccines in developing countries? Vaccine 29:1242-1247. 
5. Chan MCW, Hu Y, Chen H, Podkolzin AT, Zaytseva EV, Komano J, Sakon N, Poovorawan Y, 
Vongpunsawad S, Thanusuwannasak T, Hewitt J, Croucher D, Collins N, Vinje J, Pang XL, Lee BE, 
de Graaf M, van Beek J, Vennema H, Koopmans MPG, Niendorf S, Poljsak-Prijatelj M, Steyer A, 
White PA, Lun JH, Mans J, Hung TN, Kwok K, Cheung K, Lee N, Chan PKS (2017) Global Spread of 
Norovirus GII.17 Kawasaki 308, 2014-2016. Emerg Infect Dis 23:1359-1354. 
6. Cowley D, Donato CM, Roczo-Farkas S, Kirkwood CD (2016) Emergence of a novel equine-like 
G3P[8] inter-genogroup reassortant rotavirus strain associated with gastroenteritis in Australian 
children. J Gen Virol 97:403-410. 
7. de Graaf M, van Beek J, Vennema H, Podkolzin AT, Hewitt J, Bucardo F, Templeton K, Mans J, 
Nordgren J, Reuter G, Lynch M, Rasmussen LD, Iritani N, Chan MC, Martella V, Ambert-Balay K, 
Vinje J, White PA, Koopmans MP (2015) Emergence of a novel GII.17 norovirus - End of the GII.4 
era? Euro Surveill 20. 
8. de Graaf M, van Beek J, Koopmans MP (2016) Human norovirus transmission and evolution in a 
changing world. Nat Rev Microbiol 14:421-433. 
9. Dung TT, Phat VV, Nga TV, My PV, Duy PT, Campbell JI, Thuy CT, Hoang NV, Van Minh P, Le Phuc 
H, Tuyet PT, Vinh H, Kien DT, Huy Hle A, Vinh NT, Nga TT, Hau NT, Chinh NT, Thuong TC, Tuan 
HM, Simmons C, Farrar JJ, Baker S (2013) The validation and utility of a quantitative one-step 
multiplex RT real-time PCR targeting rotavirus A and norovirus. J Virol Methods 187:138-143. 
10. Eden JS, Chisholm RH, Bull RA, White PA, Holmes EC, Tanaka MM (2017) Persistent infections in 
immunocompromised hosts are rarely sources of new pathogen variants. Virus Evol 3:vex018. 
11. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliffe NA, 
Nakagomi O, Kirkwood CD, Fischer TK, Parashar UD, Bresee JS, Jiang B, Glass RI (2005) Serotype 
diversity and reassortment between human and animal rotavirus strains: implications for 
rotavirus vaccine programs. J Infect Dis 192 Suppl 1:S146-159. 
12. Gomez MM, Carvalho-Costa FA, Volotao Ede M, Rose TL, da Silva MF, Fialho AM, de Assis RM, 
Matthijnssens J, Leite JP (2014) A decade of G3P[8] and G9P[8] rotaviruses in Brazil: 
epidemiology and evolutionary analyses. Infect Genet Evol 28:389-397. 
13. Graves NS (2013) Acute gastroenteritis. Prim Care 40:727-741. 
14. Greenberg HB, Estes MK (2009) Rotaviruses: from pathogenesis to vaccination. 
Gastroenterology 136:1939-1951. 
15. Hakim MS, Nirwati H, Aman AT, Soenarto Y, Pan Q (2018) Significance of continuous rotavirus 
and norovirus surveillance in Indonesia. World J Pediatr 14(1): 4-12. 
16. Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, Vesikari T (2013) Major reduction of 
rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of 
RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 172:739-
746. 
    Chapter 10                               
235 | P a g e  
 
17. Hull JJ, Teel EN, Kerin TK, Freeman MM, Esona MD, Gentsch JR, Cortese MM, Parashar UD, Glass 
RI, Bowen MD, National Rotavirus Strain Surveillance S (2011) United States rotavirus strain 
surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. 
Pediatr Infect Dis J 30:S42-47. 
18. Kementerian Kesehatan Republik Indonesia (Ministry of Health, Indonesia). Profil Kesehatan 
Indonesia 2015. http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-
indonesia/profil-kesehatan-Indonesia-2015.pdf (accessed January 4, 2018) 
19. Karst SM, Baric RS (2015) What is the reservoir of emergent human norovirus strains? J Virol 
89:5756-5759. 
20. Kawai K, O'Brien MA, Goveia MG, Mast TC, El Khoury AC (2012) Burden of rotavirus 
gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 
30:1244-1254. 
21. Koo HL, Neill FH, Estes MK, Munoz FM, Cameron A, DuPont HL, Atmar RL (2013) Noroviruses: 
The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After 
Introduction of Rotavirus Vaccination. J Pediatric Infect Dis Soc 2:57-60. 
22. Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE, Child Health 
Epidemiology Reference Group of the World Health O, Unicef (2013) Global causes of diarrheal 
disease mortality in children <5 years of age: a systematic review. PLoS One 8:e72788. 
23. Lopman BA, Steele D, Kirkwood CD, Parashar UD (2016) The Vast and Varied Global Burden of 
Norovirus: Prospects for Prevention and Control. PLoS Med 13:e1001999. 
24. Martella V, Banyai K, Matthijnssens J, Buonavoglia C, Ciarlet M (2010) Zoonotic aspects of 
rotaviruses. Vet Microbiol 140:246-255. 
25. McCarthy KS, Guntapong R, Thattiyaphong A, Wangroongsarb P, Hall AJ, Olsen SJ, Holtz TH 
(2013) Outbreak of norovirus gastroenteritis infection, Thailand. Southeast Asian J Trop Med 
Public Health 44:409-416. 
26. Medici MC, Tummolo F, Martella V, Arcangeletti MC, De Conto F, Chezzi C, Magri A, Feher E, 
Marton S, Calderaro A, Banyai K (2016) Whole genome sequencing reveals genetic 
heterogeneity of G3P[8] rotaviruses circulating in Italy. Infect Genet Evol 40:253-261. 
27. Mitui MT, Chan PK, Nelson EA, Leung TF, Nishizono A, Ahmed K (2011) Co-dominance of G1 and 
emerging G3 rotaviruses in Hong Kong: a three-year surveillance in three major hospitals. J Clin 
Virol 50:325-333. 
28. Mortality GBD, Causes of Death C (2015) Global, regional, and national age-sex specific all-cause 
and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the 
Global Burden of Disease Study 2013. Lancet 385:117-171. 
29. Ng TL, Chan PP, Phua TH, Loh JP, Yip R, Wong C, Liaw CW, Tan BH, Chiew KT, Chua SB, Lim S, Ooi 
PL, Chew SK, Goh KT (2005) Oyster-associated outbreaks of Norovirus gastroenteritis in 
Singapore. J Infect 51:413-418. 
30. Nirwati H, Wibawa T, Aman AT, Wahab A, Soenarto Y (2016) Detection of group A rotavirus 
strains circulating among children with acute diarrhea in Indonesia. Springerplus 5:97. 
31. Nirwati H, Hakim MS, Aminah S, Dwija I, Pan Q, Aman AT (2017) Identification of Rotavirus 
Strains Causing Diarrhoea in Children under Five Years of Age in Yogyakarta, Indonesia. Malays J 
Med Sci 24:68-77. 
32. Oyofo BA, Subekti D, Tjaniadi P, Machpud N, Komalarini S, Setiawan B, Simanjuntak C, Punjabi N, 
Corwin AL, Wasfy M, Campbell JR, Lesmana M (2002) Enteropathogens associated with acute 
diarrhea in community and hospital patients in Jakarta, Indonesia. FEMS Immunol Med 
Microbiol 34:139-146. 
33. Patel MM, Hall AJ, Vinje J, Parashar UD (2009) Noroviruses: a comprehensive review. J Clin Virol 
44:1-8. 
34. Payne DC, Vinje J, Szilagyi PG, Edwards KM, Staat MA, Weinberg GA, Hall CB, Chappell J, 
Bernstein DI, Curns AT, Wikswo M, Shirley SH, Hall AJ, Lopman B, Parashar UD (2013) Norovirus 
and medically attended gastroenteritis in U.S. children. N Engl J Med 368:1121-1130. 
Chapter 10 
236 | P a g e  
 
35. Phumpholsup T, Theamboonlers A, Wanlapakorn N, Felber JA, Suvaporn A, Puthanakit T, 
Chomto S, Payungporn S, Poovorawan Y (2015) Norovirus Outbreak at a Daycare Center in 
Bangkok, 2014. Southeast Asian J Trop Med Public Health 46:616-623. 
36. Putnam SD, Sedyaningsih ER, Listiyaningsih E, Pulungsih SP, Komalarini, Soenarto Y, Salim O, 
Subekti D, Riddle MS, Burgess TH, Blair PJ (2007) Group A rotavirus-associated diarrhea in 
children seeking treatment in Indonesia. J Clin Virol 40:289-294. 
37. Puustinen L, Blazevic V, Salminen M, Hamalainen M, Rasanen S, Vesikari T (2011) Noroviruses as 
a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand J Infect Dis 
43:804-808. 
38. Radji M, Putman SD, Malik A, Husrima R, Listyaningsih E (2010) Molecular characterization of 
human group A rotavirus from stool samples in young children with diarrhea in Indonesia. 
Southeast Asian J Trop Med Public Health 41:341-346. 
39. Raj P, Tay J, Ang LW, Tien WS, Thu M, Lee P, Pang QY, Tang YL, Lee KY, Maurer-Stroh S, Gunalan 
V, Cutter J, Goh KT (2017) A large common-source outbreak of norovirus gastroenteritis in a 
hotel in Singapore, 2012. Epidemiol Infect 145:535-544. 
40. Seale H, Sitaresmi MN, Atthobari J, Heywood AE, Kaur R, MacIntyre RC, Soenarto Y, Padmawati 
RS (2015) Knowledge and attitudes towards rotavirus diarrhea and the vaccine amongst 
healthcare providers in Yogyakarta Indonesia. BMC Health Serv Res 15:528. 
41. Soenarto Y, Aman AT, Bakri A, Waluya H, Firmansyah A, Kadim M, Martiza I, Prasetyo D, Mulyani 
NS, Widowati T, Soetjiningsih, Karyana IP, Sukardi W, Bresee J, Widdowson MA (2009) Burden of 
severe rotavirus diarrhea in indonesia. J Infect Dis 200 Suppl 1:S188-194. 
42. Stupka JA, Degiuseppe JI, Parra GI, Argentinean National Rotavirus Surveillance N (2012) 
Increased frequency of rotavirus G3P[8] and G12P[8] in Argentina during 2008-2009: whole-
genome characterization of emerging G12P[8] strains. J Clin Virol 54:162-167. 
43. Subekti D, Lesmana M, Tjaniadi P, Safari N, Frazier E, Simanjuntak C, Komalarini S, Taslim J, 
Campbell JR, Oyofo BA (2002) Incidence of Norwalk-like viruses, rotavirus and adenovirus 
infection in patients with acute gastroenteritis in Jakarta, Indonesia. FEMS Immunol Med 
Microbiol 33:27-33. 
44. Subekti DS, Tjaniadi P, Lesmana M, Simanjuntak C, Komalarini S, Digdowirogo H, Setiawan B, 
Corwin AL, Campbell JR, Porter KR, Oyofo BA (2002) Characterization of Norwalk-like virus 
associated with gastroenteritis in Indonesia. J Med Virol 67:253-258. 
45. Sudarmo SM, Shigemura K, Athiyyah AF, Osawa K, Wardana OP, Darma A, Ranuh R, Raharjo D, 
Arakawa S, Fujisawa M, Shirakawa T (2015) Genotyping and clinical factors in pediatric diarrhea 
caused by rotaviruses: one-year surveillance in Surabaya, Indonesia. Gut Pathog 7:3. 
46. Sukhrie FH, Teunis P, Vennema H, Copra C, Thijs Beersma MF, Bogerman J, Koopmans M (2012) 
Nosocomial transmission of norovirus is mainly caused by symptomatic cases. Clin Infect Dis 
54:931-937. 
47. Teunis PF, Sukhrie FH, Vennema H, Bogerman J, Beersma MF, Koopmans MP (2015) Shedding of 
norovirus in symptomatic and asymptomatic infections. Epidemiol Infect 143:1710-1717. 
48. Utsumi T, Lusida MI, Dinana Z, Wahyuni RM, Yamani LN, Juniastuti, Soetjipto, Matsui C, Deng L, 
Abe T, Doan YH, Fujii Y, Kimura H, Katayama K, Shoji I (2017) Occurrence of norovirus infection 
in an asymptomatic population in Indonesia. Infect Genet Evol 55:1-7. 
49. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE 
(2013) Global burden of childhood pneumonia and diarrhoea. Lancet 381:1405-1416. 
50. World Health Organization (WHO) (2006). Pocket book of hospital care for children: guidelines 
for the management of common illnesses with limited resources. Geneva: World Health 
Organization (WHO). 
51. Wilopo SA, Soenarto Y, Bresee JS, Tholib A, Aminah S, Cahyono A, Gentsch JR, Kilgore P, Glass RI 
(2009) Rotavirus surveillance to determine disease burden and epidemiology in Java, Indonesia, 
August 2001 through April 2004. Vaccine 27 Suppl 5:F61-66. 
    Chapter 10                               
237 | P a g e  
 
52. Wu FT, Chen HC, Yen C, Wu CY, Katayama K, Park Y, Hall AJ, Vinje J, Huang JC, Wu HS (2015) 
Epidemiology and molecular characteristics of norovirus GII.4 Sydney outbreaks in Taiwan, 
January 2012-December 2013. J Med Virol 87:1462-1470. 
53. Zheng QM, Zeng HT, Dai CW, Zhang SX, Zhang Z, Mei SJ, He YQ, Ma HW (2015) Epidemiological 
investigation of a norovirus GII.4 Sydney outbreak in a China elder care facility. Jpn J Infect Dis 
68:70-74. 
Chapter 10 
238 | P a g e  
 
Supplementary Table 
Supplementary Table 1. Primers and probes used in this study to identify the genogroup of 
norovirus. 
 
Detection Sequence 
Norovirus I (GI) Probe AGATYGCGITCICCTGTCCA 
 Primer (F) CGYTGGATGCGITTYCATGA 
 Primer (R)  CTTAGACGCCATCATCATTYAC 
Norovirus II (GII) Probe TGGGAGGGCGATCGCAATCT 
 Primer (F) CARGARBCNATGTTYAGRTGGATGAG 
 Primer (R)  TCGACGCCATCTTCATTCACA 
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Abstract  
Background: Rotavirus is an important cause of severe diarrhoea in children. The aims of this 
study were to identify the rotavirus strains that cause diarrhoea in children in Yogyakarta 
and to determine the association between rotavirus positivity and its clinical manifestations.  
Methods: Clinical data and stool samples were collected from children hospitalised at Kodya 
Yogyakarta Hospital, Indonesia. Rotavirus was detected in stool samples using an enzyme 
immunoassay (EIA), which was followed by genotyping using reverse transcriptase 
polymerase chain reaction (RT-PCR). Electropherotyping was performed for the rotavirus-
positive samples.  
Results: In total, 104 cases were included in the study, 57 (54.8%) of which were rotavirus-
positive. Based on a multiple logistic regression analysis, age group vomiting and stool 
mucous were associated with rotavirus positivity. Most of the 56 samples subjected to 
genotyping were classified as G1 (80.36%) and P[8] (69.64%) genotypes. The genotype 
combination G1P[8] was identified as the most prevalent strain (66.07%). Of the 19 samples 
subjected to electropherotyping, 17 G1 isolates and 1 G3 isolate had long patterns, and 1 G1 
isolate had a short pattern.  
Conclusion: G1P[8] was the most dominant strain of rotavirus causing diarrhoea in children 
in Yogyakarta. Age group, vomiting and stool mucous were associated with rotavirus 
positivity. 
 
Keywords: rotavirus, acute diarrhoea, G-type, P-type, electropherotyping 
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Introduction 
Rotavirus is an RNA virus that mainly infects the gastrointestinal tract. It is the most 
prevalent agent causing severe diarrhoea among infants and young children in both 
developed and developing countries, including Indonesia (1-3). It was recently estimated 
that rotavirus is responsible for 7,200,000–11,500,000 severe diarrhoea episodes and 
133,000–284,000 deaths, most of which occur in developing countries (2). The incidence 
might be lower in countries that have introduced rotavirus vaccination (2). 
Since rotavirus diarrhoea is prevalent among children in developed and developing countries, 
it is unlikely that improvements in sanitation and hygiene will be able to lower the incidence 
of the disease. Therefore, one of the best strategies for decreasing the global burden of 
disease is development and implementation of effective vaccines (1). The current strategy 
for developing rotavirus vaccines involves oral administration of live attenuated viruses that 
protection is expected to be similar to natural rotavirus infection (4, 5). 
Rotavirus has three essential antigenic specificities, determined by the viral proteins VP6, 
VP7 and VP4. Based on the VP6 protein, rotavirus is classified into seven groups (A to G), yet 
only groups A, B and C infect humans. VP7, a glycoprotein, determines G-genotype, while 
VP4, which is protease-sensitive, determines P-genotype. VP7 and VP4 form the outer layer 
of rotavirus and elicit neutralising antibody responses. Therefore, they are implicated in the 
dual classification of rotavirus group A as G- and P-type (6).  
The effectiveness of rotavirus vaccine can be enhanced by identification of the patterns of 
circulating virus serotypes and the role of these serotypes in causing clinical illness (7). 
During vaccine implementation, strain surveillance is necessary to monitor antibody-escape 
variants and changes in the circulating rotavirus strains among humans (8).  
Two rotavirus vaccines, Rotarix and RotaTeq, have been developed by GSK and Merck, 
respectively. RotaTeq is a live attenuated pentavalent vaccine containing G1, G2, G3, G4 and 
P[8] rotavirus derived from reassortants of human and bovine strains. Rotarix is a live 
attenuated monovalent vaccine derived from the most common human rotavirus strain, 
G1P[8]. These vaccines have been proven to be highly effective for the global prevention of 
severe diarrhoea (9, 10). Before implementing the rotavirus vaccination programme in 
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Yogyakarta, it is crucial to perform a study to ensure that the vaccines used in the 
programme match with the most prevalent and clinically relevant rotavirus strain in 
Yogyakarta. 
The aims of this study were to identify the rotavirus strains currently circulating in 
Yogyakarta and to determine the association between rotavirus positivity and the illness’s 
clinical manifestation. This study provides accurate information about the rotavirus strains 
circulating in Yogyakarta before and after the implementation of the vaccination programme.  
Materials and Methods 
Study population and case definition  
From February to August 2009, we enrolled 104 children under five years of age that were 
hospitalised at Kodya Yogyakarta General Hospital, Indonesia due to acute diarrhoea. We 
defined acute diarrhoea as 3 or more instances of loose stool within 24 hours for a duration 
of fewer than 2 weeks (11). We excluded patients whose faecal samples could not be 
obtained within 48 hours of admission to the hospital. 
Clinical data collection  
The patients’ medical histories, including previous occurrences of blood and mucous in stool, 
fever, vomiting, dehydration and diarrhoea, were collected. 
Sample collection and storage  
Stool samples were collected within the first 48 hours after admission according to WHO 
protocol (12). Stool specimens were stored at 4–80C before they were transported to the 
Department of Microbiology, Faculty of Medicine, Universitas Gadjah Mada, Indonesia. The 
specimens were then aliquoted into several tubes and stored at -200C.  
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Detection of rotavirus in stool samples  
All stool samples were examined for the presence of group A rotavirus by enzyme 
immunoassay (EIA) using the IDEIATM Rotavirus (DakoCytomation) kit according to the 
manufacturer’s instructions. Other possible causes of diarrhoea were not examined. 
RT-PCR genotyping  
Rotavirus RNA was extracted from rotavirus-positive faecal specimens using Trizol 
(Invitrogen) according to the manufacturer’s instructions. Rotavirus RNA was analysed to 
determine the VP7 (G-type) and VP4 (P-type) genotypes using reverse transcriptase 
polymerase chain reaction (RT-PCR) as previously described (13-15). For G typing, the 
primers 9con1L (13) and VP7R (15) were used during the first round of RT-PCR (20 cycles) to 
amplify the 905-bp of the VP7 gene segment. Then, 9con1L was used in the second round of 
PCR (20 cycles) with the type-specific primers 9T1 (G1), 9T-2 (G2), 9T-3P (G3), 9T4 (G4) and 
9T-9B (G9) (Table 1) (13). For P-typing, the primers con2 and con3 were used in the first-
round of RT-PCR (20 cycles) to amplify the 877-bp fragment of the VP4 gene segment (14). 
Con3 was used in the second round of PCR (30 cycles) with the type-specific primers 1T-1D 
(P[8]), 2T-1 (P[4]), 3T-1(P[6]), 4T-1 (P[9]) and 5T-1 (P[10]) (Table 2) (14).  
Samples that failed to yield a detectable PCR product from secondary amplification of the 
primer-specific PCR typing were re-typed with other primers using the methods described by 
Gouvea et al. (16) and Simmond et al. (8). For G typing, the consensus primers VP7F and 
VP7R were used in the first round of RT-PCR (30 cycles) to generate the 881-bp of the VP7 
gene segment (15). VP7F was used in the second round of PCR (30 cycles) with the type-
specific primers aBT1 (G1), aCT-2 (G2), G3 (G3), aDT4 (G4) and G9 (G9) (Table 1) (16). For P-
typing, the consensus primers VP4F and VP4R were used in the first round of RT-PCR (30 
cycles) to generate a 663-bp fragment of the VP4 gene segment (8). VP4F was used in the 
second round of PCR (40 cycles) with the type-specific primers 1T-1D (P[8]), 2T-1 (P[4]), 3T-
1(P[6]), 4T-1 (P[9]) and 5T-1 (P[10]) (Table 2) (14). All PCR products were separated in 2% 
agarose gel and visualised under UV light after staining with ethidium bromide. 
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 Primer Sequence ( 5’-3’) Position 
PCR 
product 
(bp) 
References 
 
First amplification of G-typing as described by Das BK et al. (13) and Gomara MI et al. (15) 
 9con1L TAG CTC CTT TTA ATG TAT GGT AT 37 - 59 895 Das BK et al. (13) 
 VP7R AAC TTG CCA CCA TTT TTT CC 914 - 932  Gomara MI et al. (15) 
 
First amplification of G-typing as described by Gomara MI et al. (15) 
 VP7F ATG TAT GGT ATT GAA TAT ACC AC 51 - 71 881 Gomara MI et al. (15) 
 VP7R AAC TTG CCA CCA TTT TTT CC 914 - 932  Gomara MI et al. (15) 
 
Second amplification of G-typing as described by Das BK et al. (13) 
G1 9T-1 TCT TGT CAA AGC AAA TAA TG 176 - 195 158 Das BK et al. (13) 
G2 9T-2 GTT AGA AAT GAT TCT CCA CT 262 - 281 244 Das BK et al. (13) 
G3 9T-3P GTC CAG TTG CAG TGT AGC 484 - 501 464 Das BK et al. (13) 
G4 9T-4 GGG TCG ATG GAA AAT TCT 423 - 440 403 Das BK et al. (13) 
G9 9T-9B TAT AAA GTC CAT TGC AC 131 - 147 110 Das BK et al. (13) 
 
Second amplification of G-typing as described by Gouvea et al. (16) 
G1 aBT1 CAA GTA CTC AAA TCA ATG ATG G 314 - 335 618 Gouvea et al. (16) 
G2 aCT2 CAA TGA TAT TAA CAC ATT TTC TGT G 411 - 435 521 Gouvea et al. (16) 
G3 G3 ACG AAC TCA ACA CGA GAG G 250 - 259 682 Gouvea et al. (16) 
G4 aDT4 CGT TTC TGG TGA GGA GTT G 480 - 498 452 Gouvea et al. (16) 
G8 aAT8 GTC ACA CCA TTT GTA AAT TCG 178 - 198 754 Gouvea et al. (16) 
G9 aFT9 CTT GAT GTG ACT AYA AAT AC 757 - 776 179 Gouvea et al. (16) 
Table 1. Primers used for VP7 genotyping of rotavirus strains 
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 Primer Sequence ( 5’-3’) Position 
PCR 
product 
(bp) 
References 
 
First amplification of P-typing as described by Gentsch et al. (14) 
 Con-3 TGG CTT CGC TCA TTT ATA GAC A 11 - 32 876 Gentsch et al. (14) 
 Con-2 ATT TCG GAC CAT TTA TAA CC 868 - 887  Gentsch et al. (14) 
 
First amplification of P-typing as described by Simmond et al. (8) 
 VP4F TAT GCT CCA GTN AAT TGG 132 - 149 663 Simmond et al. (8) 
 VP4R ATT GCA TTT CTT TCC ATA  ATG 775 - 795  Simmond et al. (8) 
 
Second amplification of P-typing as described by Gentsch et al. (14) 
P[4] 2T-1 CTA TTG TTA GAG GTT AGA GTC 474 – 494 483 Gentsch et al. (14) 
P[6] 3T-1 TGT TGA TTA GTT GGA TTC AA 259 – 278 267 Gentsch et al. (14) 
P[8] 1T-1D TCT ACT TGG ATA ACG TGC 339 – 356 345 Gentsch et al. (14) 
P[9] 4T-1 TGA GAC ATG CAA TTG GAC 385 – 402 391 Gentsch et al. (14) 
P[10] 5T-1 ATC ATA GTT AGT AGT CGG 575 – 594 583 Gentsch et al. (14) 
Table 2. Primers used for VP4 genotyping of rotavirus strains 
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Electropherotyping 
Rotavirus RNA was extracted using Minikit (Qiagen) according to the manufacturer’s 
instructions. RNA was subjected to polyacrylamide gel electrophoresis to separate the 11 
segments of dsRNA, which were then visualised by silver staining.  
Statistical analyses  
The variables were described using frequencies and percentages. Chi-square tests and 
logistic regression analyses were used to determine the association between rotavirus 
infections and clinical manifestations using STATA 13. The variables that had P values of less 
than 0.25 according to the chi-square tests were entered into a logistic regression analysis 
model. Age group and all the clinical symptoms analysed (vomiting, stool mucous, bloody 
stool and fever) had P values of less than 0.25 (Table 3). Bloody stool was omitted because 
the chi-square test revealed cells with a count of zero. Therefore, age group, vomiting, stool 
mucous and fever were examined in the multiple logistic regression analysis. The fit of the 
model was checked using the Hosmer-Lemeshow test. The results were presented as crude 
and adjusted odds ratios with a 95% confidence interval. P values of less than 0.05 were 
considered statistically significant. 
Ethical approval 
The research protocol was approved by the Ethical Committee of the Faculty of Medicine, 
Universitas Gadjah Mada, Yogyakarta, Indonesia. Informed consent was provided by the 
parents or guardians of each child before the children were enrolled in the study. 
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Results  
From February to August 2009, 104 children under five years of age who were hospitalised 
at Kodya Yogyakarta General Hospital, Indonesia due to acute diarrhoea were enrolled in the 
study. There were 70 (67.3%) male and 34 (32.7%) female patients (Table 3). Of the 104 
samples collected, 57 (54.8%) were positive for rotavirus, as determined by EIA. 
Rotavirus diarrhoea particularly affects young children; 70.2% of the cases involved children 
under two years of age. Most cases involved children aged 12–23 months, with the next 
largest group comprised of children aged 24–59 months (Table 3). Additionally, the chi-
square tests revealed significant differences in vomiting, stool mucous and bloody stool 
between rotavirus-positive and rotavirus-negative patients (Table 3).  
We present the final model of the multiple logistic regression analysis in Table 4. There are 
four variables associated with rotavirus positivity: age group, including the 0–11-month-old 
group (adjusted OR = 0.31; CI 95% = 0.10 to 0.93; P = 0.04) and 12–23-month-old group 
(adjusted OR = 3.46; CI 95% 1.03 to 11.60; P = 0.04), stool mucous (adjusted OR = 0.24; CI 95% 
= 0.07 to 0.79; P = 0.02), and vomiting (adjusted OR = 3.97; CI 95% = 1.32 to 11.97; P = 0.01). 
In our study, only one patient had mild dehydration, and all the others (n = 103) had no 
dehydration. 
Of the 57 rotavirus-positive samples, 56 faecal specimens were characterised as G or P 
genotypes. G1 was the most prevalent genotype (80.36%), followed by G2 (16.07%) and G3 
(3.57%) (Table 5). Regarding P-typing, they were classified as P[8] (69.64%), P[4] (17.86%), 
P[6] (7.14%) or untypeable (5.36%) (Table 5). The identified G- and P-type combinations 
were G1P[8] (66.07%), G2P[4] (16.07%), G1P[6] (7.14%), G1P[untypeable] (5.36%), G3P[8] 
(3.57%) and G1P[4] (1.79%) (Table 5). 
A number of rotavirus-positive stool samples did not have sufficient volume for 
polyacrylamide gel electrophoresis (PAGE) analysis. Only 24 samples were subjected to PAGE 
analysis, and 19 isolates had good results. Eighteen samples were identified as G1, and one 
sample was identified as G3. All of them showed the migration pattern of the genome of 
rotavirus group A: 4-2-3-2. The results of electropherotyping showed that 17 of 18 G1 
isolates and 1 G3 isolate had long patterns, while 1 G1 isolate had a short pattern (Figure 1). 
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Variable n (%) of 
patients 
with 
rotavirus-
positive 
diarrhoea 
(n=57) 
n (%) of 
patients 
with 
rotavirus-
negative 
diarrhoea 
(n=47) 
n X2- 
Statistica  
(df) 
P valuea 
Gender Male 41 (71.9) 29  (61.7) 70 1.22 (1) 0.27 
 Female 16 (28.1) 18 (38.3) 34   
Age groups 0–11 11  (19.3) 25 (53.2) 36 4.57 (1) 0.03* 
 12–23 29 (50.9) 9 (19.1) 38 2.96 (1) 0.08 
 24–59 17 (29.8) 13 (27.7) 30   
Clinical 
manifestation 
Vomiting 46 (80.7) 27 (57.4) 73 6.66(1) 0.01* 
 Stool 
mucous 
6 (10.5) 17 (36.2) 23 9.83 (1) 0.00* 
 Bloody 
stool 
0 (0) 11 (23.4) 11 14.92 (1) 0.00* 
 Fever 18 (31.6) 23 (48.9) 41 3.25 (1) 0.07 
               a Chi-square test for independence 
Table 3. Characteristics and clinical symptoms of children under five years of age hospitalised at 
Kodya Yogyakarta General Hospital (n = 104). 
 
 
Variable b Adjusted OR 
(95% CI) 
P valuea 
Age group: 0–11 months vs. 24–59 monthsb -1.17 0.31 (0.10 - 0.93) 0.04 
Age group: 12–23 months vs. 24–59 
monthsb 
1.24 3.46 (1.03 - 11.60) 0.04 
Vomiting 1.38 3.97 (1.32 - 11.97) 0.01 
Stool mucous -1.41 0.24 (0.07 - 0.79) 0.02 
OR = odds ratio. a Likelihood ratio test; b reference category. 
Table 4.  Association between age groups, clinical symptoms and rotavirus positivity revealed by 
multiple logistic regression. 
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Rotavirus strains Total (%) (n=56) 
G genotype 
G1 45 (80.36) 
G2 9 (16.07) 
G3 2 (3.57) 
P genotype 
P[8] 39 (69.64) 
P[4] 10 (17.86) 
P[6] 4 (7.14) 
P[untypeable] 3 (5.36) 
G- and P-type combinations 
G1P[8] 37 (66.07) 
G2P[4] 9 (16.07) 
G1P[6] 4 (7.14) 
G1P[untypeable] 3 (5.36) 
G3P[8]  2 (3.57) 
G1P[4] 1 (1.79) 
 
Table 5.  Rotavirus genotype distribution in Kodya Yogyakarta Hospital. 
 
 
Figure 1.  Electropherotype profile of rotavirus RNA genome. Lanes 1–5: sample RW13 (G3P[8]) - 
long pattern; sample RW22 - RNA insufficient; sample RW23 (G1P[8]) - long pattern; sample RW26 - 
no RNA; sample RW30 (G1P[8]) - long pattern. Lanes 6–10 are control strains: RV3 (G3P[6]) - long 
pattern; RV4 (G1P[8]) - long pattern; RV5 (G2P[4]) - short pattern; F45 (G9P[8]) - long pattern; ST3 
(G4P[6]) - long pattern. 
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Discussion 
This hospital-based study described a high incidence of rotavirus infection in Yogyakarta, 
Indonesia. Rotavirus infection was identified in 54.8% of 104 children hospitalised with acute 
diarrhoea. Compared to previous hospital-based studies performed in Indonesia in the late 
1970s and 1990s, the incidence rate was similarly high. Bishop et al. (17) reported rotavirus 
infection in 38% of children with severe acute diarrhoea in Yogyakarta. Subekti et al. (18), 
who conducted a study in Jakarta from 1997–1999, showed that 170 of 236 (72%) children 
with diarrhoea were infected with rotavirus. Putnam et al. (19), who conducted a study in 
Medan, Makassar, Jakarta, Yogyakarta, Surabaya, Bali and Nusa Tenggara, found that 748 of 
1,660 (45.1%) children under five years of age suffered from diarrhoea due to rotavirus. 
Moreover, Soenarto et al. (20), who conducted a study of children under five years of age in 
Yogyakarta, Jakarta, Bandung, Mataram, Denpasar and Palembang in 2006, showed that 60% 
of the 2,240 children studied suffered from diarrhoea due to rotavirus. These findings 
support the need for continuous surveillance of the disease in various locations. 
Our study found a high incidence of rotavirus infection in Yogyakarta, Indonesia, which is 
comparable to the findings of similar studies in surrounding countries, such as Malaysia (38%) 
(21), Thailand (43%) (22), Cambodia (56%) (23) and Myanmar (57%) (24). Our study provides 
evidence that rotavirus infection gives a substantial burden to the diarrhoeal diseases and it 
is critical to develop an effective approach to preventing infection. 
Rotavirus infection in children clinically manifests with several symptoms, such as fever, 
vomiting and watery, bloodless diarrhoea (25, 26). These clinical manifestations are more 
severe than those of other causes of viral gastroenteritis (27). In our study, vomiting was 
associated with rotavirus positivity (Table 4), which aligns with the findings of other studies 
(20, 28). Those studies also reported that rotavirus-positive patients were less likely to have 
bloody diarrhoea (20, 28), in agreement with our study.  
Severe complications of rotavirus infection, such as bloody diarrhoea associated with 
necrotizing enterocolitis (NEC) and bowel perforation, have been described (25, 26, 29). 
Even though they have not yet been fully elucidated, several factors were associated with 
the pathogenesis of the disease (30). However, an enterotoxin protein, NSP4, and the ability 
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of rotavirus to trigger the apoptosis of intestinal cells might be the factors that most affect 
the manifestation of the disease (31).    
Our study demonstrated that the percentage of children aged 0–11 months who suffered 
from rotavirus diarrhoea was lower than that of children aged 12–23 and 24–59 months 
(Table 3). This phenomenon is probably due to the presence of anti-rotavirus 
immunoglobulin G (IgG) and IgA antibodies in breast milk (32). In their study of children in 
Yogyakarta, Chan et al. (33) found a high concentration of anti-rotavirus IgG and IgA in 
colostrum as well as in breast milk. Moreover, Clemens et al. (34) found that exclusive 
breastfeeding confers better protection against severe rotavirus infection than partial or no 
breastfeeding. However, further study is required to fully address this issue in our patient 
population. 
The genetic diversity of circulating rotavirus strains may have a crucial role in the initiation of 
the vaccination programme and its clinical evaluation. Some studies have been conducted to 
identify the rotavirus strains circulating in Indonesia. Using samples collected in Yogyakarta 
from 1978–1979, Bishop et al. (17) identified G1 (2%); G2 (9%), G3 (53%) and G4 (36%) 
strains. However, Soenarto et al. (20) reported that the G1 and G9 genotypes were the most 
prevalent, accounting for 73 (30%) and 69 (29%) of the 240 samples, respectively, followed 
by G2, which accounted for 34 samples (14%). Putnam et al. (19) reported that the rotavirus 
strains causing diarrhoea in Indonesia were P[4] (16.2%), P[6] (11.3%), P[8] (24.7%), P[9] 
(0.7%), P[10] (1.3%), P[11] (0.5%), mixed infection (3.6%) and untypeable (1.6%). However, 
Soenarto et al. (20) found that the P-type rotavirus strains causing diarrhoea were 
distributed differently: P[4] (16.4%), P[6] (55.6%), P[8] (17.5%), mixed infection (9%) and 
untypeable (1.6%).  
We found that G1P[8] was the most dominant strain of rotavirus causing diarrhoea in 
children under five years of age hospitalised at Kodya Yogyakarta Hospital. G1P[8] was also 
the predominant strain identified in Malaysia in a 1996 study (35). However, G9P[8] 
genotypes became the most common strains in Malaysia from 2001–2003 and in 2007 (21, 
35). 
In our study, G2P[4], G1P[6], G3P[8] and G1P[4] were also common causative agents. Since 
the majority of rotavirus strains circulating in Yogyakarta are similar to those circulating 
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globally, we suggest that the current rotavirus vaccines can effectively reduce the 
prevalence of rotavirus diarrhoea in children under five years of age in Yogyakarta. 
Rotavirus has several mechanisms to generate genetic diversity. One is accumulation of 
point mutation (genetic drift), which is due to the error-prone nature of RNA-dependent 
RNA polymerase (RdRp) enzyme (36). Such mutations could be introduced at the primer 
binding sites and result in typing failure (8, 15). Another important mechanism of rotavirus 
evolution is genetic shift due to reassortment of the segmented RNA genome. This event 
could lead to a new combination of G and P types (36) and introduce novel genotypes 
through zoonotic transmission (37). Both mechanisms may explain our finding that the P-
type of about 5% of samples could not be identified. The rapid evolution of rotavirus may 
increase the number of strains that cannot be genotyped with currently available assays. 
Therefore, our study underscores the importance of regularly updating typing methods to 
successfully detect the currently circulating rotavirus strains. 
Continuous monitoring is important for identifying circulating rotavirus strains before and 
after the introduction of the vaccine. It will provide information about the impact of the 
vaccine on genotype distribution and the possible emergence of less common rotavirus 
strains circulating in certain geographical areas. It is also crucial to assess the effectiveness of 
the vaccination programme against rotavirus diarrhoea. 
According to the migration of its 11 RNA gene segments, rotavirus can also be classified as 
either long or short RNA electropherotype using polyacrylamide gels. The short 
electropherotype occurs as a result of partial duplication in gene segment 11. This gene runs 
more slowly than gene segment 10; because of its standard size, gene segment 11 in long-
electropherotype strains migrates faster than segment 10 (38). In this study, we found that 
most G1 and G3 isolates had a long electropherotype. Long electropherotypes usually 
belong to the Wa genogroup, whereas short electropherotypes typically belong to the DS-1 
genogroup (36). 
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Conclusions 
We found that rotavirus caused acute diarrhoea in 54.8% of children under five years of 
aged hospitalised at Kodya Yogyakarta General Hospital. The majority (66.07%) was  G1P[8], 
the most prevalent strain identified globally. Age group, vomiting and stool mucous were 
associated with rotavirus positivity.  
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Hepatitis E virus infection 
The existence of HEV has been suggested since the early 1980s [1]. However, little efforts 
were invested to determine its global burden and epidemiology, especially when compared 
to other viral hepatitises. Therefore in chapter 2, I systematically reviewed the burden of 
HEV outbreaks by analyzing data from all global HEV outbreaks reported in the literature. 
Most outbreaks occurred in developing countries of the Asian and African continents and 
involved HEV genotypes 1 and 2. Recently, HEV outbreaks were reported from several 
countries, including India [2], Bangladesh [3], Nepal [4], Sudan [5,6], China [7], Australia [8], 
Japan [9], and Spain [10]. I thus suggest that HEV poses a serious threat for global public 
health in the future. Unfortunately, there are no effective prevention and treatment 
strategies available for HEV. To control HEV outbreaks, vaccinations are required to prevent 
its spread. Definitely, the development of effective vaccine and treatment mainly depends 
on our understanding of innate and adaptive immunity against HEV infection. In chapter 3, I 
comprehensively discuss our recent progress on understanding of immunity against HEV. 
Identification of RIG-I as a potent anti-HEV ISG provides proof-of-concept of the notion that 
RIG-I agonists may constitute novel HEV therapy and excitingly it is to be expected that these 
agonist will exhibit more limited side effects as compared to the current IFN or RBV therapy 
[11]. Manipulation of T cell immunity is also a potentially successful approach for 
prophylactic and therapeutic HEV vaccines [12,13].  
Off-label treatment, such as ribavirin, has been useful for managing some chronic cases of 
HEV infection, although ribavirin treatment failure has been reported in a subset of patients 
as well [14]. Therefore, those patients require alternative therapies to clear HEV. A study 
reported that sofosbuvir is valuable in inhibiting HEV replication and has an additive effect in 
combination with ribavirin [15]. Sofosbuvir was originally developed to target the HCV NS5B 
RNA-dependent RNA polymerase. In chapter 4, I demonstrate that sofosbuvir potently 
inhibits HCV, but not HEV in cell culture models and that observation has proven in line with 
several case reports published by others [16-18]. I thus conclude that sofosbuvir is not likely 
to be the novel drug of choice for chronic HEV treatment.  
Immune responses and antiviral treatments provide selective pressure to virus infections, 
including HEV. Viral adaptation is thus an important strategy of viruses to overcome the host 
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immune defense mechanisms and antiviral therapy and ultimately, to maintain viral fitness 
and replication competency [19]. As a single strand RNA virus, HEV replication is clearly 
error-prone due to the lack of proofreading activity of HEV RNA-dependent RNA polymerase. 
In chapter 5, we investigated the nature of adaptive response of HEV to the host immune 
system by performing a comprehensive bioinformatics study of characteristic mutations in 
the HEV genome. I demonstrated a genotype-specific prevalence and evolution of the 
specific mutations and their impact on the reduced B and T cell epitope reactivity. My study 
gives the insight that HEV genetic variants were probably associated with disease 
pathogenesis and clinical progression. The presence of such pronounced molecular evolution, 
adapting to antiviral mechanisms bodes ill for efforts directed at counteracting the virus. 
Drugs and immune-based treatments against rotavirus infection 
IFN-mediated response is known as the first defense mechanism against virus infection. IFN 
executes its antiviral effect via induction of hundreds of IFN-stimulated genes (ISGs) [20]. To 
understand the innate responses against rotavirus infection, I showed in chapter 6 that 
rotavirus infection predominantly induces type III (IFNλ1) rather than type I (IFNα and IFNβ) 
IFN responses, without functional production (secretion) of IFN proteins. Consequently, 
these responses are not sufficient to inhibit rotavirus replication. Instead, basal IFN signaling 
maintained by the ISGF3 complex appears to restrict rotavirus replication. Furthermore, I 
demonstrated that exogenous treatments by all types of IFNs can inhibit the replication of 
both rotavirus SA11 and human patient-derived rotaviruses in Caco-2 cell line as well as 
intestinal organoids through JAK-mediated induction of known ISGs. Since ISGs are the 
ultimate effectors of IFN-mediated antiviral responses, further studies are needed to identify 
specific anti-rotavirus ISGs to improve our understanding of immunity against rotavirus 
infections. 
It is known that rotavirus infection can induce the production of TNF-α in dendritic cells [21]. 
However, the exact role of TNF-α in rotavirus infection remains unexplored. In chapter 7, we 
demonstrated that TNF-α could potently inhibit rotavirus infection. Mechanistically, the 
effect was achieved by NFκB-regulated genes via the activation of classical nuclear factor κB 
(NF-κB) signaling (chapter 7). Our findings expand the previously known anti-viral properties 
of TNF-α against many other viruses, including influenza, HCV, HEV and poxviruses. In the 
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clinic, TNF-α inhibitors have been widely used as treatments in many immune-mediated 
inflammatory diseases, including inflammatory bowel disease (IBD) [22]. Whether the use of 
TNF-α inhibitors in IBD patients were associated with an increased risk of rotavirus infection 
requires further investigation. 
Gastrointestinal infections, including rotavirus, have been recognized as a potential factor of 
exacerbation and induction of flares in IBD. In IBD patients, 6-TG has been effectively used 
for the clinical treatment [23]. Interestingly, we found that 6-TG can inhibit rotavirus 
infection. Furthermore, I demonstrated that the inhibitory effect of 6-TG is achieved through 
its inhibition of the active form of Rac1 protein (GTP-Rac1) (chapter 8). Based on my findings, 
it is reasonable to investigate the incidence of rotavirus infection in IBD patients undergoing 
6-TG treatment as compared to other medications. My findings also suggest that IBD 
patients with a high risk of contracting rotavirus infections may be benefit from 6-TG therapy. 
The burden of rotavirus and norovirus infections in Indonesia 
Rotavirus and norovirus are the most important viral pathogens in causing acute 
gastroenteritis (acute diarrhea) globally. The incidence of acute diarrhea in Indonesia is 
considerably high. Diarrhea is the leading cause of infant mortality in Indonesia [24].  
Therefore, both viruses should be targeted for routine surveillance. In chapter 9, I first 
comprehensively reviewed rotavirus and norovirus surveillance in Indonesia. I identified the 
knowledge gaps in Indonesia, in which norovirus surveillances and detections were very 
limited, as compared with rotavirus.  
Globally, norovirus is associated with 18% (95% CI: 17%-20%) of diarrheal diseases [25]. The 
burden of norovirus infections is substantially high in all regions, including in high-, middle-, 
and low-income countries. Strikingly, norovirus became the most common cause of pediatric 
gastroenteritis attending the medical care in high- and middle-income countries with 
successful national rotavirus vaccination programs [26]. Therefore, norovirus should be the 
main focus for targeted prevention and control measure strategies. Unfortunately, currently 
there are limited data available on the burden, epidemiology and strain diversity of 
norovirus in middle- and low-income countries, particularly in Indonesia (chapter 9). In 
contrast with rotavirus, for which effective vaccines have been introduced, norovirus 
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vaccines remain in the development pipeline. Immunity against norovirus infection is known 
to be type-specific. Given the fact that norovirus is constantly evolving, addressing the data 
gap on molecular epidemiology of norovirus in middle- and low-income countries is 
important, especially through ongoing surveillance programs and it is relevant to support the 
vaccine development. 
Therefore, in chapter 10, we performed a one-year surveillance of rotavirus and norovirus 
infection in children under five years of age in three participating hospitals in Indonesia. I 
found that the prevalence of norovirus and rotavirus in children less than five years of age 
hospitalized with acute gastroenteritis in Indonesia were 18.47% and 54.93%, respectively. 
For norovirus, GII norovirus was much more prevalent (92%) than GI norovirus (8%), similar 
with findings of worldwide studies. Since norovirus typing is sequence-based, experiments 
are now ongoing to determine the genotypes. 
An unexpected findings of the 2015 surveillance was that I found that G3P[8] was the most 
prevalent rotavirus genotype (chapter 10). A previous surveillance conducted in 2009 
(chapter 11) demonstrated that G1P[8] was the most dominant genotype. As a segmented 
RNA virus, rotavirus is also continuously evolving. Consequently, rotavirus displays a great 
diversity because of frequent reassortment, interspecies transmission, point mutation and 
gene rearrangement events and ultimately, novel genotypes and unusual G/P type 
combinations are emerging in human populations [27]. All of these factors emphasize the 
need for continuous rotavirus surveillance to support rotavirus vaccination programs, as I 
have previously discussed in chapter 9.  
Final remarks  
Combating virus diseases in humans, including hepatitis E, rotavirus and norovirus, requires 
close and extensive collaborations between virologist, immunologist, epidemiologist, 
clinicians and many other expertises to comprehend the biology, evolution, pathogenesis, 
transmission and epidemiology of virus diseases to finally develop effective vaccines and 
antiviral therapy. Only then can the burden of severe viral infections be significantly reduced. 
This thesis is a little example on how we can apply different approaches in understanding 
the epidemiology, immunity and antiviral therapy of gastrointestinal viruses. However, we 
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have to acknowledge that more work should be done in the future to reduce the burden of 
viral infections. 
  
References 
1. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human 
hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68(6):818-24. 
2. Singh MP, Majumdar M, Goyal K, Lakshmi PV, Bhatia D, Ratho RK. Investigation of suspected 
viral hepatitis outbreaks in North West India. Diagn Microbiol Infect Dis 2016;84(4):309-14. 
3. Haque F, Banu SS, Ara K, et al. An outbreak of hepatitis E in an urban area of Bangladesh. J Viral 
Hepat 2015;22(11):948-56. 
4. Shrestha A, Lama TK, Karki S, et al. Hepatitis E epidemic, Biratnagar, Nepal, 2014. Emerg Infect 
Dis 2015;21(4):711-3. 
5. Elduma AH, Zein MM, Karlsson M, Elkhidir IM, Norder H. A single lineage of hepatitis E virus 
causes both outbreaks and sporadic hepatitis in Sudan. Viruses 2016;8(10). 
6. Ahmed SS, Soghaier MA, Mohammed S, Khogali HS, Osman MM, Abdalla AM. Concomitant 
outbreaks of yellow fever and hepatitis E virus in Darfur States, Sudan, 2012. J Infect Dev Ctries 
2016;10(1):24-9. 
7. Zhang L, Yan B, Xu A. A hepatitis E outbreak by genotype 4 virus in Shandong province, China. 
Vaccine 2016;34(33):3715-8. 
8. Pokorny AM, Pokorny CS. Local outbreak of hepatitis E: a rare cause of viral hepatitis in Australia. 
Intern Med J 2015;45(12):1300-2. 
9. Ishida S, Matsuura K, Yoshizumi S, et al. Hepatitis E outbreak at a nursing home for aged people 
in Hokkaido, Japan, between February and March 2016. J Clin Virol 2018;101:23-8. 
10. Rivero-Juarez A, Frias M, Martinez-Peinado A, et al. Familial hepatitis E outbreak linked to wild 
boar meat consumption. Zoonoses Public Health 2017;64(7):561-5. 
11. Xu L, Wang W, Li Y, et al. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E 
virus regardless of interferon production. Hepatology 2017;65(6):1823-39. 
12. Hakim MS, Ikram A, Zhou J, Wang W, Peppelenbosch MP, Pan Q. Immunity against hepatitis E 
virus infection: implications for therapy and vaccine development. Rev Med Virol 
2018;28(2):e1964. 
13. Hakim MS, Spaan M, Janssen HL, Boonstra A. Inhibitory receptor molecules in chronic hepatitis B 
and C infections: novel targets for immunotherapy? Rev Med Virol 2014;24(2):125-38. 
14. Peters van Ton AM, Gevers TJ, Drenth JP. Antiviral therapy in chronic hepatitis E: a systematic 
review. J Viral Hepat 2015;22(12):965-73. 
15. Dao Thi VL, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and 
results in an additive effect when combined with ribavirin. Gastroenterology 2016;150(1):82-5 
e4. 
16. Todesco E, Mazzola A, Akhavan S, et al. Chronic hepatitis E in a heart transplant patient: 
sofosbuvir and ribavirin regimen not fully effective. Antivir Ther 2018; doi: 10.3851/IMP3227. 
[Epub ahead of print] 
17. Donnelly MC, Imlach SN, Abravanel F, et al. Sofosbuvir and daclatasvir anti-viral therapy fails to 
clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. 
Gastroenterology 2017;152(1):300-1. 
18. van der Valk M, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity in a patient 
with chronic hepatitis E virus infection. J Hepatol 2017;66(1):242-3. 
19. Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. 
Cell Host Microbe 2010;7(6):440-51. 
Chapter 12 
266 | P a g e  
 
20. Wang W, Xu L, Su J, Peppelenbosch MP, Pan Q. Transcriptional regulation of antiviral interferon-
stimulated genes. Trends Microbiol 2017;25(7):573-84. 
21. Mesa MC, Rodriguez LS, Franco MA, Angel J. Interaction of rotavirus with human peripheral 
blood mononuclear cells: plasmacytoid dendritic cells play a role in stimulating memory 
rotavirus specific T cells in vitro. Virology 2007;366(1):174-84. 
22. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel 
disease. Autoimmun Rev 2014;13(1):24-30. 
23. Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine 
treatment in inflammatory bowel disease: a systematic review. World J Gastroenterol 
2016;22(40):9012-21. 
24. Agtini MD, Soeharno R, Lesmana M, et al. The burden of diarrhoea, shigellosis, and cholera in 
North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis 2005;5:89. 
25.  Ahmed SM, Hall AJ, Robinson AE, et al. Global prevalence of norovirus in cases of gastroenteritis: 
a systematic review and meta-analysis. Lancet Infect Dis 2014;14(8):725-30. 
26. Hakim MS, Nirwati H, Aman AT, Soenarto Y, Pan Q. Significance of continuous rotavirus and 
norovirus surveillance in Indonesia. World J Pediatr 2018;14(1): 4-12. 
27. Jain S, Vashistt J, Changotra H. Rotaviruses: is their surveillance needed? Vaccine 
2014;32(27):3367-78. 
 
 
 
  
 267 | P a g e  
 
 
Chapter 13 
 
Nederlandse Samenvatting 
Dutch Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dutch Summary 
269 | P a g e  
 
Samenvatting voor de leek 
 
Bacteriële infecties kunnen worden behandeld met antibiotica maar tot nu toe bestaat er 
voor de meeste virale infecties geen doeltreffend geneesmiddel. De symptomen, die een 
virale infectie veroorzaakt, zijn afhankelijk van de plaats waar de infectie zich bevindt, de 
uitgebreidheid van de infectie en het soort virus. Afhankelijk van de ernst en de 
behandelmogelijkheden kan een virale infectie zeer lichte verschijnselen van een zich niet al 
te prettig voelen veroorzaken, tot juist een extreem beroerd zijn, met rillingen, hoge koorts 
en verwardheid. In dit proefschrift concentreer ik mij op drie verschillende virale infecties, 
ziekte veroorzaakt door het hepatitis E virus, rotavirus en norovirus. Van al deze ziektes 
probeer ik het klinisch/epidemiologisch probleem in kaart te brengen, terwijl ik voor het 
hepatitis E virus en het rotavirus ook middels onderzoek van hun interactie met 
geneesmiddelen en het menselijk immuunsysteem ook een bijdrage probeer te leveren voor 
het ontwikkelen van nieuwe wegen voor rationele behandeling van ziekte. Hoofdstuk 1 
geeft een uitgebreide introductie, rationale en rechtvaardiging van de in dit proefschrif 
beschreven studies. 
Hepatitis E 
Eén van de verwekkers van virale hepatitis is het hepatitis E virus. Het hepatitis E virus komt 
via gastro-intestinale kanaal de bloedsomloop binnen en repliceert zich dan in de lever. Het 
beloop van de acute HEV-infectie kent meerdere fases: van subklinisch, naar acuut en 
uiteindelijk fulminant. Hepatitis E, wat in toenemende mate wordt gezien als een “public 
health concern”, is bij 0.2 – 1.0 % van de patiënten dodelijk, maar dit percentage kan in het 
laatste trimester van hun zwangerschap bij zwangere vrouwen stijgen tot een 
fataliteitspercentage van 20-25%. Daarnaast is het virus gevaarlijk voor transplantatie-
patiënten. Dergelijke patiënten ontvangen immuunsysteem remmende medicijnen die 
mogelijk de weerstand tegen het hepatitis E virus zouden kunnen verminderen. Het gevolg is 
dat zulke patiënten vatbaar zijn voor Hepatitis E. Opvallenderwijze was de last die mensheid 
meetorst als het gevolg van Hepatitis E nog nooit goed gekarakteriseerd. In Hoofdstuk 2 doe 
ik dit wel en concludeer dat het Hepatitis E virus de belangrijkste oorzaak van acute virale 
leverontsteking (wereldwijd) en geef ik een uitgebreid overzicht waar te wereld welk 
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Hepatitis E virus ziekte uitbraak heeft veroorzaakt.  In Hoofdstuk 3 ga ik dan uitgebreid in op 
de afweermechanismen die ons immuunsysteem gebruikt om te vechten, maar ik laat ook 
de belofte zien van juist preventieve vaccinatiestrategieën. De gedachte dat preventie de 
weg vooruit is met betrekking tot Hepatitis E wordt verder versterkt door de studies 
gepresenteerd in Hoofdstuk 4 en Hoofdstuk 5. In hoofdstuk 4 onderzoek de recent gedane 
suggestie dat medicatie die nuttig is bij het behandelen van Hepatitis C ook een gunstig 
effect heeft bij de behandeling van Hepatitis E.  Met celkweekproeven die ik deed, kon ik 
helaas deze suggestie niet bevestigen, de eerder gepubliceerde data lijken een artefact te 
zijn. In hoofdstuk 5 onderzoek ik het vermogen van het Hepatitis E virus om zich aan te 
passen aan antivirale strategieën. Dit blijkt jammer genoeg erg groot te zijn en het virus 
verandert gemakkelijk van structuur om zowel immuunsysteem als farmacologische 
behandeling te omzeilen. Zoals ook bediscussieerd in Hoofdstuk 12 zijn we dus nog ver weg 
wat betreft effectieve behandeling en is verder wetenschappelijk onderzoek urgent nodig. 
Rotavirus en Norovirus 
Buikloop of diarree kenmerkt zich door een hoofdzakelijk dunne, brijige tot waterige, soms 
slijmerige, ontlasting die gepaard kan gaan met ernstige uitdroging of zelfs ondervoeding.  
Het woord diarree is afgeleid van het Grieks [δια ["dia"]= door, ρεω ["reo"] = stromen]. De 
oorzaken van diarree zijn divers, zo zijn er toxische, bacteriologische en virale oorzaken. In 
dit proefschrift concentreer ik mij op virale oorzaken en met name op de zogenaamde 
rotavirussen en norovirussen. Een rotavirus is vooral bekend van dat het bij jonge kinderen 
overgeven en diarree veroorzaakt. Het is een van de ernstigere diarreeverwekkers in deze 
leeftijdsgroep, omdat de diarree die het veroorzaakt zowel erg besmettelijk als hevig is, en 
vaak ook lang aanhoudend. In ontwikkelingslanden overlijden naar schatting 600.000 
kinderen per jaar aan een rotavirus infectie. In Nederland is een rotavirus veel minder 
bedreigend door de betere uitgangstoestand (voeding, weerstand) van de patiëntjes en de 
mogelijkheid om spoedig in een ziekenhuis door middel van een infuus te worden 
gerehydrateerd, waardoor uitdroging wordt voorkomen. Toch is het ook bij ons een 
belangrijke oorzaak van ziekenhuisopnamen wegens diarree bij kinderen. Vrijwel ieder kind 
maakt echter in zijn of haar leven minstens één rotavirusinfectie door en ziekenhuisopname 
is gelukkig maar zelden noodzakelijk. Ook norovirus veroorzaakt diarree.  In dit proefschrift 
onderzoek ik de beschikbare informatie over het klinisch probleem geassocieerd met 
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rotavirussen norovirussen in Indonesië. Voor rotavirus blijkt veel informatie voorhanden, 
echter wat betreft norovirus is er schokkend weinig bekend (hoofdstuk 9). Ik ben vervolgens 
het voorkomen van rotavirussen en norovirussen in een Indonesisch ziekenhuis gaan 
onderzoeken (hoofdstuk 10). Ik vond dat in kleine kinderen (opgenomen in het ziekenhuis 
vanwege buikloop) in 18.47 % van de gevallen besmet waren met norovirus teerwijl in 54.93 %  
van de gevallen er sprake was van een rotavirusinfectie. In hoofdstuk 11 kijk ik ook nog goed 
welke stammen betrokken zijn bij deze infecties. Het klinisch probleem opgeworpen door 
deze virussen is dus inderdaad heel groot.  
Antivirale mechanismen 
Het is dus belangrijk dat het lichaam en met name het epitheel van de darm zich kan 
verdedigen tegen rotavirusinfectie. Een belangrijke gedachte hierbij is dat de zogenaamde 
interferonen hierbij een belangrijke rol spelen. In hoofdstuk 6 laat ik zien dat dergelijke 
interferonen weliswaar zeer potent zijn in het aanzwengelen van antivirale immuniteit in het 
darmepitheel, maar dat de betrokken mechanismen al constitutief continu aanwezig zijn en 
helpen de darm te vrijwaren van virale infectie. Bovendien laat ik in hoofdstuk 7 dat 
dezelfde mechanismen ook geactiveerd kunnen worden door andere niet-interferon 
ontstekingshormonen. Dus waar interferonen wel effectief in het bestrijden van virussen 
blijft hun rol in de normale afweer vooralsnog onduidelijk. Mijn werk werd nog verder op 
meer fundamenteel niveau uitgebouwd door mijn studies (hoofdstuk 8) met 6-thioguanine 
(een  immunosuppressivum dat wordt gebruikt na orgaantransplantatie maar vooral bij 
auto-immuunziekten zoals de ziekte van Crohn). Het bleek dat deze medicatie een sterk 
remmend effect had op het rotavirus en haar infectie van cellen. Ook bij deze patiënten zou 
men dus moeten kiezen voor een behandelstrategie waarin deze medicatie snel wordt 
ingezet bij die patiënten die een verhoogd risico lopen op rotavirusinfectie.  
Conclusie 
Samenvattend kan ik zeggen dat het probleem van virale infectie wellicht nog groter is dan 
gedacht en dat mechanismen waarmee mensen zich verdedigen tegen virale infectie op 
belangrijke details anders werken dan voorheen werd gedacht. Ik roep dus op tot verder 
onderzoek naar nieuwe wijzen om virusinfecties te bestrijden. 
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Name of PhD Student Mohamad Saifudin Hakim 
Erasmus MC Department Gastroenterology and Hepatology 
PhD Period October 2014 – September 2018 
Promotor Prof. Dr. Maikel P. Peppelenbosch 
Copromotor Dr. Qiuwei Pan 
 
PhD Training Year ECTS 
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and hepatology (attending) 
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2014-2018 9 
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2014-2018 4,6 
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2014-2018 4,3 
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2014-2018 4,6 
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PhD 
2011 0,6 
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The Workshop Browsing Genes and Genomes with UCSC 2012 0,4 
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